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ABSTRACT
This study set out to describe the changes in T-cell immune responses in a cohort of HIV-1-
infected children. The responses were investigated in relation to their clinical progression for
up to four years.
The main response studied was cytotoxic T lymphocyte (CTL) activity which, in adults, is
thought to be one of the major mechanisms by which primary HIV-l-viraemia is cleared and
clinical stability maintained. CTL activity was measured against four HIV gene products
(gag, tat, pol, env). Three patterns of CTL activity were seen in the HIV-1-infected children:
(i) CTL activity against HTV-pol, -gag and/or -env; (ii) CTL activity against HIV-tat and/or
-poi, (iii) no CTL activity detected. These different patterns appear to relate to different
patterns of clinical disease progression. CTL activity was also detected in children born to
HIV-1-infected mothers, who were presumed to have been exposed, but are uninfected. The
the specificity of response in these children was predominantly to HIV-env. Stimulation of
PBMCs with peptides of specific CTL epitopes of HIV-1 resulted in a change in specificity
of CTL recognition. These data suggest that the specificity of the CTL response may be
related to clinical progression of the child, and that different CTL responses are obtained by
different methods of stimulation of PBMCs.
Changes in lymphocyte surface marker expression in peripheral blood were investigated to
see if any phenotype was related to CTL activity, or was indicative of the infection status of
the child, or disease progression. Activated and memory CD8 cell subpopulations were
markedly increased soon after birth in HIV-1-infected children and remained so throughout
infection. An increase in the proportion of activated or memory CD4 cells may indicate an
imminent and accelerated CD4 cell loss, and subsequent progression to AIDS. The
lymphocyte phenotypes in HIV-1-uninfected children remained within normal ranges. CTL
activity was not related to any population in peripheral blood, but was related to by a further
expansion of memory, activated, CD8 cells in culture.
Proliferative responses were also studied, using tetanus toxoid, PHA and a combination of
recombinant HIV-1 proteins as stimuli. Proliferation to tetanus and PHA in the HIV-1-
infected children did not differ from responses seen in exposed uninfected children, donor and
v
cord blood controls.
In one HIV-l-infected child, the possible down regulation of surface CD4 expression on T
cells was investigated by developing a method using reverse transcription of RNA followed
by a polymerase chain reaction (RT-PCR) to detect messenger RNA (mRNA) for CD4.
The results indicate that the HIV-l-infected children showed anti-HIV responses through
different mechanisms. It is possible that these may contribute to the immunopathogenic
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l.l INTRODUCTION TO HIY
1.1.1 ORIGINS, DISCOVERY AND DISTRIBUTION OF HIV
The human immunodeficiency virus (HIV) is one of a family of single-stranded RNA viruses.
This family was called retroviruses because they reverse the normal cellular process of DNA
to RNA transcription (Alberts et al., 1989). RNA is transcribed to DNA using a reverse
transcriptase enzyme before being integrated into the host genome, from where active
replication of the virus can take place (Alberts et al., 1989).
Lentiviruses are a genus of retroviruses which are associated with diseases with long periods
of clinical latency, from which they derive their name. Other lentiviruses include maedi-visna
of sheep, simian immunodeficiency virus (SIV) of primates, equine infectious anaemia virus
of horses, caprine arthritis-encephalitis virus of goats, feline immunodeficiency virus of cats
and bovine immunodeficiency virus of cattle (Haase, 1986; Letvin, 1990). These viruses
have similar genetic structures based around a gag gene coding for the cone shaped core, a
pol gene which encodes for reverse transcriptase (RT) and the other enzymes involved in
integration of virus into the host genome, and an env gene which encodes for the envelope
proteins. These viruses affect the immune system by infecting T cells and/or macrophages,
thus causing persistent viraemia and immunosuppression, but often only stimulate a weak
antibody response (Haase, 1986; Letvin, 1990).
The acquired immune deficiency syndrome (AIDS) was first described in 1981 in homosexual
men in the United States. It was shown that these men were lacking T-lymphocytes which
expressed the CD4 molecule. They were also found to be susceptible to opportunistic
infections that would normally be kept under control by a healthy immune system (Gottlieb
et al., 1981; Centers for Disease Control, 1982). Montagnier's group in France isolated a
novel retrovirus from the lymph node, but not peripheral blood, of one such patient with
enlarged lymph nodes (lymphadenopathy), and named it as lymphadenopathy virus (LAV)
(Barre-Sinoussi et al., 1983). Concurrently, Gallo's group in the USA, isolated and
characterised the same retrovirus from both peripheral blood and lymph nodes of other
patients with AIDS. These isolates were found to share some properties of the human T cell
leukaemia virus types 1 and 2 (HTLV-I and HTLV-II), but were morphologically,
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biologically and antigenically distinct (Popovic et al., 1984; Levy, 1993). Gallo's group
named the virus HTLV-III, but later the name was changed to the human immunodeficiency
virus (HIV, Clavel et al., 1987).
Thus far two major human immunodeficiency viruses have been isolated, HIV-1 and HIV-2.
HIV-2 was first isolated from patients in West Africa. These individuals presented with
immunological abnormalities identical to those with AIDS, but had no antibodies for HIV-1
(Clavel et al., 1986). Isolation and further characterisation of this new virus from more
patients showed that, although related to HIV-1, it was closer to SIV, the simian counterpart
of HIV (Clavel et al., 1987; Marx et al., 1991). The similarity of HIV-2 to SIV has lead to
theories of SIV transmission to humans from monkeys (and adaption to HIV-2), followed by
a rapid evolution to HIV-1 and escape from an isolated human population (Marx et al., 1991;
Gardner and Luciw, 1988).
HIV-2 is endemic in West Africa but is found infrequently in individuals from elsewhere,
while HIV-1 has been isolated from patients from all over the world. One of the features of
HIV-1 is its high sequence variability. A number of groupings have been made, based on
serological and genotypic analysis, of env and gag sequences of HIV-1 isolates from different
parts of the world. Highly divergent strains have been found in Cameroon, Gabon and
France. Other strains of virus have been divided into subtypes denoted A to H (reviewed in
Myers, 1994). The predominant subtype found in Europe and the United States is a subtype
B virus. There is some evidence that the different subtypes of virus may be transmitted
between individuals with varying efficiency (Kunanusont et al., 1995).
HIV-1 sequence variation is also seen at the patient level, both within a single individual
(Holmes et al., 1992; Meyerhans et al., 1989) and between individuals infected with virus
from the same source (Simmonds et al., 1991). Additional pressure on the virus to mutate
could be exerted by the immune responses to HIV-1; sequence variation could be one of the
mechanisms by which HIV-1 evades recognition by the immune system (Nowak et al., 1990;
Phillips et al., 1991; Klenerman et al., 1995; Meier et al., 1995).
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1.1.2 STRUCTURE OF HIV-1
The structure of HIV-1 is presented as a schematic diagram in figure 1.1. HIV-1 is a typical
lentiviral virion (Haase, 1986; Letvin, 1990). The cone-shaped core is composed of the
p24gag protein and contains two copies of the single (sense)-stranded viral RNA (ssRNA),
closely associated with the viral RNA-dependent reverse transcriptase (RT) proteins p66pol
and p53pol, and the nucleocapsid proteins pigag and p9gag. Surrounding the core in the
inner portion of the viral membrane is the myristoylated protein pllgag, which forms the
matrix of the virion. Surrounding this is the lipid bilayer membrane, in which are embedded
seventy-two external spikes formed by the envelope glycoproteins, gp41 (the transmembrane
portion) and gpl20 (surface protein). The gpl20 has several hypervariable regions (denoted
VI to V5) and constant domains (CI to C4). The hypervariable regions (particularly the V3
loop) may affect viral interaction with the host cell. The lipid bilayer is also interspersed
with other host proteins such as the major histocompatibility complex (MHC) class I and II
antigens (Greene, 1992; Levy, 1993). The virion also contains other viral proteins, such as
the regulatory proteins vpr, nef and vif. The functions of the different proteins are
summarised in table 1.1.
1.1.3 LIFE-CYCLE OF HIV-1
HIV-1 binds to the CD4 receptor via gpl20. The exact mechanism of viral entry has not
been elucidated, but it is now known that a second receptor is required for viral entry. This
has been shown to be a family of receptors for small chemotactic peptides called (3-
chemokines (Deng et al., 1996; Dragic et al., 1996; Alkhatib et al., 1996). Once in the
cytoplasm, the viral core is uncoated and the ssRNA is reverse transcribed to single-stranded
DNA (ssDNA). The action of RT and ribonuclease converts the ssDNA into double-stranded
DNA (dsDNA). This is then translocated as a nucleoprotein complex to the nucleus while
still associated with the viral pllgag (matrix) proteins (Gallay et al., 1996). There, the
integrase enzyme, within the nucleoprotein complex, inserts the DNA into the host genome,
where the virus can remain latent within resting cells (Chun et al., 1995), but would be










Table 1.1 Gene products of HIV-1
Gene Protein (size) Function
gag 53 kD precursor, cleaved by p24 is the major core protein.
protease to give p7, p9, pl7, pl7 is the myristoylated protein lining the inner
p24 membrane of virion to stabilise the virion.
p9 is an RNA binding protein.
p7 binds RNA through 'Zinc-finger' motif, and also
binds vpr.
pol precursor RT p63, p55 generates the first-strand DNA copy of viral RNA.
ribonuclease H degrades the RNA template for second-strand copy
of DNA synthesis,
integrase pll integrates viral cDNA into the host genome,
protease pl5 used in post translational processing of viral
proteins.
env gp!60 kD precursor, cleaved gpl20, the envelope surface protein, which
by protease to give gpl20 contains variable and constant regions which
and gp41 affect binding and cellular tropism.
gp41, the envelope transmembrane protein.
tat 15 kD trans-activator viral transcription transactivator.
rev 19 kD regulator of viral
mRNA
mediates export of viral mRNA to cytoplasm and
activates gene expression, by functioning as a
switch, to allow 'early' (multiply spliced) or 'late'
(singly spliced) gene products to be expressed.
nef 25-27 kD negative /actor initially thought to be a negative regulator of gene
expression. Found to down regulate surface CD4
expression.
vif 23 kD viral infectivity /actor promotes virion maturation and infectivity.
vpu 16 kD viral protein U facilitates proper maturation and release of HIV-1
from cells. Degrades CD4 in the endoplasmic
reticulum. Found only in HIV-1.
vpr 14 kD viral protein R promotes nuclear localisation of the pre-integration
complex. Inhibits cell division and arrests infected
cells at G2/M phase of the cell cycle.
vpx 15 kD viral protein X strong homology with HIV-1 vpr but found only in
HIV-2/SIV
Table of the genes and functions of the gene products in HIV-1
Sources: (Greene, 1992; Levy, 1993; Myers et al., 1995; Rosen, 1992;
Antoni et al., 1994; Schwartz et al., 1995; Subbramanian and Cohen, 1994;
Willey et al., 1992)
The genomic organisation of HIV-1 is shown in figure 1.2. Induction of HIV-1 transcription
occurs through activation of transcriptional factors, e.g. the NF-kB family of enhancer
binding proteins. These proteins normally regulate genes involved in cell growth. The
proteins bind to, and activate, the duplicated kB enhancer element located in the U3 region
of the long terminal repeat (LTR) of proviral HIY-1. Other host factors required for HIV-1
expression are Spl, a gene regulatory protein which binds to the promoter of various
'housekeeping' genes, and the TATA factor (TFIID), which binds to the TATA box sequence
TTATAA and is critical for promoter activity and for determining the exact point of RNA
chain initiation (Antoni et al., 1994; Alberts et al., 1989).
Binding of cellular transcription factors to the LTR allows transcription of the whole genome.
This transcript is then multiply spliced to produce short RNA transcripts of about 2 kilobases
long. These encode the regulatory proteins tat, rev and nef. Tat up-regulates the
transcription of early genes, through an interaction with an RNA 'stem-loop' structure called
the 'transactivation response element' (TAR), a sequence occurring in the LTR. This tat-
TAR interaction allows longer RNA transcripts to be produced, in larger amounts (Rosen,
1992; Greene, 1992; Antoni et al., 1994).
The assembly of infectious HIV-1 virions requires structural and enzymatic proteins. The
'switch' between transcription of early and late gene products depends on rev. Rev exerts
its regulatory activity post-transcriptionally, by activating the nuclear export of unspliced and
singly spliced HIV-1 mRNA (encoding the gene products of gag, pol and env, and viral
ssRNA). Rev functions through interaction with an RNA motif called the rev response
element (RRE), which is another stem-loop structure located in the env gene. Due to mRNA
splicing, RRE is only present in the RNA species whose expression is controlled by rev. An
absence of rev produces unspliced and singly spliced mRNAs that remain and are degraded
in the nucleus (Greene, 1992; Rosen, 1992; Antoni et al., 1994).
Aggregation of the ribonucleoprotein core in the cytoplasm is followed by acquisition of the
lipid bilayer and addition of the env proteins at the cell surface. The final budding of the
virion through the plasma membrane of the cell, occurs by the cleavage mediated by HIV-1
protease and myristoylation of pl7. Vpu promotes efficient release of budding virus from
the cell surface (Greene, 1992; Subbramanian and Cohen, 1994).
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1.1.4 CELLULAR TROPISM OF HIV-1
HIV-gpl20 was shown to interact with the CD4 molecule (Dalgleish et al., 1984; Klatzmann
et al., 1984; Maddon et al., 1986), and HIV-1 was found to have the ability to infect cells
(particularly T lymphocytes) which expressed CD4. This correlated with the observations
that these cells were dramatically decreased in the first cases of AIDS (Gottlieb et al., 1981;
Centers for Disease Control, 1982). HIV-1 has also been isolated from other lymphoid cells
such as monocyte-macrophages (Pantaleo et al., 1993), B cells (Monroe et al., 1988) and
follicular dendritic cells (Embretson et al., 1993). HIV-1 has also been isolated from other
tissues such as the brain (Wiley et al., 1986; Cheng-Mayer et al., 1987) and from
haemopoietic cells (Folks et al., 1988).
Virus isolates of HIV-1 can differ in their biological properties, including their ability to
infect cells (Cheng-Mayer et al., 1990). The third hypervariable region (V3 loop) of gpl20
is thought to determine the cellular tropism of a particular viral isolate (Cann et al., 1992).
Virus isolates which preferentially infect macrophages (macrophage- or M-tropic viruses) but
also infect activated T cells in peripheral blood, are present within an individual throughout
HIV-1 infection. It is these variants which are transmitted (Wolinsky et al., 1992) and which
play a role in establishing primary HIV-1 infection (Zhu et al., 1993; Popovic and Gartner,
1987). M-tropic variants do not infect T-cell lines and are non-syncytium-inducing (NSI) in
culture (Schuitemaker et al., 1991). Viruses which preferentially infect T-cell lines (T-cell-
or T-tropic) are syncytium-inducing (SI), i.e. they form giant multi-nucleated cells in culture.
These variants have been isolated from some individuals after they have been infected for
some time. The emergence of an SI variant has been associated with disease progression
(Schuitemaker et al., 1992). Amino acid changes which increase the net positive charge of
the V3 loop are thought to be responsible for the change in virus phenotype from NSI to SI
(de Jong et al., 1992).
HIV-1 has also shown an ability to infect cells that do not express CD4 (Harouse et al., 1991;
Tateno et al., 1989) and an inability to infect cells that express high levels of CD4 (Maddon
et al., 1986; Evans et al., 1987). Therefore, other receptors are required for HIV-1 entry into
cells. These have now been identified as the receptors for chemotactic peptides, known as
the a- and [J-chemokines. These chemokines attract other cells: a-chemokines attract
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neutrophils, whereas (3-chemokines attract lymphocytes. The receptors for these chemokines
have been described as GTP-binding proteins (G proteins), which are folded in such a way
to give seven transmembrane domains (Feng et al., 1996). The receptors for a-chemokines
are denoted C-X-C-chemokine receptors (CXCR), while the receptors for P-chemokines have
been denoted as C-C-chemokine receptors (CCR). The cell tropism of the viral strains has
an effect on which receptor type is used for virus entry into cells. M-tropic viruses use the
CC-chemokine receptors, CCR5 being the receptor originally described for viral entry (Deng
et al., 1996; Dragic et al., 1996), although there is some evidence that other receptors in this
family may be used (Doranz et al., 19%; Choe et al., 1996). Conversely, T-tropic viruses
use the CXCR4 receptor, also known as Fusin, for viral entry (Alkhatib et al., 1996).
1.2 HIY-1 INFECTION IN ADULTS AND CHILDREN
1.2.1 TRANSMISSION OF HIV-1
Transmission of HIV-1 in adults, occurs through sexual contact or through exposure to
contaminated blood and blood products. AIDS was first described in homosexual men
(Gottlieb et al., 1981; Centers for Disease Control, 1982), and although heterosexual
transmission accounted for only a small proportion of cases, these were particularly reported
in the sexual partners of those in high risk groups (Harris et al., 1983; Masur et al., 1982).
Since then, many cases of heterosexual transmission have been described (Centers for Disease
Control, 1991). In the developing world, the most common route of HIV-1 transmission is
through heterosexual contact (Chin, 1990).
AIDS was soon identified in haemophiliacs and HIV-1 has been isolated from concentrated
factor VIII, made before heat treatment of batches was introduced (Zhang et al., 1991).
Many haemophiliacs treated with contaminated factor VIII were infected with HIV-1
(Simmonds et al., 1988). Similarly, blood transfusion associated transmission of HIV-1 also
occurred. Since the introduction of blood donor screening for HIV-1 antibodies, the
transmission of HIV-1 through blood products and transfusions is rare (Donegan et al., 1990).
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Intravenous drug users (IVDUs) are another defined group of people at risk of HIV-1
infection, particularly when needle-sharing is common (Robertson et al., 1986; Brettle et al.,
1987). Needle-stick injuries have also been described as a route of HIV-1 transmission
(Lange et al., 1990). In all of these routes, transmission appears to depend on different
factors, particularly the viral load of the index case (Lange et al., 1990).
1.2.1.1 Mother-child transmission of HIV-1
Vertical transmission from mother to child during pregnancy, child-birth or through breast¬
feeding is the cause of most paediatric HIV-1 infection. Mother-child transmission of both
HIV-1 and HIV-2 has been reported (European Collaborative Study, 1991; European
Collaborative Study, 1992; Blanche et al., 1989; Morgan et al., 1990). The transmission rate
is estimated as the number of HIV-infected children expressed as a percentage of the total
number of children born to HIV-infected mothers in a defined cohort. Transmission rates in
different cohorts have been estimated at between 13 and 39% of the total children (European
Collaborative Study, 1991; European Collaborative Study, 1992; Blanche et al., 1989;
Morgan et al., 1990). Factors affecting the transmission of virus have been reported to
include low maternal CD4 count (Ryder et al., 1989; Blanche et al., 1989) and p24
antigenaemia (Ryder et al., 1989). In some cohorts a protective effective of maternal anti-
gpl20 antibodies has been seen (Peuchmar et al., 1991; Devash et al., 1990), but this has not
been confirmed in other studies (Halsey et al., 1992). A more recent study indicated that
transmission was more dependent upon the tropism of the maternal HIV strain: monocytes-
macrophages from uninfected children, born to HIV-1-infected mothers, were uninfectable
in vitro with the virus isolated from their mother (Ometto et al., 1995). The timing of
transmission (i.e. early or late in pregnancy, or at birth) is not clear. Studies on foetal or
placental material have been contradictory: virus has been isolated from 8-week gestation
foetuses (Lewis et al., 1990) and from 12 week foetuses (Backd et al., 1993) suggesting that
transmission occurs early in pregnancy. However, in these studies, possible contamination
by maternal blood was not excluded (Brossard et al., 1995). Other studies suggest that
transmission occurs later on in pregnancy (Brossard et al., 1995; Ehrnst et al., 1991;
Peuchmar et al., 1991) or at delivery. Strong evidence for infection at delivery has been
shown by a study of twins, which indicated that exposure to maternal blood and mucous
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during delivery could increase transmission, as the first-born of twins discordant for HIV-1
infection was more likely to be infected (Goedert et al., 1991). This was further supported
by studies that showed that Caesarean section, as opposed to vaginal delivery, decreased the
transmission rate (European Collaborative Study, 1992; Goedert et al., 1991). More recently
prophylactic AZT treatment of the mother during the last trimester of pregnancy, and of the
child during the first six weeks after birth, has been shown to reduce the transmission of
HIV-1 (Sperling et al., 1996), also indicating that transmission occurs late on in pregnancy.
Post-natal transmission through breast-feeding, estimated at approximately 15% has also been
reported (European Collaborative Study, 1992; Blanche et al., 1989; van de Perre et al.,
1991), which is supported by the isolation of HIV-1 from colostrum (Vonesch et al., 1992).
1.2.2 LABORATORY DIAGNOSIS OF HIV-1
HIV-1 infection is diagnosed, in adults, with an anti-HIV-1 antibody test using enzyme-linked
immunosorbent assay techniques and confirmed by western blotting (Margolick et al., 1992;
Simmonds et al., 1988). The polymerase chain reaction (PCR) or virus culture from
peripheral blood mononuclear cells (PBMCs) are techniques used for confirmation of HIV-1
infection.
Diagnosis of HIV-1 infection in children cannot depend on the detection of antibodies, due
to the presence of maternal antibodies. These are passively transferred across the placenta
late on in pregnancy and can persist for up to 18 months of age. After this time, any
circulating anti-HIV-1 antibody is presumed to be the child's own response to HIV-1
infection, and thus its presence can be used diagnostically (Centers for Disease Control,
1987). Other techniques have been developed to diagnose HIV-1 infection as soon as
possible after birth. The most widely used are PCR (de Rossi et al., 1991; de Rossi et al.,
1992; Rogers et al., 1989), the culture of HIV-1 from PBMCs (Eschaich et al., 1991; Kline
et al., 1993; de Rossi et al., 1991), and p24 antigen levels (de Rossi et al., 1991; Rogers et
al., 1989). Comparison of these techniques has shown PCR to be more sensitive than virus
culture (Eschaich et al., 1991; de Rossi et al., 1991), which in turn was found to be more
sensitive than p24 antigen assays (Kline et al., 1993; Rogers et al., 1989). Other techniques
have been developed, such as in vitro antibody production (Amadori et al., 1988), IgA-
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specific anti-HIV-1 antibodies (Weiblen etal., 1988), and enzyme-linked immunospot assays
(Nesheim et al., 1993), but these have been found not to be as sensitive or reliable (de Rossi
et al., 1991). In some children, diagnosis was not possible at birth, although, in all these
assays, sensitivity increased with age. Thus, a negative result is not necessarily diagnostic
of the absence of HIV-1 infection (Cassol et al., 1992; de Rossi et al., 1991; Rogers et al.,
1989), but may be a reflection of the timing of vertical transmission. Bryson et al., (1992)
defined in utero transmission of HIV-1 as having occurred if HIV-1 can be detected in cord
or peripheral blood within 48 hours of birth, using co-culture or PCR techniques. Likewise,
they defined intrapartum transmission of HIV-1 as having occurred if HIV-1 cannot be
isolated from cord or peripheral blood during the first week of life, but can be isolated
subsequently, and if the child was not breast-fed.
1.2.3 CLINICAL MANIFESTATIONS OF HIV-1 INFECTION
In approximately 5-10% of HIV-1-infected adults, an acute viral illness similar to infectious
mononucleosis, has been described, with distinct clinical features including fever, lethargy,
headache and lymphadenopathy (reviewed in Tindall and Cooper, 1991). After primary
infection there is usually a period where the individual is clinically asymptomatic, as is
common in lentiviral infections. The length of this asymptomatic period varies between
people (Bird, 1992). Non-specific signs and symptoms, e.g. persistent generalised
lymphadenopathy (PGL), tend to appear with increasing frequency before the onset of more
severe infections resulting from compromised immune function. Diseases associated with the
onset of AIDS include opportunistic infections e.g. Pneumocystis carinii pneumonia (PCP),
cytomegalovirus infection (CMV), toxoplasmosis, oesophageal candidiasis; neoplasms e.g.
Kaposi's sarcoma, non-Hodgkins lymphoma and an increased incidence of bacterial and
mycobacterial infections (Moore et al., 1991; Farizo et al., 1992). Other symptoms include
an increased incidence of allergies (Carr et al., 1991), abnormal endocrine function
(Grinspoon and Bilezikian, 1992), cardiomyopathy (Cohen et al., 1986) and haematological
abnormalities (Doweiko, 1993). AIDS indicator diseases occur with similar frequencies
within different risk groups, but the spectrum of diseases may be different between risk
groups, and may reflect other socio-economic differences of these populations, unrelated to
HIV-1 infection (Margolick et al., 1992; Farizo et al., 1992). For example, an increased
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incidence of bacterial infections (pneumonia, sepsis, pulmonary mycobacteria) is seen in
IVDUs compared to other risk groups (Farizo et al., 1992; Selwyn et al., 1992). Kaposi's
Sarcoma is seen almost exclusively in homosexual men. There is evidence this is caused by
another infectious agent belonging to the Herpes family of viruses (Kaposi's sarcoma herpes
virus or human herpes virus 8), and that this is also transmitted sexually (Volberding, 1992;
Schalling et al., 1995).
In children, the clinical pattern of diseases is different from that seen in adults. In particular,
a biphasic clinical pattern of HIV-1-disease progression has been noted in perinatally infected
children: those who progress to AIDS and die within about two years of birth, and those who
progress more slowly (Galli et al., 1995; European Collaborative Study, 1991; Dulidge et al.,
1992; Blanche et al., 1994). In one study, children who had been defined as infected in
utero, were also those who progressed more quickly (Dickover et al., 1994). Other studies
have suggested that the rate of progression is due to the virus strain transmitted and,
therefore, the rate of progression in the child is directly related to that of the mother (Tovo
et al., 1994; Blanche et al., 1994). The spectrum of clinical disease in children is different
from that found in adults. In children an increased incidence of recurrent bacterial infections
is seen (The National Institute of Child Health, 1991). Encephalopathy, cardiomyopathy and
failure to thrive are more common in infected children than in adults (Brouwers et al., 1995;
Lipshultz et al., 1992). The range of opportunistic infections is also different from that seen
in adults: an increased incidence of candidiasis, PCP and lymphocytic interstitial pneumonia
(LIP, pneumonia associated with an influx of lymphocytes in the interstitial spaces) is seen,
with a decreased incidence of toxoplasmosis and CMV infections (Neumann et al., 1994;
Turner et al., 1993; Tovo et al., 1992; Scott et al., 1989).
Onset of an AIDS-defining illness in a child within 6 months of birth, particularly PCP and
lymphoma, has a very poor prognosis (Galli et al., 1995; Turner et al., 1993; Tovo et al.,
1992; Scott et al., 1989). However, the diagnosis of LIP or bacterial infections, within the
same time period, does not have the same severe prognosis and the child could live for
several years (Italian Register for HIV Infection in Children, 1994). The onset of clinical
signs is significantly later in longer surviving children but the occurrence of severe diseases
still occurs (Galli et al., 1995; Italian Register for HIV Infection in Children, 1994).
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1.3 THE IMMUNE SYSTEM AND RESPONSES TO HIV-1
1.3.1 INNATE IMMUNITY
The main components of the innate, or natural, immune system are physical barriers, such
as skin and mucosal surfaces, non-lymphoid cells such as granulocytes, mast cells,
macrophages and Complement. Granulocytes are phagocytic cells which contain bactericidal
enzymes. These cells are involved in the clearing of extracellular bacteria. Mast cells and
basophils have granules that contain potent mediators, which are released on encounter with
an allergen, to induce an inflammatory immune response. Natural killer (NK) cells are
involved in killing tumour cells or virally-infected cells. These demonstrate cytotoxic activity
without the need for prior activation. Macrophages and monocytes have a central role as
antigen presenting cells. These cells phagocytose or endocytose bacteria and viruses, and
process the bacterial or viral antigens. Peptides derived from these antigens are presented on
the surface of the cells to T lymphocytes in such a way that antigen-specific responses can
be elicited (see 1.3.2.2.1). Formation of antibody-antigen complexes can lead to the
activation of the Complement system. This is a complex system of enzymes and plasma
glycoproteins which act in an enzyme cascade in inflammatory reactions. These reactions
ultimately lead to the destruction of bacteria or cells by lysis.
Acquired immunity is antigen-specific and develops in response to the different antigens
encountered. The major effector cells of specific immune responses are the lymphocytes.
These are found mainly within lymphoid tissues, but a proportion circulate through peripheral
blood. Lymphoid tissues include the thymus, spleen, tonsils, regional lymph nodes and gut-
associated lymphoid tissue (GALT), such as Peyers patches and the appendix. These tissues
are important in generating and maintaining the many antigen-specific responses required
from lymphocytes in a mature immune system. Lymphocytes are broadly classed into T and
B lymphocytes.
1.3.2 ACQUIRED IMMUNITY AND RESPONSES TO HIV-1
17
1.3.2.1 B Lymphocytes
B lymphocytes (B cells) develop from haemopoeitic stem cells. During development, a
complex series of differentiation events, including gene rearrangement, leads to the expression
of immunoglobulin (Ig) on the cell surface. Activation by antigen allows the B cell to
differentiate further into an antibody-secreting cell (a primary antibody response, also known
as seroconversion) or a memory cell. Re-stimulation of the resting memory cell, by the same
antigen, leads to more antibodies being produced (a secondary antibody response). The
secondary response occurs more rapidly, and produces larger quantities of high affinity
antibodies than the primary response. There are 5 classes of antibody produced by B cells :-
(i) IgG is the most abundant class of antibody, and is important in the secondary
immune response to antigens. This is the only class of antibody which crosses the
placenta during pregnancy, and is important in the neonate during the first weeks of
life. This antibody binds to antigens to form antibody-antigen (immune) complexes.
When this occurs on the surface of bacteria, this is known as opsonisation. The
opsonised bacteria are then removed by macrophages or lysed by Complement.
(ii) IgA covers all the external mucosal surfaces and secretory IgA occurs in mucosal
secretions. This is the primary antibody in mucosal immunity and is particularly
important in the gut and lungs.
(iii) IgM is the antibody initially formed on the surface of B cells. Further maturation of
the B cell leads to expression of IgD. IgM is a potent activator of the Complement
system.
(iv) IgD acts almost exclusively as membrane receptors for antigen.
(v) IgE is primarily involved in immunity against parasitic infections and allergic
reactions and binds to mast cells causing a release of histamines.
Antibodies to HIV-1 can be detected within approximately two weeks of exposure (Ariyoshi
et al., 1992), with antibodies to different HIV-1 proteins actively being produced from B cells
(Vendrell et al., 1991; Delfraissy etal., 1992). Increased anti-p24 antibody is associated with
a better clinical outcome than anti-gpl20 at seroconversion (Cheingsong-Popov et al., 1991).
Neutralising antibodies are defined as those which block the infectivity of the virus in vitro
(Poignard et al., 1996). Neutralising antibody epitopes have been mapped on gpl20, and
include the V3 loop, the V1/V2 segment, the C4 domain, the CD4-binding site and epitopes
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which are unmasked once gpl20 has bound to CD4 (reviewed in Poignard et al., 1996). An
epitope has also been defined on gp41 and is denoted the 2F5 epitope (Poignard et al., 1996).
However, many of these neutralisation sites were analysed using laboratory-adapted strains
of HIV-1 (Weiss et al., 1986; Broliden et al., 1993). Only a specific CD4-binding site
epitope and the 2F5 epitope have been found to cross neutralise a broad spectrum of primary
isolates (Poignard et al., 1996).
1.3.2.2 Cell mediated responses
1.3.2.2.1 Antigen presentation
To elicit a cell mediated response, the antigen has to be presented to T lymphocytes in a
certain way so as to be recognised by the effector cell. Antigen presenting cells (APCs)
process antigens in two different ways, depending on the source of the antigen (reviewed in
Germain and Margulies, 1993). These are outlined in figure 1.3, which shows the different
pathways for processing exogenous and endogenous antigens.
Exogenous antigens (e.g. bacteria, viruses that have not infected cells, extracellular proteins)
are endocytosed into the APC. These are degraded in endosomes (an intracellular
compartment) by proteases to produce peptides. The peptides are translocated to another
compartment, called the MHC class II compartment (MIIC), which contains the major
histocompatibility complex (MHC) class II molecule. The MHC class II molecule consists
of an a-chain and a 6-chain, which, when associated non-covalently, make a groove into
which peptide can bind. When in the endoplasmic reticulum (ER), these a- and B- subunits
form a non-covalendy bound trimer with a glycoprotein called invariant chain (Ii) (Germain
and Margulies, 1993). MHC class II (i.e. the a/B/Ii trimer) is transported from the ER,
through the golgi to the MIIC. There the peptides derived from the exogenous antigen are
loaded onto the groove, displacing the invariant chain, and are then transported to the cell
surface (Germain and Margulies, 1993). There the peptide-MHC class II complex can be
recognised by T cells expressing CD4, to induce an immune response.
















intracellular microbial proteins) are degraded in the cytosol by a proteosome. The resultant
peptides, usually about nine amino acids long, are then transported into the rough ER. This
is accomplished by a heterodimeric, membrane-associated 'transporter of antigenic peptides'
(TAP). Once in the ER, the peptides encounter the newly synthesised MHC class I molecule,
which consists of a glycoprotein heavy chain, non-covalently associated with a small
glycoprotein called 8-2 microglobulin. 8-2 microglobulin is not anchored to the membrane
and can exist either in association with the MHC class I heavy chain, or free in plasma and
tissue fluids. The heavy chain is folded in such a way as to produce three domains: the a-1
and a-2 domains form a groove into which peptides of approximately nine amino acids can
bind, while the a-3 domain binds CD8. The heavy chain requires the binding of 8-2
microglobulin and peptide for release from the ER into the Golgi. The bound peptide-MHC-
class I complex is then transported through the Golgi, into a secretory vesicle and thence to
the cell surface (Germain and Margulies, 1993). Once at the cell surface, the bound peptide
is recognised by T cells expressing CD8, to induce an effector response.
HIV-1 infection of macrophages (Pantaleo et al., 1993; Zhu et al., 1993) and dendritic cells
(reviewed in Cameron et al., 1996) could affect their ability to present antigen to T cells.
Cultured dendritic cells infected with HIV-1, have been reported to transmit HIV-1 to co-
cultured autologous T cells, in the presence of an immune stimulant (Tsunetsugu-Yokota et
al., 1995; Cameron et al., 1996).
1.3.2.2.2 T lymphocytes
T lymphocytes develop from precursor cells in haemopoietic tissue. These migrate to the
thymus, where the cells undergo differentiation into one of two lineages: those that express
CD4 (CD4 cells) or those that express CD8 (CD8 cells). T cells differ from B cells in that
T cells only recognise antigen which has been processed by APCs. Other cell surface
molecules are also necessary for the interaction of the T cell with APCs or its target cell,
such as the leucocyte function antigen (LFA-1, or CD 11a) interaction with the intercellular
adhesion molecule (ICAM-1, Paul, 1993).
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1.3.2.2.2.1 CD4 cell responses
CD4 cells recognise peptide antigens presented by MHC class II molecules. The T-cell
receptor (TCR) associates with the CD4 molecule to form a complex which recognises the
peptide presented on the MHC class II molecule. The recognition of antigen by the CD4
molecule causes signal transduction acting through intracellular tyrosine kinases. This results
in activation of the CD4 cell and the subsequent production of cytokines (low molecular
weight 'messenger peptides'). Initial studies in the mouse showed that the influence of
different cytokines levels on this activated CD4 cell allowed it to differentiate into either a
T-helper 1 (Th-1) cell or a T-helper 2 (Th-2) cell. Th-1 cells produce interleukin 2 (IL-2)
and gamma-interferon (IFN-y), whereas Th-2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13.
Figure 1.4 shows the affect of cytokine production on the differentiation of CD4 cells, and
the subsequent affect of cytokines on other cells (Kemeny et al., 1994; Kos and Engleman,
1996; Mosmann and Sad, 1996; Romagnani, 1992). The production of Th-1 cytokines is
associated with responses mediated by effector cells, whereas Th-2 cytokines are associated
with responses mediated by antibodies, secreted factors or Complement (Clerici and Shearer,
1993). The cytokine production is mutually inhibitory, in that Th-1 cytokines inhibit the
production of Th-2 cytokines and vice versa (see figure 1.4). The dichotomy of the T-helper
responses is important in the immune responses to different pathogens. Th-1 responses are
effective against protozoa, fungi, bacteria and viruses, and are involved in autoimmunity and
transplant rejection. Th-2 responses are effective against parasites, are involved in allergic
reactions and in the control of pregnancy (Mosmann and Sad, 1996).
CD4 responses can be, to a certain extent, assessed by the use of proliferation assays to
specific exogenous soluble antigens. The addition of exogenous antigen to PBMCs in
culture, allows the APCs present to process the antigen for recognition by CD4 cells. The
CD4 cells become activated and release cytokines, activating other cells in the culture. The
resulting level of proliferation is then measured by the incorporation of 3H-thymidine into
replicating DNA. The total proliferative capacity of T cells can be assessed by measuring
the responses to T cell mitogens such as phytohaemagglutinin (PHA). This is a plant lectin
which acts by stimulating the TCR, but the ability to do so is dependent on the expression
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In HIV-1 infection, the depletion or dysfunction of CD4 cells increases the likelihood of
opportunistic infections. Many studies have assessed the function of PBMCs in vitro, before
the loss of CD4 cell numbers in vivo. Proliferative responses to recall antigens such as
Tuberculin purified protein derivative (PPD), tetanus toxoid (IT), Candida antigens,
diphtheria toxoid (DT), Cryptococcus antigens and influenza antigens have all been studied
and found to be reduced in HIV-1-infected adults (Pontesilli et al., 1995; Ranki et ai, 1989;
van Noesel et al., 1990; Hoy et al., 1988; Clerici et al., 1989) and children (Borkowsky et
al., 1990; Chirmule et al., 1995). Proliferation to HIV-1 antigens has been found in a small
proportion of HIV-1-infected adults (Pontesilli et al., 1995; Ranki et al., 1989) and children
(Borkowsky et al., 1990). Lymphoproliferative responses to mitogens such as
phytohaemagglutinin (PHA), pokeweed mitogen (PWM) and anti-CD3 antibodies (a-CD3)
are lost later in disease in adults (Hoy et al., 1988; van Noesel et al., 1990; Janossy et al.,
1993; Graters et al., 1991; Hoffman et al., 1989) and children (Chirmule et al., 1995). A
pattern of lymphoproliferative defects has been established in asymptomatic adults before
CD4 cell loss is seen: recall responses to HIV-1 are lost first, then to other antigens, followed
by responses to allogenic antigens, followed by responses to mitogens (Janossy et al., 1993;
Clerici et al., 1989), PWM responses being lost before PHA responses (Hoffman et al.,
1989). The loss of proliferative responses is associated with an increased likelihood of
clinical progression (Giorgi et al., 1987; Chirmule et al., 1995). Several mechanisms to
explain the loss of proliferative function have been postulated, such as a switch from the
production of Th-1 to Th-2 cytokines by CD4 cells (Clerici and Shearer, 1993), although Th-
2 cytokine production has also been found to be dysregulated (Diaz-Mitoma et al., 1995).
Another possible mechanism is the selective loss or dysfunction of memory cells (Janossy
et al., 1993; van Noesel et al., 1990; Graters et al., 1991) possibly through infection of these
cells with HIV-1 (Schnittman et al., 1990; Cayota et al., 1990; Cayota et al., 1993), though
this has not been found in all studies (Giorgi et al., 1987; Hoy et al., 1988).
1.3.2.2.2.2 CD8 responses
CD8 cells recognise peptide antigens (of approximately nine amino acids long) which are
presented by MHC class I molecules. These peptides, which fit into the peptide binding
groove of the class I molecule, have amino acid motifs which are specific for that particular
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HLA-type (Nixon and McMichael, 1991). Particular amino acids bind the peptide into the
groove (anchor residues), while other residues interact with the T-cell receptor (Paul, 1993).
It has also been shown that MHC processing and presentation of peptide can be mimicked
using exogenous synthetic peptides corresponding to the epitope sequence (Townsend et al.,
1986). In addition, amino acid changes within an epitope can abolish a specific CTL
response (Townsend et al., 1986), either by preventing the binding of peptide to the HLA
molecule (Couillin et al., 1995), by non-recognition by the effector cells (Phillips et al., 1991)
or by antagonising the CTL response to the corresponding wild type variant (Klenerman et
al., 1994; Bertoletti et al., 1994).
The recognition of peptide leads to activation of the CD8 cell which subsequently can mature
and differentiate into a cytotoxic T lymphocyte (CTL). A second co-stimulatory signal is
required and occurs through the interaction of a surface molecule, CD28, with its ligand B7,
usually expressed on APCs. Differentiation of CTLs requires IL-2, normally produced from
Th-1 cells (see figure 1.4) (Paul, 1993). The exact mechanism by which mature CTLs kill
target cells is not clear (Paul, 1993), but various mechanisms have been postulated: the CTL
binds to its target cell and releases cytotoxic granules containing perforin, a potent cytolytic
protein. The release of other cytokines, or the induction of apoptosis (programmed cell
death), are other mechanisms by which cell lysis may occur (Paul, 1993).
CTL responses are measured by the stimulation of PBMCs in culture, using specific or non¬
specific stimuli. Target cells express the specific viral antigens and are labelled with 51Cr
chromium. The ability of the CTLs to recognise and lyse target cells is measured by the
release of 51Cr into culture supernatant.
CTL activity, mediated by MHC-restricted CD8 cytotoxic T lymphocytes has been found in
HIV-1 infection, to both structural and regulatory gene products (Watret et al., 1993;
Lamhamedi-Cherradi et al., 1992; Walker et al., 1988; Walker et al., 1987; Hoffenbach et
al., 1989; Koup et al., 1989; Ho et al., 1993). CTLs detected soon after infection with HIV-1
are involved in the control of primary viraemia (Borrow et al., 1994; Lamhamedi-Cherradi
et al., 1995). These are maintained during the asymptomatic phase of infection, but are lost
with disease progression (O'Toole et al., 1992; Pantaleo et al., 1990a). Specific CTL
epitopes have been mapped in different proteins (Nixon et al., 1988; Brander et al., 1995).
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CTL activity is mediated by (phenotypically) activated cells expressing CD38 and HLA-DR
(Ho et al., 1993; Watret et al., 1993; Pantaleo et al., 1990a; van Baalen et al., 1993). Loss
of CTL activity has been associated with several mechanisms, such as an inability of cells
to clonogenically expand in vitro (Pantaleo et al., 1990a; Pantaleo et al., 1990b; Watret et
al., 1993), although it has been found that general cytolytic function is still present even if
HIV-1-specific lysis has decreased (Pantaleo et al., 1990a). Mutations within HIV-1, to
evade recognition of the virus by CTLs, have also been described (Phillips et al., 1991). In
addition, HIV-1 variants, with mutations at specific CTL epitopes have been found, which
prevent recognition of wild-type sequences by CTLs (Meier et al., 1995; Klenerman et al.,
1994).
The importance of CTLs in the immune response against HIV-1 infection has prompted
studies of infusion of autologous cells into patients (Klimas, 1992; Herbermann, 1992;
Koenig et al., 1995). Preliminary results of studies which infused mitogen- or lymphokine-
activated cells showed good clinical responses in patients with AIDS (Herbermann, 1992;
Klimas, 1992). However, the infusion of a single CTL clone into a patient did not prevent
disease progression (Koenig et al., 1995). CTLs have been detected in various organs, such
as lung (Plata et al., 1987), cerebrospinal fluid (CSF) (Sethi et al., 1988), lymph nodes
(Hoffenbach et al., 1989), and spleen (Cheynier et al., 1994). Increased destruction of cells
by CTLs may contribute to the pathological damage seen in these tissues (Embretson et al.,
1993; Pantaleo et al., 1993; Zinkernagel, 1995). CTLs release cytokines on encounter with
their antigens which could affect the way in which other cells react to HIV-1, and possibly
increase HIV-1 transcription (Jassoy et al., 1993; Bollinger et al., 1993).
HIV-1-specific CTL activity has also been studied in children, but to a lesser extent than in
adults (Luzuriaga et al., 1991; Cheynier et al., 1992; Buseyne et al., 1993; McFarland et al.,
1994; Luzuriaga et al., 1995). In some studies, the CTL activity appeared to be of a similar
pattern to that found in adults (Cheynier et al., 1992; McFarland et al., 1994), whereas others
have found a less consistent detection pattern (Buseyne et al., 1993; Luzuriaga et al., 1991;
Luzuriaga et al., 1995).
CTLs are thought to lyse HIV-1-infected cells. However, CD8 cells have also been shown
to release an antiviral factor which suppresses HIV-1 replication in CD4 cells (Walker and
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Levy, 1989; Walker et al., 1989). This suppression was found to be non-MHC restricted,
mediated by a soluble factor and decreased with clinical progression of the individual
(Mackewicz et al., 1991; Mackewicz and Levy, 1992). There has been a suggestion that this
CD8 antiviral factor may be released by CTLs (Bollinger et al., 1993; Tsubota et al., 1989).
Candidates for this antiviral factor include IL-16 (Baier et al., 1995) and small chemotactic
peptides (p-chemokines), RANTES, MlP-la and MIP-lp (Cocchi et al., 1995). However,
although these have some anti-HIV-1 activity, these are not the same as the antiviral factor
originally described (Levy et al., 1996).
14 IMMUNOLOGICAL MARKERS OF HIV-1 DISEASE
PROGRESSION
Although it was thought that viral latency was a feature of the asymptomatic phase of
infection, it is now clear the virus is actively replicating and causing pathological changes in
lymphoid tissue (Pantaleo et al., 1993; Embretson et al., 1993). This was also indicated by
the rapid turnover of CD4 cells and plasma virions (Ho et al., 1995; Wei et al., 1995)
although peripheral blood cell numbers are maintained. It has been suggested that these cell
numbers were maintained by proliferation of the cells rather than replenishment from the
thymus (Ho et al., 1995).
As was found in the earliest cases, those who presented with AIDS-defming illnesses had
very few circulating CD4 cells (Gottlieb et al., 1981; Centers for Disease Control, 1982). As
the decrease in CD4 cell count, in peripheral blood, occurs later on in the asymptomatic
phase of HIV-1 infection, it can therefore be used as a predictor of onset of AIDS (Phillips
et al., 1992). However individual CD4 cell count variability can make these measurements
less reliable (Aledort et al., 1992; Hoover et al., 1992). In both adults and children different
serological, virological and immunological factors have been extensively studied to identify




Total immunoglobulin (Ig) levels have been studied in individuals. These, particularly IgA
levels in serum, have been found to increase with disease progression, a phenomenon found
in both adults (Fernandez-Cruz et al., 1990; Chaisson et al., 1992) and children (d'Arminio
Montforte et al., 1990). Specific anti-HIV-1 antibodies have been found to be lost with
disease progression in both adults and children, and are associated with an increased risk of
severe clinical disorders (Fernandez-Cruz et al., 1990; Dulidge et al., 1992; van de Perre et
al., 1992).
Measurement of substances which are reflective of cell turnover, such as 8-2 microglobulin
(the light chain subunit of the MHC-class I molecule) and neopterin (a compound derived
from stimulated macrophages), are also increased in the serum of both adults and children
with disease progression and decreased CD4 counts (Fernandez-Cruz et al., 1990; Fahey et
al., 1990; Chaisson et al., 1992; Ellaurie et al., 1992).
1.4.2 VIROLOGICAL MARKERS
An increased viral load, as measured by plasma RNA levels, or the ability to culture HIV-1
from plasma or cells (Eschaich et al., 1991; Venet et al., 1991; Bouscarat et al., 1996), and
increased HIV-1 replication (Michael et al., 1992) all appear to be associated with clinical
disease progression and decreased CD4 levels. In both adults and children, p24 antigenaemia
has also been found to be increased with low CD4 levels in some studies (Ellaurie et al.,
1992; Fernandez-Cruz et al., 1990) but not in others (Italian Register for HIV Infection in
Children, 1994; Dulidge et al., 1992; Venet et al., 1991). Direct comparison of plasma p24
and viral RNA in children undergoing anti-retroviral therapy showed that these markers do
not vary in the same way (Bush et al., 1996), implying that the p24 levels could include
levels of antigen from defective virus, whereas RNA levels are more indicative of viral
replicative ability.
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1.4.3 LYMPHOCYTE SURFACE MARKERS
The expression of different antigens on the surface of CD4 and CD8 lymphocytes has been
shown to be associated with particular cellular functions. These antigens and their associated
functions are summarised in table 1.2. There appears to be a large amount of overlap in the
expression of different antigens on the same cells. No one surface marker is definitive for
a particular function. For example, there is not a 'memory' phenotype as such, but both
CD45RO and CD1 la (and other antigens) have been described as being expressed on memory
cells (Sanders et al., 1988a).
The expression of these markers in HIV-1 infection have been assessed at different stages and
are summarised in table 1.3. The measurement of the expression of two antigens may be
more informative or predictive of disease progression, than the measurement of single
antigens. For example, an increase in CD8 cells expressing HLA-DR, but not CD38, is found
in asymptomatic infected adults and long term survivors (Giorgi and Detels, 1989; Ho et al.,
1993; Giorgi et al., 1994), while an increase in CD8 cells expressing CD38, but not HLA-
DR, is associated with onset of AIDS in adults (Levacher et al., 1992). However, anti-HIV-1
specific CTLs are been shown to be CD8 cells that express both CD38 and HLA-DR (Ho et
al., 1993). The increased CD8 cell number seen in HIV-1 infection, has been reported to be
due to an increase in the proportion of phenotypically activated and memory effector cells,
expressing CD45RO, CD38, HLA-DR and CD57 (Choremi-Papadopoulou et al., 1994;
Vingerhoets et al., 1995; Landay et al., 1993; Kestens et al., 1994; Prince and Jensen, 1991)
and a decreased proportion of CD8 cells expressing CD28 or CD45RA (Borthwick et al.,
1994; Landay et al., 1993; Prince and Jensen, 1991).
1.5 HIV-1-EXPOSED INDIVIDUALS
HIV-1 has been detected by PCR and in situ hybridisation in individuals who remained
negative to HIV-1 antibodies (Pezzella et al., 1989). There have also been reports of children
born to HIV-1-infected mothers, from whom HIV-1 has been detected by PCR or isolated by
culture and who have later become seronegative (European Collaborative Study, 1991; de
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Table 1.2 Expression of lymphocyte surface markers
Antigen Expression and functional role
CD45 Leucocyte common antigen. Different isoforms are expressed through
differential splicing of the mRNA (Wallace and Beverley, 1990; Clark and
Ledbetter, 1989). The antigen has tyrosine phosphatase activity in the
cytoplasm which is involved in cell signal transduction.
CD45RO The isoform of CD45 expressed on memory or immunologically primed T
cells (Akbar et al, 1988; Sanders etal., 1988b; Merkenschlager et al., 1988;
Akbar et al., 1991; Beverley, 1990; Sanders et al., 1988a). Determines
cytokine release from CD4 cells (Akbar et al., 1991). Expressed on
cytotoxic CD8 effector cells (Vanham et al., 1991; Merkenschlager and
Beverley, 1989; de Jong et al., 1991). Memory cells recirculate through the
tissues to lymph node (Picker et al., 1993; Mackay, 1991).
CD45RA Isoform of CD45 expressed on immunologically naive cells (de Jong et al.,
1991), which once primed, express the CD45RO moiety through a CD45RA+
CD45RO+ double positive intermediate (Akbar et al., 1988; Akbar et al.,
1991; Beverley, 1990; Picker et al., 1993; Yamashita and Clement, 1989).
This unidirectional switch appears to be true for CD4 cells, but not CD8 cells
(Sohen et al., 1990; Rabin et al., 1995; Okumura et al., 1993; Scala et al.,
1995). Elimination of stimulating antigen may allow the CD45RO cells to
revert to CD45RA cells, while retaining memory for antigen (Beverley,
1990). These cells induce CD8 cells to suppress immunoglobulin production,
hence called 'suppressor-inducer' cells (Akbar et al., 1988; Merkenschlager
and Beverley, 1989; Morimoto et al., 1985; Schnittman et al., 1990). Naive
lymphocytes recirculate through high endothelial venules to the lymph node
(Picker et al., 1993; Mackay, 1991).
HLA-DR Product of the DR locus of MHC class II gene. Detectable on macrophages
and B cells, and induced on immunologically activated T cells (Pantaleo et
al., 1990b; Ziegler-Heitbrock et al., 1988; Miyawaki et al., 1991; Picker et
al., 1993).
CDlla a chain of leucocyte function antigen 1 (LFA-1). Initially described as
being able to differentiate between CD8 cells with cytotoxic and suppressor
functions, based on the intensity of expression (Sohen et al., 1990; Morimoto
et al., 1987). Expressed on memory cells (Rabin et al., 1995; Picker et al.,
1993; Sanders et al., 1988a).
CD57 Expressed on T cells and NK cells (Remy et al., 1991; Yabuhara et al.,
1990; Wang et al., 1994). Cells expressing this marker are important against
viral infections (Bonagura et al., 1992). Suppresses generation of EBV-
specific CTL through a cell-mediated action (Wang et al., 1994). Possibly
a marker for suppressor or anergic T cell subpopulations (Wang et al., 1994).
CD38 Normally expressed on activated or immature T and B cells and monocytes
(Kestens et al., 1992; Giorgi and Detels, 1989; Fletcher et al., 1992;
Ziegler-Heitbrock et al., 1988; Picker et al., 1993; Malavasi et al., 1994).
Possibly involved in cell activation and/or cell adhesion (Malavasi et al.,
1994).
CD28 Expressed at low level on thymocytes, more so on T cells and is up-regulated
by activation, with an increase in Th-1 cytokine production and CD25 (the
IL-2 receptor) expression (Linsley and Ledbetter, 1993). Interacts with the
B7 ligand on APCs; acts as a co-stimulatory signal for T cell activation,
required for antigen-specific T cell responses (Linsley and Ledbetter, 1993).
Absence of CD28 co-stimulation leads to T cell anergy and/or clonal
inactivation (Linsley and Ledbetter, 1993), which can be reversed on addition
of IL-2 (Vingerhoets et al., 1995; Linsley and Ledbetter, 1993). Signal
transduction occurs through calcium-dependent and -independent pathways.
Functions of antigens expressed on the surface of lymphocytes
Table 1.3 Lymphocyte surface markers in HIV-1 infection
Antigen Change seen in HIV-1 infection
CD4 Number and proportion of CD4 cells decreased at seroconversion (Zaunders
et al., 1995) and further decrease with disease progression (Levacher et al.,
1992; Zaunders et al., 1995). Onset of AIDS associated with low CD4 cell
number.
CD8 Proportion and number of CD8 cells increased at seroconversion (Yagi et al.,
1991; Zaunders et al., 1995) and throughout disease (Giorgi and Detels,
1989; Scala et al., 1995; Zaunders et al., 1995). Loss of CD8 cells seen
before onset of AIDS (Margolick et al., 1995).
CD45RO Decreased expression on CD4 cells of adults in some studies (Shearer and
Clerici, 1991; van Noesel et al., 1990; Klimas et al., 1991; Zaunders et al.,
1995) but not in others (Giorgi and Detels, 1989; Vanham et al., 1991;
Watret et al., 1993; Kestens et al., 1994). Expressed on CD4 cells which
were found to be preferentially infected with HIV-1 (Schnittman et al., 1990;
Cayota et al., 1990). Expressed on CD4 cells which also show an increased
expression of CD38 and HLA-DR (Choremi-Papadopoulou et al., 1994;
Kestens et al., 1994), which correlated with a decreased CD4 level and
presence of HIV-1 antigen (Kestens et al., 1994). Increased expression on
CD8 cells of both adults and children (Froebel et al., 1991; Plaeger-Marshall
et al., 1993; Rabin et al., 1995; Watret et al., 1993; Bouscarat et al., 1996;
Landay et al., 1993). Cells also show increased co-expression of CD38 or
HLA-DR (Bouscarat et al., 1996; Choremi-Papadopoulou et al., 1994; Prince
and lensen, 1991; Zaunders et al., 1995) and CD57 (Prince and lensen,
1991).
CD45RA Decreased expression on CD4 cells of adults and children in some studies
(Plaeger-Marshall et al., 1993; Plaeger-Marshall et al., 1994; Zaunders et al.,
1995), no change in others (Fletcher et al., 1992). Decreased expression on
CD8 cells of both adults and children (Plaeger-Marshall et al., 1993; Rabin
et al., 1995; Scala et al., 1995; Landay et al., 1993; Plaeger-Marshall et al.,
1994; Prince and Jensen, 1991; Roederer et al., 1995; Zaunders et al., 1995).
HLA-DR Increased expression on CD4 and CD8 cells of adults and children (Vanham
et al., 1991; Kestens et al., 1992; Ziegler-Heitbrock et al., 1988; Giorgi and
Detels, 1989; Pantaleo et al., 1990b; Miyawaki et al., 1991; Bouscarat et al.,
1996; Levacher et al., 1992; Landay et al., 1993; Kestens et al., 1994;
Plaeger-Marshall et al., 1994; Prince and Jensen, 1991; Zaunders et al.,
1995; Stites et al., 1989). This increased expression is less marked with the
onset of AIDS (Levacher et al., 1992). Expressed on CD8 cells which
thought to be responsible for suppression of HIV-1 replication (Landay et al.,
1993).
CD1 la Increased expression on CD8 cells of adults (Watret et al., 1993; Cavallin et
al., 1993; Scala et al., 1995; Zaunders et al., 1995). Possible relation to
increased IgG production due to decreased number of suppressor cells
(Morimoto et al., 1987; Cavallin et al., 1993). Increased proportion of CD8
cells expressing CD45RA and CDlla seen which correlates to decreased
CD4 levels (Scala et al., 1995).
CD57 Increased expression on CD8 cells of both adults and children
(Ziegler-Heitbrock et al., 1988; Kestens et al., 1992; Bouscarat et al., 1996;
Levacher et al., 1992; Gupta, 1986; Plaeger-Marshall et al., 1993; Landay et
al., 1993; Plaeger-Marshall et al., 1994; Prince and Jensen, 1991), with
decrease in NK activity (Gupta, 1986). Suppresses anti-HIV-1 CTL activity
and replication (Joly et al., 1989; Plaeger-Marshall et al., 1992). Also
suppresses NK and LAK activity through release of a soluble factor
(Sadat-Sowti et al., 1991).
CD38 Increased expression on CD4 and CD8 cells of both adults and children
(Kestens et al., 1992; Bird and Watret, 1992; Plaeger-Marshall et al., 1993;
Landay et al., 1993; Kestens et al., 1994; Plaeger-Marshall et al., 1994).
This increase correlates with disease progression and can be used in disease
staging (Giorgi et al., 1994; Bouscarat et al., 1996; Levacher et al., 1992;
Prince and Jensen, 1991). The level of co-expression of HLA-DR on CD8
cells expressing CD38 correlates with viral load (Bouscarat et al., 1996).
The intensity of CD38 expression on CD8 cells in children increased with
disease progression, and occurred on CD8 cells which were co-expressing
HLA-DR (Plaeger-Marshall et al., 1994). Expressed on anti-HIV-1-specific
CTLs (Ho et al., 1993).
CD28 Decreased expression on CD4 and CD8 cells of adults (Caruso et al., 1994;
Bouscarat et al., 19%; Choremi-Papadopoulou et al., 1994; Vingerhoets et
al., 1995; Borthwick et al., 1994). Loss of CD28 expression parallels the
increase of HLA-DR, CD45RO and CD38 expression on CD4 cells but not
CD8 cells (Choremi-Papadopoulou et al., 1994).
Expressed on CD8 cells thought to be responsible for suppression of HIV-1
replication (Landay et al., 1993).
Changes in antigen expression on lymphocytes as a consequence of HIV-1 infection
Rossi et al., 1991; Bryson et al., 1995; Roques et al., 1995; Rogers et al., 1989). This could
be due to infection with defective virus. However, there is evidence that active immune
responses occur in exposed individuals (including those from whom no evidence of HIV-1-
infection is seen) which may clear virus before infection becomes established (reviewed in
Rowland-Jones and McMichael, 1995). HIV-1-specific CTL activity has been detected in
adults (Langlade-Demoyen et al., 1994; Pinto et al., 1995) and children (Cheynier et al.,
1992; Luzuriaga et al., 1991; Rowland-Jones et al., 1993) as have lymphoproliferative
responses to HIV-1 antigens (Kelker et al., 1992; Borkowsky et al., 1990; Clerici et al.,
1994; Clerici et al., 1993b).
More recently, individuals have been identified who appear to be resistant to HIV-1 infection.
These individuals were first described as having high plasma levels of the P-chemokines
RANTES, MlP-la and MIP-lp (Paxton et al., 1996). Further investigation showed that they
have a 32 bp deletion in both alleles for the chemokine receptor CCR5, which causes aberrant
folding of the protein, leading to the non-expression of the receptor on the cell surface
(Samson et al., 1996; Liu et al., 1996). CCR5 has been shown to be the co-receptor for entry
of M-tropic viruses, and the cells from these individuals were found to be uninfectable with
M-tropic strains of HIV-1. Heterozygosity for this mutation (i.e. one normal allele and one
allele containing the 32 bp deletion), gives a lower level of expression of CCR5 on the cell
surface, but those receptors that are present allow the entry and replication of HIV-1 (Dean
et al., 1996; Huang et al., 19%).
16 EDINBURGH COHORT OF HIV-I-INFECTED DRUG
USERS
The Edinburgh cohort of HIV-1-infected intravenous drug users (IVDUs) has been studied
since 1985 when it was found that many were infected with HIV-1. Retrospective analysis
of stored blood samples showed that the first IVDUs were infected in 1983 and HIV-1 was
transmitted further by the sharing of needles (Robertson et al., 1986; Brettle et al., 1987).
Phylogenetic analysis of HIV-1 isolates from this cohort indicates that they were all infected
with a similar strain of HIV-1 (Holmes et al., 1995). Approximately one third of these drug
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users are women, some of whom have borne children since becoming infected with HIV-1.
The children are seen at regular intervals at a follow-up clinic (Mok et al., 1989a; Mok et al.,
1989b), when clinical, virological and immunological markers of disease are monitored.
1.6.1 IMMUNOLOGICAL STUDIES IN CHILDREN AND OVERVIEW OF
THESIS
As HIV-1 was first identified in homosexual men and was less widely spread in the
heterosexual population, most initial cohort studies were carried out in homosexual men.
Many functional studies have been performed in adults, analysing different immunological
responses (see 1.3). However, fewer studies of immunological function have been carried
out in children. Those which have been done, have been cross-sectional studies of one
particular aspect (e.g. CTL activity, lymphocyte surface marker expression or proliferative
responses). Longitudinal studies in children have, mostly, been confined to clinical studies
of the natural history of HIV-1 infection.
Children are born with an intact, but 'virgin', cellular immune system. Therefore, in the first
few months after birth, innate immune mechanisms such as NK cells (which do not require
prior activation to function) have an important role against infection (Yabuhara et al., 1990).
Maternal antibodies, which cross the placenta before birth, and the antibodies in breast milk,
particularly colostrum, would have some effect against specific antigens encountered during
this time, until the child is able to make antibodies for itself (Wilson, 1986; Pabst and Kreth,
1980). However, even these mechanisms may be reduced, compared to adult levels, as
different aspects of the immune system mature at different rates (Pabst and Kreth, 1980).
Exposure to different environmental, food and bacterial antigens, causes the immune system
to become activated and to develop immunological memory (Cummins et al., 1994; Pabst and
Kreth, 1980). Little is known about the development of cell-mediated responses in
immunologically naive individuals. The measurement of surface markers on lymphocytes,
in children, has indicated that the expression of some of these markers is age-related
(Hayward et al., 1989) and indicate the immaturity of these lymphocytes.
It was decided to prospectively follow the children born to the HIV-1-infected mothers in the
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Edinburgh IVDU cohort to investigate changes in T-cell mediated immunity, comparing those
in infected and exposed uninfected children. In addition, lymphocyte surface marker analysis
was performed to see whether changes in marker expression were related to clinical disease
progression.
The results of the lymphocyte surface marker analysis, together with the clinical profile of
the children, are presented in chapter 3. These are described first, as the functional responses
are related to clinical disease progression in the children. The main T-cell mediated response
studied was CTL activity, and these results are presented in chapter 4. As an example of
another T-cell mediated response, the proliferative capacity of the cells to different stimuli
is presented in chapter 5. During the study, one child was noted who had a disproportionate
level of CD3 cells compared to CD4 or CD8 cells. These cells were further investigated and
the results are presented in chapter 6. Chapter 7 brings all these results together and
discusses their relevance to each other, in the light of other studies in children.
Some of the data presented in this thesis has already been published, and the papers are
presented in the appendix. The data presented in the bulk of this thesis were collected by me,
whereas the published papers include data collected by other people as part of collaborative
studies on these children.
1.6.2 DEFINITIONS
Throughout this thesis several terms are used, in relating to children, which need to be clearly
defined.
HIV-1-INFECTED those children who have been confirmed to be infected with HIV-1
(see 1.2.2).
HIV-1 -exposed a term used for all children born to HIV-1-infected mothers,
including the known infected children. These children, by virtue of
their mothers HIV-l-status, are presumed to have been exposed to
HIV-1 in utero.
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Exposed uninfected those children, born to HIV-l-infected mothers, who have been
confirmed to be uninfected with HIV-1 and have lost all maternal
antibody.
Indeterminate those children, born to HIV-l-infected mothers, but who have not
lost maternal antibody. These children do not have any other
indicators of HIV-1 infection. During analysis of the results in this
thesis, children who were initially indeterminate were reclassified as
HIV-l-infected or exposed uninfected.
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2 0 GENERAL MATERIALS
2.0.1 CELL CULTURE REAGENTS
RPMI culture medium was obtained from Protein Fractionation Centre, Edinburgh, UK.
Penicillin/Streptomycin was obtained from Gibco, Life Technologies Ltd, Paisley, UK, and
stored at -20°C before use.
Glutamine was obtained from Gibco and stored at -20°C before use.
Foetal Calf Serum (FCS) was obtained from Globepharm Ltd, Esher, UK. This was heat
inactivated for 1 hour at 56°C before use and batch tested for growth of cell lines. The same
batch was used for CTL assays throughout this study, which was stored frozen at -20°C
before use.
RPMI denotes RPMI medium, containing Penicillin (100 units/ml), Streptomycin (100
pg/ml), and Glutamine (2 mM), and R10 denotes RPMI (as above) containing 10% (v/v)
heat-inactivated FCS.
Saline (0.9% w/v) was obtained from Baxter Healthcare Ltd, Thetford, UK.
Phosphate buffered saline (PBS) tablets were obtained from Oxoid, Unipath, Basingstoke,
UK. PBS was made up at 1 tablet/100 ml distilled water.
2.0.2 DISPOSABLE TISSUE CULTURE PLASTICS
Unless otherwise indicated, tissue culture materials were obtained from Costar, High
Wycombe, UK at tissue culture grade. These include:
stripettes (25ml, 10ml, 5ml, 2ml, 1ml)
clusters (6-,24-,48-,96-well)
flasks (225cm2, 75cm2, 25cm2)
filters (0.8pm, 0.45pm, 0.22pm)






Cryovials were obtained from Nunc (UK).
2.1 SEPARATION OF LYMPHOCYTES
Materials:
Lymphoprep (Nycomed, Birmingham, UK)
Saline
RIO
Heparinised whole blood was diluted 1:2 with saline and layered on to Lymphoprep (5ml)
in a 10ml tube, taking care not to mix the blood at the interface. The tubes were centrifuged
at 2100 rpm for 30 minutes, at room temperature, with the brake off. The buffy layer,
containing the peripheral mononuclear cells (PBMCs), was carefully removed with a pastette
and transferred to another 10ml tube. Sterile saline or PBS was added to make the volume
up to 10ml and the tubes were centrifuged again at 1700 rpm for 15-20 minutes. The cell
pellet was resuspended in 10ml saline and centrifuged at 1100 rpm for 5 minutes. The cell
pellet was then resuspended in R10 for use as required.




Freezing mix, which contains 40% (v/v) RPMI, 50% (v/v) FCS and 10% dimethyl
sulphoxide (DMSO).
Freezing box containing propan-2-ol, which controls the rate of freezing of the cells
to -1°C per minute when placed in a -70°C freezer (Nunclon, UK).
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Cells were spun down, washed in RIO and counted. The cell pellet was suspended in 1ml
freezing mix, transferred to a cryotube which was put into a freezing box. Cells were




Cells were thawed quickly at 37°C in a water bath and transferred to a 10ml tube. An equal
volume of RIO was added dropwise, with shaking. The cells were left to equilibrate over
several minutes. Another equal volume of RIO was added dropwise, with shaking. The cells
were left to equilibrate over several minutes. The cells were washed twice in RIO, counted
and used as required.
2.3 LYMPHOCYTE SURFACE MARKER ANALYSIS
2.3.1 TWO COLOUR ANALYSIS
Unless otherwise indicated, the antibodies were obtained from Becton Dickinson (BD),
Oxford, UK.
-PE denotes that the antibody was conjugated to phycoerithrin.
-FITC denotes that the antibody was conjugated to fluorescein isothiocyanate.
-RD1 denotes that the antibody was conjugated to rhodamine.
-PerCP denotes that the antibody was conjugated to peridinal chlorophyll protein
Materials:
A panel of antibodies was used (see below).
FACSLyse™ was obtained from BD
Saline or PBS
1% (w/v) paraformaldehyde in PBS (1% PAF)




Control anti-IgG 1 -PE/anti-IgG2-FITC
CD3/DR anti-CD3(Leu4)-PE/anti-HLA-DR-FITC








CD8/CD1 la anti-CDlla(S6Fl)-RDl/anti-CD8-FITC (Coulter, Luton,UK)
CD8/CD57 anti-CD8(Leu2a)-PE/anti-CD57(Leu7)-FITC
CD8/RA anti-CD8(Leu2a)-PE/anti-CD45RA(Leu 18)-FITC
Each antibody mix (lOpl) was added to diluted whole blood (lOOpl) in a separate round-
bottomed tube and incubated at room temperature for 15 minutes. Red cells were lysed by
the addition of FACSLyse™ (2ml) and incubating at room temperature for a further 10
minutes. The tubes were centrifuged at 1 lOOrpm for 5 minutes, washed in saline or PBS, and
centrifuged again. The cells were fixed in 1% PAF (400pl) and stored at 4°C until they were
analysed on a FACScan™ (BD) using the SimulSET™ programme (BD, detailed below).
2.3.1.1 SimulSET™ programme
This programme uses automatic instrument control settings to distinguish lymphocyte
populations from the other cell populations in whole blood. This is by virtue of the cell size
which is detected by the forward scatter (FSC), the cell granularity which is detected by side
scatter (SSC) and an antibody combination of anti-CD45 and anti-CD 14 (the leucoGATE™
tube). All leucocytes express CD45 (hence the leucocyte common antigen) but at different
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intensities. Lymphocytes and monocytes are of a similar size and granularity, but monocytes
are distinguished by the high intensity of expression of both CD 14 and CD45. Lymphocytes
do not express CD 14. Granulocytes are recognised by their increased size, granularity and
by a lower intensity of expression of CD45 than that shown by lymphocytes. Once the
lymphocyte population had been defined a 'gate' was drawn around this population. For
subsequent tubes, all cells within this gate were counted and all other cells were regarded as
irrelevant. An example of the printout with these definitions is presented in figure 2.1.
The control tube used irrelevant antibodies to correct for background staining. The simulset
programme automatically set markers, such that less than 1% of the cells were above
background staining. These markers were used for subsequent tubes to define those cells
which expressed the antigen being studied. The percentage of the cells within the
lymphocyte gate which fell into each quadrant was automatically given by the programme.
Quadrant 1 contained those cells which were only expressing the antigen detected by the PE-
conjugated antibody; quadrant 2 contained cells which were expressing both the antigens of
interest; quadrant 3 contained the cells which were not expressing either of the antigens of
interest; quadrant 4 contained those cells which were only expressing the antigen detected by
the FITC-conjugated antibody (see fig 2.1)
Throughout these experiments the percentage of CD4 (or CD8) cells which co-expressed the
antigen of interest was calculated:
percentage of CDX+ CD4 cells = CDX+ CD4 x 100
total CD4
where the value for CDX+ CD4 is from quadrant 2, and the total CD4 value was obtained
by addition of quadrant 2 to quadrant 1 or 4, depending on the fluorochrome used for CD4
in that particular antibody combination.
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Figure 2.1 SimulsSET™ Software
An example of the printout obtained from the SimulSETTM software for the a)
LeucoGATE™, b) Control tubes, and c) the CD3/CD4 tube.
a) LeucoGATE™ tube.
The left hand box shows the forward (FSC) and side-scatter (SSC). The leucocyte
populations are indicated within this box: the lymphocytes are shown as the green population,
the monocytes as the red population, the granulocytes as the blue population and cell debris
in pink. The line drawn around the green population is the lymphocyte gate.
The right hand box shows the staining of the cells which fell within the lymphocyte gate.
The y-axis shows the staining from anti-CD 14, and the x-axis shows the staining from the
anti-CD45. A few contaminating cells show the differences in staining for the respective
populations: the red population (monocytes) stained well for both antibodies. A few
granulocytes (blue population) are shown to the left of the main lymphocyte (green)
population. These granulocytes do not stain for anti-CD 14. The intensity of staining for
anti-CD45 was less for granulocytes than that for the lymphocytes. The cell debris did not
stain for either anti-CD14 or anti-CD45.
b) Control tube
This box shows the non-specific background staining of the cells. Markers have been set
such that 99% of the cells are unstained and fall within quadrant 3. The quadrants are
shown. The numbers (denoted %L) are the percentages of the gated lymphocytes which fell
into each quadrant.
c) CD3/CD4 tube
This box shows the way in which the gated lymphocytes expressed CD3 and CD4, above the
background staining set by the markers . The cells within quadrant 1 (upper left) are those
which expressed CD4 but not CD3. The cells within quadrant 2 (upper right) are those cells
which expressed both CD3 and CD4. The cells within quadrant 3 (lower left) are those
which expressed neither CD3 nor CD4. The cells within quadrant 4 (lower right) are those
which expressed CD3 but not CD4. The numbers (denoted %L) are the percentages of the
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FSC Mean : 121 Gated Events : 2352
SSC Mean : 12 Total Events : 10000
2.3.2 THREE COLOUR ANALYSIS
2.3.2.1 Two-step method
This was carried out in two steps, using two layers of antibodies.
Materials:









These were all obtained from Dr. G. Janossy, Royal Free Hospital, London, UK.
The second layer antibodies were:
goat-anti-mouse-FITC
streptavidin-Tricolour
These were obtained from Bradsure Biologicals, Market Harborough, UK





The second layer antibody was:-
streptavidin-Tricolour
The first layer antibody mix (lOpl) was added to diluted whole blood (lOOpl) and incubated
at room temperature for 10 minutes, then the cells were washed in saline and centrifuged at
1500 rpm for 5 minutes. The second layer antibody mix (10pl) was added and incubated for
10 minutes at room temperature. FACSLyse™ (2ml) was added and incubated at room
temperature for 10 minutes, following which the cells were centrifuged at 1100 rpm for 5
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minutes, washed in saline, and centrifuged again at 1100 rpm for 5 minutes. The cells were
then fixed in 1% PAF (400]il) and stored at 4°C until analysed on FACScan™ using the
LYSIS™II and PAINT-a-GATE™ programmes (BD).
2.3.2.2 One-step method
This was carried out in the same way as above only using directly conjugated antibodies.








For both these antibody combinations, a control tube was set up, using the antibodies from
the two-colour analysis.
The antibody mix (lOpl) was added to diluted whole blood (lOOpl) and incubated at room
temperature for 15 minutes. FACSLyse™ (2ml) was added and incubated at room
temperature for 10 minutes. The cells were centrifuged at 1100 rpm for 5 minutes, washed
in saline, and centrifuged again at 1100 rpm for 5 minutes. The cells were fixed in 1% PAF
(400pl) and stored at 4°C until analysed on FACScan™ using the LYSIS™II and PAINT-a-
GATE™ programmes (BD).
2.3.2.3 LYSIS™II and PAINT-a-GATE™ Programmes
Cells were acquired on a FACScan™, using the LYSIS™II programme (BD, instrument
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control settings were those defined by Dr. M. Armitage). As in the two-colour analysis a
lymphocyte gate could be defined by size and granularity of the cells (from FSC and SSC).
The control tube was used to adjust the detector settings, so that the background fluorescence
on each channel (FL-1, FL-2 or FL-3) was less than 10.
The cells were analysed using the PAINT-a-GATE™ programme (BD), which uses
overlapping colours to identify different populations of cells expressing one or more of the
antigens of interest. Histograms were used to define background values from the control
tube, for each fluorescent channel (FL-1, FL-2, FL-3) and markers were set. As in the two-
colour analysis, the markers were used to define cells expressing the antigens. The
'autopainf facility within PAINT-a-GATE™ allowed cells expressing more than one antigen
to be defined by different colours and the percentage of cells expressing each colour was
automatically calculated. As in the two-colour method, the percentage of CD8 cells
expressing one or more antigen was calculated using the same equation (2.3.1).
2 4 GENERATION OF EBV-TRANSFORMED B CELL LINES
Materials:
Epstein-Barr Virus (EBV) supernatant from B958 Marmoset cell line (obtained from
S. Lockett). B958 cells were cultured to confluence and then starved (i.e. fresh
medium was not added) for 7 days. The culture supernatant was collected and stored
in liquid nitrogen. A 1:10 dilution of the supernatant was found to transform 1 x 106
PBMCs, freshly isolated from cord blood (S. Lockett, personal communication).
RIO
Cyclosporin A (lOpg/ml)
Freshly separated PBMCs (as described in 2.1) were suspended in RIO (2ml) in a bijou.
EBV supernatant (200pl) and Cyclosporin A (20pl) was added. The cells were left for one
week, and then fed by removing medium (1ml) and replacing with fresh RIO (1ml). This
was repeated every week until the cells transformed. New cell lines were cultured for at least
two months from addition of EBV, to ensure that the cell-lines were established. Lines were
frozen down (at more than 1 x 107 cells/vial) and stored in the vapour phase of liquid
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nitrogen. B-cell lines, throughout this thesis, are referred to as the patient number with a
prefix of 'E', e.g. P125 goes to EP125. B cell-lines were thawed and grown up on receipt
of a sample for a CTL assay (see 2.6).





Crystal Violet (0.5% (w/v) in 20% methanol, and filtered through a 0.45pm filter)
Vaccinia constructs used in CTL assays (see 2.6.2.1).
0.25% (v/v) Trypsin (obtained from Gibco) in RPMI
TK143- cells were grown on a monolayer in 75cm2 flasks, one flask used for each construct
to be tested. Cells were trypsinised and washed in R10. Single cell suspensions were made
by pipetting cells vigorously. The cells recovered from each flask, were each resuspended
in R10 (30ml), divided into the wells of a 6-well plate and incubated overnight at 37°C.
Virus stock was diluted in RPMI in 10-fold dilutions from 1:103 to 1:1010. R10 was removed
from the cell monolayers in the 6 well plates. Virus (1ml) was added to each monolayer
using dilutions from 1:106 to 1:1010, with one well containing RPMI alone as a control. The
plates were incubated for 1 hour at 37°C, rocking every 10 minutes. Virus or medium was
removed and R10 (5ml) added, after which the plates were incubated at 37°C for 2-3 days.
The medium was removed and the cells fixed in 10% Formalin for 20 minutes at room
temperature. Crystal Violet was used to visualise plaques by adding for 2 minutes, after
which it was rinsed off with tap water. A well with a countable number of plaques was
identified and these were counted (y). The number of plaque forming units (pfu) is calculated
as y multiplied by the dilution factor.
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2.6 CTL ASSAYS
2.6.1 GENERATION OF CTL EFFECTOR CELLS
2.6.1.1 Co-culture of cells with autologous PHA-stimulated cells
Materials:
RIO
PHA-medium - RIO containing 5jjg/ml Phytohaemagglutinin (PHA-P)
Lymphocult (Biotest, UK)
Freshly separated PBMCs were suspended in RIO (1ml) in a 10ml tube. 10% (lOOpl) of the
cells were added to PHA-medium (1ml) in another 10ml tube. Both tubes were incubated
at 37°C for 2 days. The tubes were spun at 1100 rpm for 5 minutes, the cell pellets were
combined and resuspended in R10 (2ml) in a 24-well plate. This is counted as day 0 of
culture. The surrounding wells were filled with sterile distilled water (2ml) to limit
evaporation. The culture was incubated at 37°C for 7 days. Cells were put into a 10ml tube
and spun at 1100 rpm for 5 minutes. Supernatant was kept for cytokine analysis. The cells
were resuspended in R10 (2ml) containing 5% Lymphocult. Lymphocult was added (lOOpl)
every 3-4 days until the cells were used in a CTL assay. It was aimed for CTL assays to be
performed between 10 and 15 days after combination of cells in culture.
2.6.1.2 Peptide stimulation
R10
Peptides (of between eight and ten amino acids) of CTL epitopes (obtained as a gift
from Dr. Sarah Rowland-Jones, Institute of Molecular Medicine, Oxford).
Lymphocult
Interleukin-7 (IL-7) at a concentration of lpg/ml
Freshly separated PBMCs were suspended in R10 (2ml) in a 24-well plate. All the HLA-
specific peptides available (20pl of lmg/ml peptide solution) were added, according to tissue
type of cells. The surrounding wells were filled with distilled sterile water (2ml) to limit
Materials:
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evaporation. The plate was incubated at 37°C. Lymphocult (200pl) was added every 3-4
days until the cells were used in a CTL assay. It was aimed for CTL assays to be performed
after 14 days in culture.
On some occasions, IL-7 (50pl) was added to the peptide stimulated cultures on day 0 (i.e.
as the cells were stimulated) and then, concurrently with the addition of Lymphocult.




Vaccinia vectors: p55-gag from HIV-111IB (ARP253). Donated to the MRC
AIDS Reagent Programme, NIBSC, UK by Professor A.
McMichael and Dr. D. Nixon.
Wild type vaccinia, (vSC8), expressing 8-galactosidase.
Donated to the MRC AIDS Reagent Programme, NIBSC,
UK by Dr. B. Moss.
pol (VVTG3167), tat (VVTG3196) and env (VVTG1132)
from HIV-1bru. These were obtained from Transgdne,
Strasbourg, France.
These constructs were kindly grown by Prof. F. Gotch, Chelsea and
Westminster Hospital, London, UK.
51Cr Sodium Chromate (CJS4), Amersham Life Sciences, Amersham, UK.
The autologous B cell-line, corresponding to the sample in culture for CTL, was thawed and
grown as required. Cells were washed and resuspended at 1 x 106 cells/ml in RIO. 6 x 1ml
aliquots were put into 10ml tubes, and 1 x 106 pfu of each of the vaccinia-HIV constructs
added (1 construct per tube): gag, tat, pol, env, and vaccinia control, leaving one tube as a
medium control. These were incubated overnight at 37°C. Cells were washed twice in RPMI
and incubated with lOOpCi 5ICr for 1 hour at 37°C. Cells were washed three times in RPMI,





The same peptides used to stimulate the cells
The autologous B cell-line, corresponding to the sample in culture for CTL, was thawed and
grown as required. Cells were washed and resuspended at 1 x 105 cells/ml in RIO. 1ml
aliquots were put into 10ml tubes, one for each HLA-locus for which peptide was available
and incubated overnight at 37°C. These were spun down and incubated with lOOpCi 51Cr for
1 hour at 37°C. The cells were washed once in RPMI and 2pl of each peptide was added
to each of the tubes for each HLA-locus. Cells were incubated for 1 hour at 37°C, washed







'Spot-on' filtermats (1205/402), obtained from Wallac and Berthold, UK
Bags for filtermats, obtained from Wallac and Berthold
'B-Scint' for filtermats, obtained from Wallac and Berthold
Aliquots (lOOpl) of target cells were added to a 96-well U-bottomed plate in duplicate for
sample lysis. For spontaneous lysis, aliquots were added in quadruplicate to RPMI (lOOpl).
For total lysis, aliquots were added in quadruplicate to 5% Triton-X (lOOpl). The effector
cells were harvested, spun down and resuspended in RIO (2ml) and counted. The
effector:target (E:T) ratio was calculated by dividing the number of cells/ml by 5 x 104. If
the E:T ratio was less than 5:1, the assay was abandoned (except for peptide stimulated
effector cells). Cell suspension (lOOpl) was added to the duplicate wells of target cells. The
remaining effector cells were analysed phenotypically for effector cell populations as
described in 2.3, omitting the lysis step. The plate was incubated for 4 hours at 37°C.
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Supernatant (35pl) was carefully removed (so as not to disturb cells), dotted onto filter mats
and dried. When dry these were bagged and counted on a Betaplate scintillation counter
(Wallac-Berthold). Results were calculated as:
% specific lysis = (sample release - spontaneous release) x 100
(total release - spontaneous release)
Specific lysis of greater than 10% above medium or vaccinia controls was considered a
positive specific result.




Poly-L-Lysine diluted 1:4 in ultra-pure water
PBS
RPMI
Cold acetone:methanol (1:1) stored at -20°C
1% paraformaldehyde (w/v) in PBS (1% PAF)
1% bovine serum albumin (w/v) in PBS (1% BSA)
Parafilm
Mowiol mounting medium containing DABCO
mouse anti-tat antibody ADP3021 donated to the MRC AIDS Reagent project by
Dr. Helland and Dr. Szilvay, Bergen, Norway.
mouse anti-RT antibody ADP381 donated to the MRC AIDS Reagent project by
Dr. Ferns and Dr. Tedder, London, UK.
mouse anti-gpl60/gp41 antibody ADP306 donated to the MRC AIDS Reagent
project by Dr. Daniels, London, UK.
mouse anti-p55/pl8 antibody ADP315 donated to the MRC AIDS Reagent project




Photographic film (35mm) 1600ASA
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B-cells were infected with vaccinia-HIV constructs overnight as for the CTL assay targets
(see 2.6.2.1). A coverslip was used for each vaccinia-construct-infected line tested. One
coverslip was placed in each well of a 6-well plate. Poly-L-Lysine was added to a level
which covered the coverslip, and incubated at 37°C for 20-30 minutes. The coverslip was
washed 2-3 times in PBS, using a vacuum pump to remove the liquid. The plates were
allowed to dry in air for approximately 30 minutes. The vaccinia-construct-infected B cells
were spun down and resuspended in RPMI (500pl). The cells were placed on the coverslip
and incubated for 1 hour at 37°C. The cells were washed once in PBS, and excess cold
methanol/acetone was added for 2 minutes. The cells were washed twice in PBS, and excess
1% PAF was added and incubated at 4°C for 1 hour. The PAF was removed and excess 1%
BSA was added for 10 minutes at room temperature. A damp tissue was laid on a box lid,
and strips of parafilm were laid on top, labelled according to the wells in each plate. Drops
of diluted antibody (1:100 in PBS, 95pl) were placed on the parafilm, the appropriate
antibody for each construct. The coverslip was removed from the plate using forceps, drained
on a piece of tissue and placed cell-side down on top of the drop of antibody. The box lid
was then covered with foil and incubated at room temperature for 20-30 minutes. The
coverslip was "floated" off using PBS and a pastette (i.e. PBS was gently squirted under the
coverslip until it floated, as, if it was pulled off, the cells would be removed). The coverslip
was put back into the 6-well plate, which still contained the 1% BSA, cell-side up. The cells
were washed 2-3 times in PBS. Drops of diluted (1:100 in PBS) goat-anti-mouse-FITC
antibody (95pl) were placed on the parafilm, as before. The coverslip was removed from the
plate using forceps, drained on a piece of tissue and placed cell-side down on top of the drop
of antibody. This was all covered with foil and incubated at room temperature for 20-30
minutes. The coverslip was "floated" off using PBS and put back into the 6-well plate, still
containing the 1% BSA, cell-side up. The cells were washed 2-3 times in PBS. Microscope
slides were labelled and a drop of Mowiol was put onto the slide. The coverslip was drained
and placed cell-side down onto the Mowiol. The edges were sealed with nail varnish to




Cytokine kits for IL-2, IL-4, IL-6 and IFN-y were obtained from Genzyme and used
according to the manufacturers instructions.
2 8 PROLIFERATION ASSAYS
Materials:
RPMI containing 10% human AB serum (R10/AB)
3H-thymidine (TRA-310) obtained from Amersham, UK
Recombinant Tetanus Toxoid from Clostridium tetanii, obtained from Calbiochem
Novobiochem, UK.
Phytohaemagglutinin (PHA-P)
A 'cocktail' of recombinant HIV-1 proteins (rHIV cocktail) was made, all
recombinants obtained from the MRC AIDS Reagent Project. This cocktail
contained:-
recombinant HIV-1SF gpl20 (expressed in CHO cells), >90% pure. ARP629
(donated by Dr. K. Steimer, Chiron Corporation.)
recombinant HIV-1MN gpl20 (expressed in Baculovirus), >95% pure
ARP646.
recombinant HIV-1LAI/BRU gag p24 (expressed in Baculovirus), >90% pure.
ARP620.
recombinant HIV-1lav Reverse Transcriptase (p66) (expressed in E.coli)
ARP631.1 (donor Dr. D. Stammers, Glaxo Wellcome, UK.)
recombinant HIV-lniB nef (expressed in E.coli), >90% pure. EVA650 (donor
Dr.V Erfle, Munich, Germany.)
recombinant HIV-lIim tat (expressed in E.coli). >90% pure. EVA658 (donor
Dr. J. Raina, Agmed Corps, USA.)
Glass filtermats (1205/401) obtained from Wallac and Berthold
Bags for filtermats, obtained from Wallac and Berthold
'8-Scint' for filtermats, obtained from Wallac and Berthold
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Tetanus toxoid (TT) and PHA were made up at concentrations of 5pg/ml and lgg/ml, which
would give final concentrations in the assay, of 2.5jig/ml and 0.5pg/ml. The rHIV-1 proteins
were combined at concentrations of 2.5 and 0.5 jjg/ml of each protein, to give final
concentrations, in the assay, of 1.25pg/ml and 0.25pg/ml. Aliquots (lOOpl) of each
concentration of TT, PHA and rHIV cocktail were plated out into a 96-well U-bottomed plate
in quadruplicate, with medium in sexlicate as control. Freshly separated PBMCs were
counted and suspended in R10/AB at a concentration of lxlO6 cells/ml. Cells (lOOpl) were
added to each antigen. The plate was incubated at 37°C for 6 days, and then labelled with
3H-thymidine at lpCi/well, incubated for a further 18 hours, and harvested with distilled
water onto filtermats. The filtermats were dried, bagged and counted on a Betaplate counter.
For the medium control, the highest and the lowest counts from the six wells were discarded
and only four wells were used in the analysis. The geometric means for all the wells were
calculated for each stimulus and the medium control. The stimulation index was calculated
for all the stimuli as:-
stimulation index = geometric mean cpm of stimulus x 100
geometric mean cpm of medium




RIO containing 2.5pg/ml Polybrene (Aldrich, UK)
MT2 cell line
The MT2 cell line was maintained in RIO, in a log phase. Culture supernatants (0.5ml) were
obtained from Dr. M. Arnott, Medical Microbiology, University of Edinburgh. These were
separated PBMCs from children, which had been cultured with 2xl06 PHA-blasted donor
PBMCs. The cultures had been fed with fresh PHA-blasts every week and tested for p24
antigen. These supernatants were cultured with 0.25 x 106 MT2 cells in R10/2.5pg/ml
polybrene (2.5ml) in a 24-well plate. The other wells in the plate were filled with sterile
57
water (2ml) to reduce evaporation. The culture was incubated for 7 days at 37°C. The cells
were checked for syncytia formation using an inverted microscope. Culture supernatant (1ml,
including the cells) was transferred to fresh R10/2.5pg/ml polybrene medium (1.5ml) in a
clean 24-well plate. Cultures were discarded after 4 weeks.
2 10 REVERSE TRANSCRIPTASE (RT) ASSAY
Materials:
5X RT mix:-
750 mM potassium chloride, KC1
50mM magnesium chloride MgCl2
50mM Tris/HCl pH 8.0
2.5mM ethylene glycol tetraacetic acid EGTA
0.5% (v/v) Triton X-100
125pg/ml Bovine Serum Albumin (BSA)
10% ethane-diol in DEPC-water (0.1% diethyl procarbamine in distilled
water and sterilised)
This was made up in batches and stored at -20°C
lOOmM dithithreitol (DTT)
75pg/ml poly-rA-oligo-dT(12_18) (Pharmacia 27-7878-02)
1 pCi/well 3H-Thymidine-5'-Triphosphate (3H-TTP) (Amersham TRK324)
Trichloroacetic acid (TCA, 100% (w/v)) diluted to 10% (v/v) or 5% (v/v) in DEPC-
water.




70% methanol or ethanol (Hayman Ltd, Witham Essex,UK) AR grade
4ml round bottomed tubes
DEAE-impregnated filtermats (Wallac 1205/405)
Nitrogen gas
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The final volume (Vf) for 2.5X reaction mix was calculated for the number of samples to be
assayed. The figure in brackets is an example to give a final volume of 500pl of 2.5X
reaction mix.
1/10 Vf (50pl) of 3H-TPP was placed in a 4ml round-bottomed tube. Approximately half the
volume was evaporated off under a nitrogen gas stream to remove the ethanol. 1/20 Vf
(25pl) of DTT, 1/13.3 Vf (37.5pl) of poly rA-oligo-dT and 1/2 Vf (250pl) 5X RT mix was
added. The volume was made up to Vf with DEPC-treated water (162.5vil). 2.5X reaction
mix was added (lOpl/well) to the inner 60 wells of a 96-well V-bottomed plate. Samples
were assayed in triplicate, and at two concentrations (neat and diluted 1:3 in PBS). Sample
(15pl) was added to each well. The plate was sealed with a plate sealer and incubated at
37°C for 48 hours. The reaction was stopped with 10% TCA containing 50pg/ml RNA
(150pl/well). The plate was placed on ice for 15 minutes and then harvested with 5% TCA,
3% sodium pyrophosphate and 70% methanol in successive washes, onto DEAE-impregnated
filtermats. The filtermats were dried, bagged with scintillant and counted on a beta-plate
counter.
2 11 CELL SEPARATION USING MINIMACS COLUMNS
Materials:
PBS containing 0.2% BSA - staining buffer
PBS containing 0.5% BSA - running buffer
PBS
mouse anti-CD4 (QS410 supernatant obtained from Donald Innes)
anti-mouse-IgG immunomagnetic beads obtained from Binding Site, Birmingham,
UK.
Mini-MACS separation columns obtained from Eurogenics, UK.
Screw top tubes (2ml).
Cells were counted, a small aliquot was taken for FACScan analysis (see 2.3.1) and the rest
were suspended in staining buffer (lOOpl). CD4+ve cells were removed by positive
selection, i.e. an anti-CD4 antibody was added (1ml), mixed and incubated at 4°C for 40
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minutes. Cells were washed in PBS and resuspended in staining buffer (lOOpl). Magnetic
beads (20pl) were added, mixed and incubated for 10 minutes at 4°C. Cells were mixed
again and incubated at 4°C for a further 10 minutes. The cell/bead suspension was added to
a primed mini-MACS column fitted in the magnet, followed by running buffer (500pl) and
the fraction collected. The column was washed through with running buffer (2 x 500pl) and
collected into a 2ml tube. This was the 'negative' fraction (i.e. containing cells not
expressing CD4). The mini-MACS column was removed from the magnet and washed
through with running buffer (3 x 500pl), eluting the cells which were attached to beads into
another 2ml tube. This was the 'positive' fraction (i.e. cells expressing CD4). The cells were
centrifuged at 3000 rpm for 5-10 minutes. Supernatant was removed and the cell pellet was
snap frozen at -70°C ready for extraction.
2.12 EXTRACTION OF DNA AND RNA
2.12.1 EXTRACTION OF DNA/RNA
Materials:
TNE buffer 0.5% SDS + 10%
0.11M sodium chloride NaCl
55mM Tris pH 8.0
l.lmM etheylene diamine tetraacetic acid EDTA pH 8.0
0.55% sodium dodecyl sulphate SDS
TNE buffer 0.1% SDS
0.1M NaCl
50mM Tris pH 8.0
ImM EDTA pH 8.0
0.1% SDS
Phenol containing hydroxychinolin (lg/kg phenol) and saturated with T10E1
(Phenol/TE)
Chloroform:isoamyl alcohol 50:1 (v/v)
Phenol/TE:chloroform/isoamyl alcohol 1:1 (v/v)
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Conical screw cap tubes (1.5ml)
Fine-tipped pastette
A solution of TNE buffer 0.5% SDS containing lmg/ml proteinase K and 40pg/ml poly A
was made up from: 9 volumes of TNE buffer 0.5% SDS + 10% added to 1 volume of
proteinase K and 20pl/ml poly A. The solution was pre-incubated at 37°C for 10 minutes
to inactivate RNAases. The samples to be extracted (lOOpl plasma/serum/cell pellet) were
put into small conical tubes. TNE 0.5% SDS/proteinase K/poly A solution (0.4ml) was added
to each extraction tube. The tubes were vortexed thoroughly and incubated at 37°C for 2
hours. Phenol/TE (450pl) was added to each tube, vortexed thoroughly, and centrifuged at
13000 rpm for 15 minutes. The upper layer (water phase) was transferred, using a fine-tipped
pastette, to a fresh tube containing phenol/chloroform (1:1, 450pl) and TNE 0.1 SDS (75pl).
The tubes were vortexed thoroughly and centrifuged at 13000 rpm for 10 minutes. The water
phase was transferred to fresh tube containing 450pl chloroform:isoamyl alcohol, mixed
extensively and centrifuged at 13000 rpm for 10 minutes. The water phase was transferred
to a fresh tube containing 3M sodium acetate pH 5.2 (40pl). These were mixed, absolute
ethanol (800pl) was added and allowed to precipitate overnight at -20°C. The tubes were
centrifuged at 13000 rpm for 20 minutes. The DNA/RNA pellet was washed with 80%
ethanol (1ml) and centrifuged at 13000 rpm for 5 minutes. The precipitate was dried on a
hot block at 40°C, before resuspension in 20pl DEPC-water.
2.12.2 EXTRACTION OF RNA USING STRATAGENE MICRO RNA
ISOLATION KIT
Materials: (all the reagents were obtained as a kit from Stratagene, UK)
'Solution D', a denaturing solution containing guanidine isothiocyanate and 8-









Conical screw cap tubes (1.5ml)
Fine-tipped pastettes
Volume D is the volume of solution D used in the extraction. This volume is adjusted
according to the number of cells in the sample: lOOpl of solution D is required for every 106
cells processed, and all other reagent volumes are relative to volume D. The volume quoted
is that used for 1 x 106 cells, as an example.
Solution D (lOOpl) was added to extraction tubes containing the sample. To this 2M sodium
acetate (lOpl) was added. Water-saturated phenol (lOOpl) was then added, ensuring the
lower phenol layer was used. Chloroform:isoamyl alcohol was added (20pl). The tubes were
capped and vortexed vigorously. The tubes were centrifuged for 5 minutes at 14000 rpm so
that two phases were visible. The upper layer was transferred to clean tubes, using a fine-
tipped pastette. Glycogen was added as an RNA carrier (lpl). Isopropanol (lOOpl) was
added to the RNA solution and mixed well. The tubes were centrifuged at 14000 rpm for
30 minutes. The supernatant was removed and pellet washed in 200pl of 75% ethanol
(lOOpl), and the pellet dried on a hot block at 40°C rapidly. The RNA was resuspended in
20pl DEPC-water.





A small aliquot (5pl) of the resuspended RNA or DNA was diluted in DEPC-water (700pl).
The spectrophotometer was zeroed against DEPC-water at 260 and 280nm. The same cuvette
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was used for the sample. The absorbance at 260 and 280nm was measured for each sample
(Ausubel et al., 1997).
The amount of DNA (pg/pl) was calculated as:- A260 x 50 x dilution factor x 1000
The amount of RNA (pg/pl) was calculated as:- A260 x 40 x dilution factor x 1000
2.13 RT-PCR FOR CD4, ACTIN AND HIV-1
2.13.1 REVERSE TRANSCRIPTION OF mRNA TO cDNA
2.13.1.1 Reverse Transcription using AMV-RT
Unless otherwise indicated all materials are from Promega, Southampton, UK.
Materials:
RNA (0.5pg)
0.5pg oligo (dT)15 primer
RT buffer (50mM Tris-HCl pH 8.3, 5mM KC1, lOmM MgCl2, lOmM DTT, 0.5mM
Spermidine)
0.66mM dNTPs
13 U RNAsin (an RNAase inhibitor)
10 U AMV Reverse transcriptase
DEPC-water
0.5 ml Eppendorf tubes
GeneE Thermocycler (ABI, UK)
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. A control containing DEPC-water instead of RNA (RNA-ve) was
also used. The tubes were incubated on a thermocycler at 42°C for 1 hour.
63
2.13.1.2 Reverse Transcription using Expand™-RT
Materials:
0.5pg oligo (dT)15 primer
0.5pg RNA
DEPC-water to make up to total volume of 20pl
Reverse transcriptase buffer (50mM Tris-HCl; 40mM KC1; 5mM MgCl2; 0.5% Tween
20 (v/v), pH 8.3), obtained from Boehringer Mannheim, UK.
lOmM DTT, obtained from Boehringer Mannheim, UK.
0.66mM dNTP
13 U RNAsin (RNAase inhibitor)
50 U Expand™ Reverse transcriptase, obtained from Boehringer Mannheim, UK.
0.5ml Eppendorf tubes
GeneE Thermocycler
The RNA, oligo-dT primer and DEPC-water were combined in an eppendorf tube, and were
denatured at 65°C for 10 minutes on a thermocycler. The tubes were immediately cooled on
ice. The reagents were added to the tube, to give the final concentrations (as above). A
control containing DEPC-water instead of RNA (RNA-ve) was also used. The tubes were
incubated on a thermocycler at 42°C for 1 hour.
2.13.2 PCR FOR CD4
2.13.2.1 Primary PCR
Materials:
2pl cDNA (from 2.13.1)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
0.5pM CD4 primer (sense, see below)
0.5pM CD4 primer (antisense, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
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GeneE thermocycler
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. A control containing DEPC-water instead of cDNA (cDNA-ve) was
also used. The tubes were incubated on a thermocycler with the following programme:-
4 minutes at 94°C (denaturing)
1 minute at 94°C, 1.5 minutes at 50°C, 2 minutes at 72°C, for 30 cycles
10 minutes at 72°C (extension)
2.13.2.2 Secondary PCR
Materials:
2pl primary product (from 2.13.2.1)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
0.5pM CD4 primer (sense, see below)
0.5pM CD4 primer (antisense, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. These were incubated on a thermocycler using the same programme
as used in the primary PCR.
CD4 primer sequences
Sense CD4-1 5' CCA CAA TGA ACC GGG GAG TCC CTT TTA GGC (+,70bp)
CD4-3 5' GTG GTG CTG GGC AAA AAA GGG G (+,155bp)
CD4-5 5' GAC CTG AAG AAC AAG GAA GTG TC (+,837bp)
CD4-6 5' AGA TGG GCA AGA AGC TCC CGC (+,891 bp)
Antisense CD4-2 5' GCA CTG GCA GGT CTT CTT CTC ACT GAG (-,1416bp)
CD4-4 5' GGT GCC GGC ACC TGA CAC AGAA (-,1350bp)
All primers were synthesised by Oswel DNA Services, Southampton UK.
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Primer combinations:
Primary PCR: CD4-1 and CD4-2, giving a primary product of 1346bp
CD4-5 and CD4-2, giving a primary product of 579bp
Secondary PCR: CD4-3 and CD4-4, giving a secondary product of 1195bp
CD4-6 and CD4-4, giving a secondary product of 459bp
Primers CD4-1 - CD4-4 and PCR programme were obtained from Fomsgaard et al (1992).
Primers 5 and 6 were designed from the cDNA sequence as in Maddon et al (1985) (see
chapter 6).
When PCR reactions for CD4 were performed in parallel with those for HIV-1 and B-Actin,
the thermocycler programme for B-Actin was used (see 2.13.3).
2.13.3 PCR FOR ACTIN
2.13.3.1 Primary PCR
Materials:
2pl cDNA (from 2.13.1)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
lpM B-Actin primer pair (from Stratagene, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. A control containing DEPC-water instead of cDNA (cDNA-ve) was
also used. The tubes were incubated on a thermocycler with the following programme
(manufacturers recommendation):-
5 minutes at 94°C (denaturing)
5 minutes at 60°C (annealing)
1.5 minutes at 72°C, 45 seconds at 94°C, 45 seconds at 60°C, for 35 cycles
10 min at 72°C (extension)
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Actin primer sequences (obtained from Stratagene):
Sense 5' TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA (+, 1038bp)
Antisense 5' CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG (-, 1905bp)
These gave a product of 661 bp
2.13.3.2 Secondary PCR
Materials:
2pl primary product (from 2.13.3.1)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
0.25pM 6-Actin primer (sense, see below)
0.25pM B-Actin primer (antisense, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. These were incubated on a thermocycler using the same programme.
Actin primer sequences (synthesised by Oswel DNA Services, Southampton, UK):
Sense 5' GCC CTG GAC TTC GAG CAA GAG ATG GCC A (+, 1231 bp)
Antisense 5' CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG (-, 1905bp)
These gave a product of 501 bp
2.13.4 PCR FOR HIV-1
2.13.4.1 Primary PCR
Materials:
2pl cDNA (from 2.13.1)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
0.5pM HIV-1 primer (sense, see below)
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0.5pM HIV-1 primer (antisense, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
GeneE thermocycler
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. A control containing DEPC-water instead of cDNA (cDNA-ve) was
also used. The tubes were incubated on a thermocycler with the following programme:-
25 seconds at 94°C, 35 seconds at 55°C, 2.5 minutes at 68°C, for 30 cycles
7 min at 68°C (extension)
Primer sequences
Sense NARS 5' CTC TAG CAG TGG CGC CCG AAC AGG GG (+, 173bp)
Antisense 534A 5' CTA TGA TTA CTA TGG ACC AC (-, 5725 bp)
These gave a product of 215bp
2.13.4.2 Secondary PCR
Materials:
2pl primary product (from 2.13.41)
Taq polymerase reaction buffer (50mM KC1, lOmM Tris-HCl pH 9.0, 0.1% Triton
X-100)
0.5pM HIV-1 primer (sense, see below)
0.5pM HIV-1 primer (antisense, see below)
33pM dNTPs
2.5 U Taq DNA polymerase (Taq)
The above reagents were combined in 0.5ml eppendorf tubes, at the above concentrations in
a final volume of 20pl. These were incubated on a thermocycler using the same programme.
Primer sequences
Sense M661 5' CCA GAG GAG CTC TCT CGA CGC AGG (+, 217bp)
Antisense 534A 5' CTA TGA TTA CTA TGG ACC AC (-, 5725 bp)
These gave a product of 179bp
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Agarose (electrophoresis grade) obtained from Flowgen, UK
10X TBE buffer: 540g Tris Base
275g Boric Acid
200ml 0.05M EDTA pH 8.0
made up to 5 litres with distilled water. This was diluted as
required.
Ethidium Bromide (lOmg/ml)
A 1.3% agarose (w/v) solution in TBE buffer was made by heating the agarose in the buffer.
The solution was allowed to cool with mixing. While still liquid, ethidium bromide was
added (3pl/100ml agarose solution). The gel was poured on to a gel tray with combs as
required and allowed to set. The samples (lOpl) were loaded into each well, and a well for
for pGEM markers was also used. These markers give DNA bands of specific sizes: 2645bp,
1605bp, 1198bp, 676bp, 517bp, 460bp, 396bp, 350bp, 222bp, 179bp, 126bp, 75bp, 65bp,
51 bp and 36bp. The gel was put into a gel tank containing TBE buffer and run at 150V for
1.5 hours. The DNA was visualised on a UV light box and photographed.
2 14 DATA ANALYSIS
Throughout this thesis, data analysis and statistics were performed using either the Microsoft
Excel programme on Windows 3.1 Microsoft Office (copyright Microsoft Corporation), or
by using Minitab (Minitab Data Analysis Software, Minitab Inc., version 7.2, 1989).
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During the asymptomatic phase of infection in adults, despite a lack of detectable virus in the
periphery, HIV-1 has been shown to cause pathological changes within lymphoid tissue
(Pantaleo et al., 1993; Embretson et al., 1993). This is also indicated by the rapid turnover
of CD4 cells and plasma virions (Ho et al., 1995; Wei et al., 1995) although cell numbers
within peripheral blood are maintained. Those individuals who develop AIDS-defining
illnesses usually have very few circulating CD4 cells (Centers for Disease Control, 1982).
The CD4 cell count in peripheral blood decreases later on in the asymptomatic phase of HIV-
1 infection and can, therefore, be used as a predictor of the onset of AIDS, or for determining
the timing of prophylactic therapy for opportunistic infections (Phillips et al., 1992).
However, in some, AIDS can develop despite quite high levels of circulating CD4 cells,
while others can remain healthy with a negligible CD4 cell count (J.A. Whitelaw, personal
communication). In both adults and children different serological, virological and
immunological factors have been studied to identify prognostic markers, which would more
specifically predict the loss of CD4 cells and, hence, clinical progression.
The expression of different antigens on the surface of CD4 and CD8 lymphocytes is
associated with particular cellular functions (summarised in table 1.2). Many of these have
been assessed at different stages of HIV-1 infection in adults, both as markers of disease
progression and to identify antigen expression which may give some clues to the mechanisms
involved in the immunopathogenesis of HIV-1 (summarised in table 1.3).
In HIV-1-infected children there have been fewer studies of lymphocyte surface marker
expression. One complication of this type of study, is the fact that some of the markers are
indicators of cell maturity and the levels of expression change naturally with the increasing
age of the child (Hayward et al., 1989). For this reason, conclusions drawn from studies in
HIV-1-infected adults cannot be extrapolated to children. This study was undertaken to
monitor, longitudinally, the percentages of CD4 and CD8 T lymphocytes in peripheral blood,
together with the clinical pattern of HIV-1 infection in this cohort of children. The
expression of activation and memory markers on both CD4 and CD8 cells was also measured,
by dual-colour and triple-colour immunofluorescence, to ascertain whether the expression of
these markers differed from that in adults. The marker expression was related to the clinical
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pattern and the CD4 level, to determine whether any markers were indicative of HIV-1
infection in children, or predictive of disease progression.
One of the main problems encountered in studying children is the availability of normal
controls, as it is considered unethical to take blood from a child for a study from which it
will not directly benefit. To overcome this, residual peripheral blood samples were obtained
from 168 children (aged 0 - 122 months) who were HIV-1-uninfected, not suffering from any
immunological defect or infectious disease, and who had had blood samples taken for other
reasons. From these data, charts of centiles were calculated for the lymphocyte surface
markers studied here (by Professor G. Raab, Napier University, Edinburgh), which showed
the normal age-related changes seen in these markers (Aldhous et al., 1994a, appendix). The
data from the infected children were plotted on these charts, as shown in the results.
Part of the data (up to July 1994) has been published (Aldhous et al., 1996, appendix). The
data presented here includes and continues that study. Several children have now progressed
clinically.
32 METHODS
Lymphocyte surface markers were measured using dual- or triple-colour immunofluorescence
and flow cytometry (see 2.3.1 and 2.3.2 respectively). Briefly, diluted whole blood (lOOpl)
was incubated for 15 minutes with each antibody combination (lOyl) at room temperature.
After red cell lysis and washing in PBS, the cells were fixed in 1% paraformaldehyde in PBS.
Cells were acquired on a FACScan™ and analysed using SimulSET™, LYSIS™II and
PAINT-a-GATE™ programmes (Becton Dickinson), as described in 2.3.3.1 and 2.3.2.3.
33 RESULTS
The normal range charts were constructed as age-related centiles, the normal range being
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defined as those values which fall between the 3rd and the 97th centiles (Aldhous et al.,
1994a, appendix). Values for fifteen HIV-1-infected children were plotted on the normal
range charts for each marker, and the data presented for those which showed changes outwith
the normal ranges. Details of the children are outlined in table 3.1. This table includes the
route of infection, the age range over which the child was monitored and the overall clinical
status during the study period.
3.3.1 CD4 AND CD8 CELLS
3.3.1.1 CD4 cells
For each child, the percentage of lymphocytes expressing CD4 (CD4%) was plotted on the
normal range charts and are presented in figure 3.1 (a-c). The first and last CD4% recorded
are shown for each child in table 3.2, together with the relevant age-centile and the length
of time over which the children were studied. The highest and lowest CD4% observed are
also given, to show the range over which the CD4% fluctuated during the study period. The
children fell into three main groups and each group is presented separately:-
I Those children of greater than 60 months (5 years) of age, whose CD4% remained
steady (see figure 3.1(a), P6, P27, P69 and P121). Two of these can be classified
as long-term non-progressors as they had CD4% within the normal range (~10-25th
and ~3rd-5th centiles for P69 and P27 respectively) at 108 months (9 years) of age.
From table 3.2, the first and last CD4% for P6, P27 and P121 were within 2% of
each other, corresponding to the crossing of one centile. For P69, a drop of 10% was
seen which corresponds to the crossing of two centiles.
II Those children of over 60 months (5 years) of age whose CD4% decreased (see
figure 3.1(b), P92, PI 10, PI 16, CB and AF). Of these, three have died and one has
AIDS with recurrent Candida infections. From table 3.2, the first and last CD4%
showed a large decrease of over 20% for three of these children (P92, PI 10 and
PI 16), with a corresponding drop to below the third centile. For CB and AF, the
CD4% was consistently below the third centile. For all these children the
fluctuations appeared less than those seen in the children of group I.
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Table3.2
CD4and8percentagesi eripheralbloodfchil r n
ChildTimeofstudyCD4%f rst-la(range) ofchild(months)centiles*
P65719-(29-3) <3rd(5th-<3rd) P275829-(36-0) 5th-3rd(25th-< ) P69535-2(37-3) 25th-3rd( 0th-<3 ) P121542 -3(37- ) 5th-<3rd(25th-<3 ) P925826-(30-1) 5th-«3rd(10th-«3 ) PI105733-1(36-9) >10th-«3rd(25th«3r ) PI1642 -0(26-) 5th-«3rd(5th-«3 )
CD8%first-la(range) centiles+
CD4%grouping8
54-63(75) >97th-»97th(» 7th-97 ) 52-3 >97th 46-53 >97th 38-61 97th-»97th(59-42) (»97th-95t ) (59-41) (»97th-90t ) (61-38) (»97th-97t ) 43-53 >97th 35-57 95th-»97th 37-9 97th-90th(72-43) (»97th->97th) (68-2 ) (»97th-75t ) (65-33) (»97th-90t )
II II
II
CB154-6(6-3) «3rd( ) AF340-1( -) «3rd( ) P125485-31(52-23) 50th-10th(50th-3rd) P1313569-14(69- ) 97th-<3rd(97th-<3r ) P132266 -3(69) 90th-10th(90th-10th) P142197-21(28) <3rd(5th-r ) P1261349-8(49) 50th-«3rd(50th-«3r ) P1303419-2(24) «3rd(< -rd)
81-64(83) »97th->97th»97th->97th 59-3(7811) »97th-75th( 7th«3rd)
II II
27-41 75th-97th 18-30 10th-90th 22-30 >25th-<90th 26-53 50th->97th
(57-26) (»97th-75t ) (36-17) (97th-10 ) (32-2 ) (>90th-10t ) (53-26) (»97th-50t )
III III III III
49-9(295 ) >97th-»97th(75th»97t )
37-64(64) 95th-»97th(»97th-0t )
fast fast
Ill All the children of less than 60 months of age were, initially, grouped together (PI25,
PI26, P130, P131, P132, P142, see figure 3.1(c)). All, except one (P142), were
followed from birth. Four children had a CD4% below normal levels (PI26, PI30,
P131 and PI42). P131 showed a steadily decreasing CD4% from birth, but was
within normal ranges until 21 months of age. From table 3.2, it can be seen that this
child had the highest decrease in CD4%. PI42, whose first sample was received at
41 months of age, had a stable CD4% at just below the third centile. PI25 and
P132 have also decreased in CD4%, from the 50th and 90th centile, respectively, to
the 10th centile (table 3.2).
Two of these children (P126 and P130) were, subsequently, grouped separately, as
both had CD4% below the 3rd centile within 3 months of birth. PI26 died of AIDS
at 17 months, and P130 was developmentally delayed, though it is not clear whether
or not this is due to HIV-1. These children were classed as fast progressors (Dr. J.
Mok, personal communication) and are referred to as such for the rest of the study.
3.3.1.2 CD8 cells
For each child, the percentage of lymphocytes expressing CD8 (CD8%) was plotted on the
normal range charts. As for the CD4%, the first and last CD8% recorded are shown for each
child in table 3.2, together with the relevant age-centile. The highest and lowest CD8%
observed are also given, to show the range over which the CD8% fluctuated during the study
period. Figure 3.2 shows representative plots from the slow progressors: group I (P27), group
II (P92) and group III (P125). The CD8% from a fast progressor is also shown (P130). The
CD8% was found to be increased in all the older children (groups I and II) above the normal
range. The CD8% in the group I children remained steady, at or above the 97th centile. The
CD8% from the group II children was found to decrease, after the CD4% decreased, and up
to two years before death. In the group III (younger) children the CD8% crossed the 97th
centile at about 24 months of age. An exception to this was seen in the fast progressors, as
these children showed a CD8% above the normal range at a much earlier age (between 6 and
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3.3.2 CO-EXPRESSION OF ACTIVATION AND MEMORY MARKERS ON
CD4 AND CD8 CELLS
3.3.2.1 CD4 subpopulations
The percentages of CD4 cells co-expressing CD45RO, CD45RA or HLA-DR (CD4
subpopulations) were calculated and plotted on the normal range charts (data not shown).
The CD4 subpopulations remained within normal ranges throughout infection. There were
a few children who showed a sustained increase in the percentage of CD4 cells expressing
HLA-DR or CD45RO. These children were all from group II (P92, PI 16 and CB). The
increase in expression of these markers occurred after, or at the same time as the overall
CD4% started to decrease.
3.3.2.2 CD8 subpopulations
The percentage of CD8 cells co-expressing CD45RO, CD45RA, HLA-DR, CD1 la and CD57
(CD8 subpopulations) were calculated and plotted on the normal range charts. Figures 3.3(a-
e) show representative plots from group I (P27), group II (P92) and group III (PI25). The
results from a fast progressor are also shown (PI30).
With a few exceptions, the expression of CD45RO, CD45RA and HLA-DR on CD8 cells was
outwith normal ranges throughout the study in these children (see figures 3.3(a-c)). For
CD45RO, CD45RA expression, three children showed levels within normal ranges (P69,
PI 16 and P121, not shown) and for HLA-DR expression, two children (P69 and P121, not
shown) showed levels within normal ranges. In all the children the expression of CD1 la was
outwith the normal range throughout infection (see figure 3.3(d)). The levels of CD57
expression on CD8 cells were within the normal ranges for all, but one, of the children. The
exception was one of the fast progressors (P130), who showed markedly raised and sustained
levels above the 97th centile (see figure 3.3(e)). Another child (PI 16) fluctuated in and out






































3.3.3 CO-EXPRESSION OF CD38 AND CD45RO ON CD8 CELLS BY
TRIPLE-COLOURED IMMUNOFLUORESCENCE
(CD38/CD45RO/CD8 TRIPLE)
An increase in the expression of CD38 and CD45RO on CD8 cells (Prince and Jensen, 1991)
has been shown to be associated with an increased likelihood of CD4 cell loss in adults
(Bofill et al., 1996). These markers were studied by triple-colour immunofluorescence to see
whether the same holds true in children. No normal ranges for these markers have been
established in children, so the results are shown as the comparison of marker expression in
HIV-1-infected and -exposed uninfected (EU) children at different ages.
The HIV-1-infected children (113 results from 18 individuals) and EU children (123 results
from 60 individuals) were plotted against age (in months). The total CD8% was found to be
increased in the infected children, compared to the EU (data not shown), in a similar way to
that seen in the dual-colour data. The proportion of CD8 cells expressing CD45RO was also
found to be increased in HIV-1-infected children, in a similar pattern to that seen by dual
colour fluorescence. This confirms that the results seen using this triple-colour system are
comparable to those results obtained by dual-colour immunofluorescence.
The percentage of CD8 cells expressing CD38 was plotted against age (months) and are
presented in figure 3.4. The expression of this marker decreased with increasing age, with
a great deal of overlap between the groups of children. A linear regression analysis showed
that the expression of this marker was significantly age dependent (p<0.001), but no
difference was seen between HIV-1-infected and EU children (p = 0.16, S. Hutchinson and
S. Lewis, MRC BIAS, personal communication).
The percentage of the CD8 cells expressing both CD45RO and CD38 together was plotted
against age (months) and are shown in figure 3.5. A regression analysis showed that, for the
EU children there was no age-relation in the expression of this marker (p = 0.15). By
comparison, the HIV-1-infected children showed a significantly raised expression of this
marker (p<0.001, S. Hutchinson and S. Lewis, MRC BIAS, personal communication). The
outlying point in the 73-84 month age band was due to higher levels of expression of this
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found to increase (not shown). This marker differentiated between infected and EU children
with a cut off level at about 20% expression.
3.3.3.1 Comparison of CD38/CD45RO/CD8 triple with CD4%
As the expression of this triple, in HIV-1-infected adults, is associated with a decreased
CD4% and disease progression (Bofill et al., 1996), the percentage of CD8 cells co-
expressing CD45RO and CD38, in the infected children, was compared with the CD4%. The
CD4% data approximated to a normal distribution, but the data for the triple did not. A
normal distribution was obtained by taking the square-root of each of the values. The square-
root of the triple was plotted against CD4% and is presented in figure 3.6. A linear
regression line was plotted through the points, which showed that the highest expression of
the triple was seen in those children with the lowest CD4%. Correlation values (r, calculated
using Microsoft Excel) for the comparison of the CD4% with the transformed data, and a
correlation value of r >0.45 (for n = 17 children) was taken to be significant (Wardlaw,
1985). A negative correlation was found between the CD4% and the square-root of the
CD38/CD45RO/CD8 triple (r = -0.523) in the HIV-1-infected children.
3.3.4 RELATION OF LYMPHOCYTE SURFACE MARKERS TO VIRAL
MARKERS
3.3.4.1 Relation of CD8 subpopulations to viral culture
The children followed from birth (P125, P126, P130, P131, P132) were routinely monitored,
by virus culture, for the diagnosis of HIV-1 infection. The virus-culture results (from Dr. M.
Arnott, Dept Medical Microbiology, University of Edinburgh) were compared with the
corresponding expression of the CD8 subpopulations at the same time points. The results for
the five children are presented in table 3.3. In two children (PI25 and PI26), an increase in
the CD8 subpopulations occurred at the same time that vims was first isolated. In one child
(P131), the increase in CD8 subpopulations was seen consistently over four months, prior to
HIV-1 being isolated in culture. In one child (PI32), at one month of age, the CD8
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§ virus culture results form Dr. M Arnott, Dept Medical Microbiology, University of
Edinburgh
+ identified as a fast progressor
norm all CD8 subpopulations in normal ranges
1 one or more CD8 subpopulation outwith normal range
neg culture HIV-negative
pos culture HIV-positive
subpopulations were within normal ranges, but HIV-1 was isolated from the same blood
sample. In another child (PI30), where virus was isolated at 3 weeks of age, no blood was
available for subpopulation analysis. Thus in three of five children, an increase in one or
more CD8 subpopulations was seen at the same time or before virus was isolated in culture.
3.3.4.2 Relationship between lymphocyte marker and viral phenotype
The emergence of a syncytium-inducing (SI) strain of HIV-1 has been associated with an
increased likelihood of onset of AIDS (Schuitemaker et al., 1992). To ascertain whether
there was any association between the presence of SI viral phenotypes and any lymphocyte
phenotype, virus-culture supernatant (from Dr. M. Arnott) was co-cultured with MT2 cells
(as described in 2.9). Syncytia were seen in the MT2-cultures from five of fourteen children
tested. Of these, four children were from group II (P92, PI 10, PI 16, and AF) and one was
from group III (PI42). These results are marked by arrows on figures 3.1(b) and 3.1(c). The
time at which the SI variant was detected varied relative to the fall in CD4%. In two
children (AF and PI 16), the CD4% had started to decrease before the emergence of the SI
variant. In another two children (PI 10 and P142) an SI phenotype emerged before the loss
of CD4 cells: for one of these (P142), the CD4% was still steady at 60 months of age. For
a fifth child (P92) an SI phenotype was seen at the first time of testing at 74 months of age,
but the CD4% had already decreased to 9%. Attempts to phenotype the virus in small
samples of archive material from this child (P92) were unsuccessful. The emergence of an
SI variant of HIV-1 was not associated with any change in the level of expression of any
CD4 or CD8 subpopulation. No SI variants were seen in the group I children, or the other
group III children including the fast progressors.
34 DISCUSSION
The use of flow cytometry in monitoring the lymphocyte surface markers in peripheral blood
is well established, and is routinely used to measure CD4 lymphocyte counts in HIV-1
infection (Landay et al., 1990). In adults, the CD4 percentage and cell count in peripheral
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blood decrease during the asymptomatic stage of HIV-1 infection, and this loss is associated
with the onset of AIDS (Taylor et al., 1989; Hoover et al., 1992). In adults, the expression
of different antigens on CD4 and CD8 cells has been used as surrogate markers to predict the
loss of CD4 cells and disease progression (Levacher et al., 1992; Zaunders et al., 1995;
Kestens et al., 1994). This study was undertaken to investigate these surface markers on the
CD4 and CD8 cells of HIV-1-infected children, to determine whether any particular marker
was indicative of HIV-1 infection in children or was associated with disease progression.
The expression of some of the markers studied is related to age and, therefore, the age-related
changes in normal children were defined (Aldhous et al., 1994a, appendix). Normal range
charts of the percentage of cell expressing a particular marker at different ages were
constructed as age-related centiles. The results obtained from the HIV-l-infected children
were plotted on these charts. Throughout this study, the results were presented as percentages
of lymphocytes, rather than absolute counts, as percentages are less likely to fluctuate and,
therefore, give more consistent results longitudinally (Taylor et al., 1989). In addition, the
error in measuring the white blood cell counts, from which absolute counts are calculated,
has been shown to increase significantly the error of reported absolute values of CD4 and
CD8 cell numbers (Hoover et al., 1992).
3.4.1 CD4 CELLS AND SUBPOPULATIONS
The children could be easily divided into three groups according to age and CD4%. The
children in group I had CD4% which were steady at ages over 60 months. These children
are clinically stable, and none have any AIDS-defining illnesses. The children under 60
months of age were all, initially, grouped together (group III). No clear pattern of CD4%
change has emerged in these children, apart from the two who were classed as fast
progressors; these two children will be discussed separately. The five children in group II
have all shown a CD4% decrease. Of these, four have developed AIDS, but the defining
conditions occurred once the CD4% had decreased to under 5% of the total lymphocytes.
This indicates that there may be some mechanism by which the immune system remains
functional, despite a low level of CD4 cells in peripheral blood. CD4 and CD8 cells
originate in the thymus from stem cells which express both molecules on the cell surface
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(Levy et al., 1988). In adults the thymus is obsolete, but in children it is still functional
(George and Ritter, 1996). It is possible that cells emerging from the thymus may traffic
directly into tissues rather than remain in the periphery, from where the blood was sampled,
thus giving a consistently low CD4%.
Due to fluctuations in the CD4%, it is not always clear whether a drop in CD4% is transient,
or a result of HIV-1 disease progression. Hence repeated blood samples are recommended,
to verify sudden drops in the CD4 level. However, an accompanying increase in activation
or memory markers (HLA-DR and CD45RO) on CD4 cells indicated that the CD4% decrease
was due to disease progression. Memory cells (expressing CD45RO) have been reported to
be infected preferentially with HIV-1 (Schnittman et al., 1990; Cayota et al., 1990) and these
cells are increasingly activated during infection (Kestens et al., 1994). Therefore, an increase
in activated or memory cells could contribute to the mechanisms of CD4 cell loss. It has
since been suggested that both memory and naive CD4 cells can be infected with HIV-1.
The same study also claimed that HIV-1 replication depends on the differentiation stage of
the cells, the disease stage of the individual and the activation signal used (Cayota et al.,
1993). This could also explain the differences between those studies which have seen a
selective loss of CD4 cells expressing memory markers (Shearer and Clerici, 1991; van
Noesel et al., 1990; Klimas et al., 1991) and those, including this one, which did not (Giorgi
and Detels, 1989; Vanham et al., 1991; Watret et al., 1993; Kestens et al., 1994).
3.4.2 CD8 CELLS AND SUBPOPULATIONS
In adults, an increased percentage of CD8 cells has been reported at seroconversion (Yagi et
al., 1991; Zaunders et al., 1995), which was maintained throughout disease (Giorgi and
Detels, 1989; Scala et al., 1995; Zaunders et al., 1995). This increase was accompanied by
an increased proportion of activated or memory CD8 cells, which may be involved in the
immune response against HIV-1 (Rowland-Jones et al., 1993). In the slow progressing
children studied here, the CD8% was increased in the children of over 60 months of age, and
remained so throughout the study, only decreasing in a few children before death. For the
children followed from birth, the CD8% was within normal levels until about 24 months.
This may be a reflection of an immature immune system showing a delayed response
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following perinatal infection. However, the levels of activation and memory markers on the
CD8 cells were increased at a much earlier age in these children, and remained so throughout
infection, although the levels both within and between children varied.
The percentage of CD8 cells expressing CD45RO were found to be within normal levels in
four children, three of whom became infected overseas. This raises the possibility that these
children are infected with non-subtype B HIV-1 strains, which may produce different immune
responses in individuals. However, the fourth child is a long-term survivor from the
Edinburgh cohort. In adults, cases of long-term survivors with normal CD4 counts and a low
HIV-1 burden have been described (Ferbas et al., 1995; Dalod et al., 1996;
Lamhamedi-Cherradi et al., 1995). These patients also had a low level of activated CD8 cells
and a lack of anti-HIV-1 functional responses, similar to those seen in this child.
In adults, CD8 cells have been described as being chronically activated by virtue of the
increased co-expression of CD45RO and CD38, and the increased co-expression of CD45RO
and HLA-DR (Prince and Jensen, 1991). The co-expression of CD45RO and CD38 on CD8
cells was markedly raised in children with HIV-1 infection, compared to EU children. The
expression of CD38 on CD8 cells, by itself, cannot be used as an independent marker of
disease progression in children as it can in adults (Levacher et al., 1992; Bofill et al., 1996).
This is because the CD38 expression, induced by activation of the cell is not easily
distinguished from the residual CD38 expression on immature cells. In EU children from
birth and up to about 24 months of age, CD38 was expressed on 90-100% of CD8 cells and
the levels of expression decreased with age (figure 3.4). This confirms the findings of
Hulstaert et al., (1994), who also showed that in adults, only about 40% of the CD8 cells
express CD38 constitutively. Thus, the induction of CD38 due to activation of cells is more
easily measured in adults than in children. Plaeger-Marshall et al., (1994) described a
population of cells which were brighdy stained for CD38, in HIV-1-infected children, and
interpreted this as defining a population of activated cells. In the HIV-1-infected children
studied here, no brightly staining cells were seen. Instead, the CD38 expression on activated
cells, rather than immature cells, was distinguished by the co-expression of CD45RO. The
increase in expression of the triple marker in the infected, compared to the EU children, was
more marked than that of either CD45RO or CD38 expression on CD8 cells alone. This is
because the expression of both markers individually (i.e. CD45RO or CD38 on CD8 cells)
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is age-related and, to account for this, normal age-related ranges were required. The co-
expression of both markers together is not age-related, as, in EU children, the increase in
expression of one marker occurred as the expression of the other decreased. There was an
inverse relationship between the CD4% and the proportion of these activated CD8 cells. The
exact nature of this relationship requires further study, but the co-expression of CD38 and
CD45RO on CD8 cells may be a useful marker for disease progression in children.
Rabin et al., (1995) defined naive CD8 cells as expressing high levels of CD45RA and
CD62L (L-selectin) but expressing CD1 la only dimly. They showed that this population was
decreased in HIV-1-infected adults and children, and that the numbers of cells with this
phenotype correlated with the CD4 count. In the children studied here, the co-expression of
CD1 la with CD45RA was not monitored and the expression of CD45RA on CD8 cells alone
was not related to the changes in the percentage of CD4 cells, as found in other studies
(Rabin et al., 1995; Scala et al., 1995; Roederer et al., 1995). The CD45RA expression on
CD8 cells was found to change in a reciprocal manner to the CD45RO expression (i.e. an
increase in CD45RO was accompanied by a decrease in CD45RA expression) confirming that
the CD8 cells expressed one or other of the isoforms (Wallace and Beverley, 1990).
CDlla is the a-chain of LFA-1, an adhesion molecule which binds to its ligand, ICAM-1.
This LFA-1-ICAM-1 binding is essential for interaction of T cells with their targets (Springer,
1990). The expression of CDlla on CD8 cells was markedly increased outwith normal
ranges in the infected children, indicating that these CD8 cells may be readily interacting with
other cells.
The increased expression of activation, memory and markers of cell-cell interactions on CD8
cells indicates that these cells are involved in immune mechanisms in response to HIV-1
infection in these children.
3.4.3 FAST PROGRESSORS
Two children (P126 and P130) showed different levels of expressions of markers, compared
with the other children of less than 60 months of age. Clinically, these were classed as fast
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progressors as one had developed AIDS and died at 17 months, and the other was
developmental^ delayed. A low CD4% was seen in both children by 3 months of age, but
neither showed any marked or sustained increase in the expression of any activation or
memory markers on CD4 cells. This was unexpected, given the increase in activation
markers seen on the CD4 cells of the older children who progressed clinically. However, a
recent report indicated high levels of HIV-1 provirus in CD45RA+ (nai've) CD4 cells in
children who also showed rapid CD4 cell loss (Sleasman et al., 1996). The authors suggested
that, although thymocytes also express CD45RO and are infectable with HIV-1 in vitro, HIV-
1-infected thymocytes are probably deleted intrathymically, and that in in utero infected
children, the CD45RA+, as well as CD45RO+ CD4 cells appear to be a target for HIV-1
infection (Sleasman et al., 1996). Thus CD4 cell depletion is through the loss of both
CD45RA+ and CD45RO+ cells, and hence, these children would not show any
disproportionate increase in either of these subpopulations, as was seen in the two children
studied here.
The percentage of CD8 lymphocytes was increased in the fast progressors at a much earlier
age than that seen in the other children followed from birth. Studies in SCID/hu mice (mice
with severe combined immunodeficiency (SCID), with human foetal liver and thymus tissue
implanted under the kidney capsule (Aldrovandi et al., 1993)) have indicated that HIV-1
infection in these organs leads to a severe depletion of CD4 cells with a corresponding
increased proportion of CD8 cells emerging from the thymus (Bonyhadi et al., 1993;
Aldrovandi et al., 1993; Su et al., 1995). One possibility is that these children were infected
with strains of virus which have targeted the thymus as opposed to other organs. This is
unlikely, as comparison of the viral sequences from one of these fast progressing children
(P130) with those from two other group III children (P125 and P132), has shown that there
is no more difference between these variants, than between other HIV-1 variants from the
Edinburgh drug users (C.M. Wade, Dr A. Leigh Brown, personal communication).
Alternatively, these results may reflect a difference in timing of transmission of HIV-1, with
the two fast progressors being infected at an earlier time point perinatally (i.e. in utero as
opposed to intrapartum), causing an earlier change in T cell phenotypes. The first definition
of in utero infection, by Bryson et al (1992), was that if virus was isolated (by PCR or
culture) from samples taken within the first 48 hours of birth, then the child was infected in
utero. If no virus was isolated during this time period, but was isolated from a sample taken
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at a later date, then the child was infected intrapartum. Thus far, no direct method has been
found to distinguish between in utero and intrapartum infection. In this study, neither child
was tested for virus culture or PCR during the first 48 hours after birth, so it cannot be
ascertained whether these children were infected in utero, according to this definition.
However, the CD4% and CD8% were also outwith normal ranges at an earlier age than those
seen in the other children followed from birth. Therefore, fast progressors were considered
to have been infected in utero, on the basis of virus isolation, a markedly decreased
percentage of CD4 cells, an increased percentage of CD8 cells and increased CD8
subpopulations at an early age.
3.4.4 RELATION OF LYMPHOCYTE SURFACE MARKERS TO
PROGRESSION AND DIAGNOSIS OF HIV-1 INFECTION
There appears to be some factor which influences clinical progression at between
approximately 48 and 60 months (4-5 years) of age, as the children either continue with a
steady CD4%, or they start to lose CD4 cells at a faster rate. One possibility is the
emergence of an SI virus phenotype, which, in some studies, has been associated with an
increased progression to AIDS (Schuitemaker et al, 1992). These virus variants kill cells by
causing the formation of syncytia (giant multi nucleated cells in susceptible cell lines in
vitro). Five children studied here had an emergent SI variant of HIV-1. In these children,
there were those whose CD4 cell loss started before the emergence of the SI variant, and
those from whom an SI variant was seen before the loss of CD4 cells. These results indicate
the tension and balance between the immune system and HIV-1. The timing of the
emergence of the SI variant may have some effect on the immune response. It is not clear
in these cases whether the SI variant directly caused the loss of CD4 cells (whether syncytia
are formed in vivo is not clear), or whether the loss of CD4 cells allowed an SI variant to
emerge due to decreased immune function or surveillance; in these children there is evidence
for both scenarios. For the latter scenario, the children whose CD4% had already decreased,
both died within 12 months of the SI phenotype emerging. This suggests that in an already
compromised immune system, a more virulent virus cannot be overcome immunologically.
For the former scenario, the other three children are still alive, at up to 30 months after the
SI virus was first seen. This supports the suggestion that the SI variant may have an effect
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by increasing the loss of CD4 cells (Schuitemaker et al., 1992). None of the children with
a steady CD4% (or a very slow decline) past 60 months of age, have shown an SI phenotype.
The expression of different markers on CD4 and CD8 cells was examined to identify any
marker which was indicative of HIV-1 infection. Plaeger-Marshall et al., (1994) did not find
any surface marker that was clearly diagnostic for HIV-1 infection in children. However, in
HIV-1-infected adults, Zaunders et al., (1995) did find an increased expression of activation
and memory markers on CD8 cells contributed to HIV-1 diagnosis in adults. In the children
studied here, an increase in activation and memory markers (CD45RO, HLA-DR and CD1 la)
was seen in infected children soon after birth which could be indicative of HIV-1 infection,
particularly as the increased expression of these markers was maintained. However, these
markers were increased at about 3 months of age, whereas in adults, the increase in markers
were seen at about the same time as seroconversion (Zaunders et al., 1995). This could be
reflective of the immaturity of the immune system in these children. In other viral infections
the increased expression of these markers has been found to be transient, i.e. the levels of the
CD8 subpopulations returned to within normal ranges once the infection was cleared (Watret
et al., 1993; Miyawaki et al., 1991; and unpublished results). This indicates that these cells
were stimulated by viral antigens, through some undefined mechanisms, and that once the
infecting agent was removed, the cells were removed (Akbar et al., 1994) and the marker
expression returned to normal levels. Likewise, the non-activation of CD8 cells in EU
children, indicates that there is no infectious agent (such as HIV-1) to stimulate these cells.
Therefore, the levels of subpopulations within normal ranges indicate that these children are
not infected with HIV-1.
In summary, this study showed that increased expression of activation markers on CD8 cells
can be used as an indication of HIV-1 infection in children born to HIV-1-infected mothers.
A decrease in CD4% concurrent with an increased expression of activation markers on the
CD4 cells can indicate disease progression. The relation of lymphocyte surface markers to
the functional capacity of CD4 and CD8 cells in immune responses will be further examined
in chapters 4 and 5.
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4.1 INTRODUCTION
Cytotoxic T lymphocytes (CTLs) play a significant role in the immune response to viral
infections. In some, such as influenza or Epstein-Barr virus infections, CTL activity is
responsible for clearing virus from the body (McMichael et al., 1983; Tomkinson et al.,
1989); in others, such as Hepatitis B, there is evidence that CTLs are involved in the
destruction of the liver tissue (Chisari and Ferrari, 1995). In HIV-1 infection, the CTL
response is thought to play a major role in the clearing of primary viraemia in adults
(Lamhamedi-Cherradi et al., 1995; Brander et al., 1995). This CTL activity persists in
seropositive asymptomatic individuals, decreasing with clinical disease progression
(Hoffenbach et al., 1989; Koup et al., 1989). More recently it has been suggested that CTLs
may cause some of the pathological damage seen in HIV-1 infection (Zinkernagel, 1995).
Initial studies in HIV-1-infected adults identified different regions of the HIV-1 virion which
elicited a CTL response, such as HIV-gag (Nixon et al., 1988; Koup et al., 1989), HYV-pol
(Walker et al., 1987; Walker et al., 1988) and HIV-env (Hoffenbach et al., 1989). Since then
studies have focused on HIV-gag and HTV-pol, as these are more highly conserved across
HIV-1 strains than HlV-env. CTL epitopes within HIV-1 have been defined (van Baalen et
al., 1993; Meyerhans et al., 1991; Brander et al., 1995). These are specific sequences of
viral peptides which correspond to the peptide binding motifs defined for different MHC-class
I molecules (reviewed in Brander and Walker, 1995).
Little work on HIV- 1-specific CTLs has been done in children. Vertical HIV-1 infection takes
place in the context of a developing and immature immune system. Little is known about
the differences between CTL responses to viruses transmitted in utero compared to those
transmitted intrapartum. Although the cellular immune system is thought to be functionally
mature at birth, little is known about the development of CTL responses in immunologically
naive individuals. Therefore, children are an important group to study, as the conclusions
drawn from studies of CTL responses in adults need to be verified in children.
A longitudinal, prospective study of HIV-1-specific CTL activity in children, born to HIV-1-
infected mothers, was undertaken to address some of these questions. Some of these children
are HIV-1-infected, and the others are presumed to have been exposed to HIV-1, but
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remained uninfected (EU children). CTL responses to different HIV-1-proteins, specifically
HIV-gag, -tat, -pol and -env were measured. Possible relationships between the specificity
of the CTL response, the age of the children, and clinical disease progression were
investigated. The phenotypes of lymphocytes in whole blood and the effector cell
populations were also examined, to determine whether it was possible to identify specific
surface markers which were associated with the presence of CTL activity. The production
of cytokines in culture was measured to see whether the levels of Th-1 or Th-2 cytokines
were related to the development of CTL responses.
Some of the results have been published (Aldhous et al., 1994b; Froebel et al., 1994,
appendix). The published results for the HIV-1-infected children have been included and
extended in the longitudinal analysis presented here. The results for the exposed uninfected
children in these papers have not been included as these were performed before the start of
this thesis.
42 METHODS
Peripheral blood samples (approximately 2 ml) were obtained from 33 children. CTL assays
were performed using separated PBMCs which had been co-cultured with autologous PHA-
activated cells as effector cells (bulk culture method). Autologous EBV-transformed B-cell
lines, infected with vaccinia-HIV constructs expressing the gene products from HIV-gag, -tat,
-pol and -env, were used as target cells, in a 4-hour 51Cr chromium release assay (as
described in 2.6.1.1, 2.6.2.1 and 2.6.3).
For some children, effector cell populations were also stimulated with HIV-1 peptides, and
assayed against target cells infected with vaccinia-HIV constructs or pulsed with peptide (as
described in 2.6.1.2, 2.6.2. and 2.6.3).
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43 RESULTS
Details of the HIV-1-infected children are summarised in table 4.1. In this table the children
are grouped according to their CD4% profile, as outlined in chapter 3 (3.3.1). The age range
over which each child was studied, the number of CTL assays carried out for each child and
the specificity of the responses are also given.
4.3.1 LONGITUDINAL CTL ACTIVITY IN CHILDREN BORN TO HIV-1-
INFECTED MOTHERS
4.3.1.1 HIV-l-infected children
Sequential CTL assays were carried out in 13 HIV-l-infected children over different periods
of time (range 10-46 months, table 4.1). For the bulk culture method, the frequency of the
responses is presented in table 4.2. CTL activity was detected in 9/13 (69%) children
(CTL+ves) on at least one occasion. CTL activity was not detected in 4/13 (31%) infected
children; these are called CTL-ve throughout this chapter. The specificity of the CTL
response in individual children changed on different occasions of testing, and all the CTL+ve
children except one (P142, who was tested three times) had occasions when CTL activity was
not detected.
The most frequent response was seen to HI"V-pol, followed by HIV-gag and -tat, with
responses to HIV-env seen infrequently (see table 4.2). The CTL+ve children could be
divided into two groups by CTL specificity: those with CTL activity to HIV-pol, HlV-gag
and HIV-env, (P6, P27, P130, P131 and P142) and those with predominant CTL activity to
HIV-pol and HIV-to/ (P92, PI 10, P121 and P126). All but one child (P131) showed CTL
activity to HIV-pol.
4.2.1.2 HIV-l-exposed, uninfected (EU) children
CTL assays were carried out in 20 children, born to HIV-l-infected mothers, and so were
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Table 4.1 HIV-1-infected children studied for CTL activity
Child Age range+ CTL+ve / total assays++ Disease
(months) (specificity) Progression
Group I+
P6 79 - 126 3/6 pollgag
P27 71 - 120 5/8 pollgaglenvf
P121 28 - 53 2/4 tat/pol
P69 88 - 132 0/7
Group II
P92 53 - 102 4/6 gag§ltat/pol AIDS
P110 21 - 70 4/6 tat/pol low CD4%
P116 40 - 52 0/4 died at 78 months
Group III
P125 4 - 42 0/4
P131 2 - 28 1/2 gag
P132 9 - 26 0/1
P142 47 - 60 3/3 gaglpollenv
Fast progressors++++
P126 3 - 13 1/4 tat/pol died at 17 months
P130 4 - 30 2/3
•
gag/pol developmentally delayed
Ages at first and last CTL assays
Bulk culture assay
Groups based on CD4% and age, as outlined in chapter 3
Children defined as clinical fast progressors (see chapter 3)
a borderline response to HIV-c/iv (10.7%) was seen on one occasion


































Numberofinfect drEUchildrenwithresponsestdiffer tHIV-1-g es,oa yccasionfs aysh wn.
presumed to have been exposed to HIV-1. Those confirmed as being uninfected had no
indicators of HIV-1 infection, i.e. they were negative for PCR, HIV-1 antigen (p24) and virus
culture (results from Dr. M. Arnott, Dept. Medical Microbiology, University of Edinburgh)
and had levels of CD8 subpopulations within normal ranges in whole blood (see chapter 3).
Those whose infection status was not confirmed (i.e. indeterminate, see 1.6.2), only had
maternal antibody as an indication of exposure to HIV-1, and these were grouped with the
EU children. CTL activity was detected in 7/20 (35%) of the EU children (see table 4.2).
To determine whether CTL responses to HIV-1 were detected more frequently in infected or
EU children, a chi-squared analysis was performed. This showed that there was no
significant difference in the number of CTL+ve and CTL-ve children between the groups (yj
= 2.453, p = 0.245).
4.3.1.3 Effect of method variation on CTL specificity
The CTL assays were carried out after different numbers of days in culture and at different
effector:target (E:T) ratios. To assess whether these methodological differences affected
which gene product was detected, the CTL+ve results, from both infected and EU children,
were combined and analysed for day of assay and the E:T ratio. These results are presented
in table 4.3. In addition, whether the age of the child was important in the detection of a
CTL response, was also investigated and is included in table 4.3.
CTL assays were performed after culturing the cells for between 10 and 23 days (see 2.5.1.1).
A previous result had shown there was a difference in the specificity of the response, when
effector cells from the same culture were assayed on different days (Aldhous et al., 1994b,
appendix). To see whether the CTL specificity was associated with the time of culture of the
effector cells, the day of assay were compared for each HIV-gene product (table 4.3). There
was no correlation between the construct recognised and the day of assay.
The E:T ratios (i.e. the number of effector cells per target cell) of the assays were between
10:1 and 54:1, depending on the number of cells recovered from the culture. To see whether
the number of effector cells was associated with the specificity of recognition, the mean E:T
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4.3). There was no correlation between the E:T ratio and the specificity of construct
recognition.
Initial results using the bulk culture method, had indicated that there may be a relationship
between the age of the child and the specificity of construct recognition. It appeared that
KLV-tat and HYV-pol were recognised in the younger children, and that a response to HIV-
gag developed later in infection (Aldhous et al., 1994b, appendix). Since then, CTL activity
to HlV-gog has also been detected in younger children. To see whether the age of the child
was associated with which HIV-gene product was recognised, the mean age for the different
CTL specificities were compared (table 4.3). There was no correlation between the age of
the child and the specificity of construct recognition. CTL responses were detected in
children as young as two months, showing there is no age 'threshold' before which responses
develop.
4.3.2 RELATION OF CTL ACTIVITY TO DISEASE PROGRESSION IN
HIV-1-INFECTED CHILDREN
The HIV-1-infected children were divided into groups according to age and CD4% (groups
I, II, III and fast progressors) as defined in chapter 3. Disease progression was defined as
those children in whom AIDS-defining diseases had been diagnosed, or had a low CD4% (see
table 4.1).
Group I contained those children of over 60 months of age, with a steady CD4%.
Representative results from CTL+ve and CTL-ve children (P27 and P69, respectively) are
shown in figure 4.1 (a) and (b), and the results for each child are summarised in table 4.1.
CTL responses were seen in three of four children, predominantly to HIV-pol, -gag and -tat,
with a borderline response to -env in one child. CTL activity was lost in all these children
while the CD4% was still steady. No CTL activity was detectable after 108 months from one
child (P27, figure 4.1(a)), although the child was followed for a further 6 months and two
more occasions of assay. Similarly, CTL responses were detected to HIV-1 detected from
another child (P6) at 93 months, and was followed for a further 30 months, but no CTL
activity was detected on two more occasions. Likewise, in another child (P121), CTL activity
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Figure 4.1 CTL activity in relation to CD4% profile in slow progressors
The specific lysis of target cells (i.e. after subtraction of background lysis from
medium and vaccinia controls) infected with different constructs (gag, tat, pol, env)
is shown. The horizontal line is drawn at 10% specific lysis, above which the result
is considered to be positive. The age at which each assay was done is shown on the
x-axis (this axis is not linear). The corresponding CD4% for the blood sample at that
age is also plotted (right y-axis).
Representative results from the group I children (those with a steady CD4%, at ages
older than 60 months) are shown.
(a) CTL+ve child (P27 is presented. Similar results were also seen in P6 and
P121).
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was detected at 28 and 35 months, but not on two further occasions at 45 and 53 months.
The fourth child in this group (P69) showed no CTL activity (see figure 4.1(b)) but still had
a steady CD4%.
Group II contained those children of over 60 months whose CD4% had decreased.
Representative results from CTL+ve and CTL-ve children (P92 and PI 16, respectively) are
shown in figure 4.1 (c) and (d), and the results for each child are summarised in table 4.1.
CTL responses were detected in two of three children to HIV-po/ and HIV-tot, but, apart
from one borderline response, not to HIV-gag or -env. The CTL+ve children maintained
responses while the CD4% was decreasing. For one child (P92, shown in figure 4.1(c)), CTL
activity was lost at 78 months, once the CD4% had decreased to 9%. For the other child
(PI 10, not shown) the CTL response was maintained despite a low CD4%. The third child
in this group (PI 16) showed no CTL activity, but whose CD4% still decreased (figure
4.1(d)).
Group III contained those children younger than 60 months, who were not fast progressors.
Representative results from CTL+ve and CTL-ve children (P142 and PI25, respectively) are
shown in figure 4.1 (e) and (f), and the results for each child are summarised in table 4.1.
CTL responses were detected in two of four children to HIV-po/, HIV-gag and HIV-env.
One of these (PI42) showed CTL activity to target cells infected with each of these three
vaccinia-HIV constructs (figure 4.1(e)). Another child (P131) showed CTL activity to HIV-
gag at one time point. The other two children (P125, shown in figure 4.1(f), and P132) were
consistently CTL-ve.
4.3.2.1 Fast progressors
To assess whether the specificity of the CTL responses was different in fast progressors, the
results of two such children (P126 and P130) are shown in figure 4.2 (a) and (b),
respectively, and summarised in table 4.1. Both children were HIV-1-culture positive at 3
weeks of age and both had a CD4% below the 3rd centile at 2 months of age (see chapter
3). One child (PI26) showed CTL activity to HIV-tot and HIV-po/, on one occasion at 6
months of age, but not at 3, 9 and 13 months of age. This child died of AIDS at 17 months.
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Figure 4.1 CTL activity in relation to CD4% profile in slow progressors
Representative results from group II children (those with a decreased CD4% at ages
older than 60 months) are shown.
(c) CTL+ve child (P92 is presented. Similar results were also seen in PI 10).
(d) CTL-ve child (PI 16 is presented).






Figure 4.1 CTL activity in relation to CD4% profile in slow progressors
Representative results from group III children (those children younger than 60
months, not including the fast progressors) are shown.
(e) CTL+ve child (P142 is presented. Similar results were also seen in P131).
(f) CTL-ve child (P125 is presented. Similar results were also seen in P132).
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Figure 4.2 CTL activity in fast progressors
Results from the fast pogressors are shown.
(a) CTL activity in PI26
(b) CTL activity in PI30


















The other child (P130) showed CTL activity to HIV-gag at 8 months, and to HIV-gag and
HI\-pol at 30 months. These CTL responses, in terms of specificity, were not different from
those seen in children from groups I, II or III.
4.3.3 NON-DETECTION OF CTL ACTIVITY IN HIV-1-INFECTED
CHILDREN
Four HIV-1-infected children (P69, PI 16, P125, and P132) were consistently negative for
CTL activity using the bulk culture method. These children were further investigated to
determine whether this was due to some methodological differences between these and the
CTL+ve children. The expression of the HIV-gene product on the surface of the target cells,
and whether the B cell line functioned efficiently as a target cell were both investigated. In
addition, the effect of an alternative method of stimulation of the CTL effector cells was
assessed (see 4.3.4).
4.3.3.1 Expression of HIV-gene product from vaccinia-constructs by B cells
Non-expression of the HIV-gene product, after infection with the vaccinia-constructs, on the
surface of the cells, could be one explanation for the lack of CTL activity in these children.
To check whether this was the case, aliquots of B-cells were infected with each vaccinia-HIV
construct overnight. These cells were stained with anti-HIV-1 antibodies (a-p55/pl7, a-
gpl20, a-tat and a-RT), followed by a FITC-conjugated goat anti-mouse antibody and
visualised by fluorescent microscopy, as described in 2.7.2. B-cells from both a CTL-ve
(P69) and a CTL+ve (PI 10) child, were used. Representative results are presented in figure
4.3 and show that both cell lines expressed the HIV-1-proteins efficiently on the cell surface.
4.3.3.2 Comparison of B cell line function
One CTL-ve child (PI25) was found to be the same HLA-type as a CTL+ve child (P92). To
assess whether the B cells from the CTL-ve child functioned effectively as target cells, CTL
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Figure 4.3 Expression of HIV-constructs by B cells
Representative photographs of the cells infected with the vaccinia-constructs. The
proteins expressed on the surface of the cell were detected by an anti-HIV-1
antibodies and FITC-conjugated goat-anti-mouse, and visualised by fluorescent
microscopy. The brightly staining cells are those which express the protein of
interest on the cell surface.
(a) a B-cell line from a CTL+ve child (PI 10) infected with HIV-env, stained
with an anti-gpl20 antibody
(b) a B-cell line from a CTL-ve child (P69) infected with HIV-env, stained with
an anti-gpl20 antibody
 
assays were carried out using B cells from both children as targets. These were infected with
vaccinia-HIV constructs (HIV-gag, HIV-po/ or the vaccinia-construct control (vac)) and
uninfected aliquots were used as medium controls (med). Effector cells were from the CTL-
ve child (P125). Two different methods were used to stimulate the effector cells: the bulk
culture method, and specific stimulation by a pool of HIV-1-peptides (see 4.3.4). The results
are presented in figure 4.4. Lysis was seen to the medium control and vaccinia-construct-
infected targets, but no HIV-1-specific lysis was seen above these levels. Therefore, the non-
detection of CTL in this child (P125), is probably due to an absence of CTLs or non-
recognition by the effector cells, rather than deficient target cell function.
4.3.4 CTL ASSAYS USING PEPTIDE STIMULATED EFFECTOR CELLS
In the bulk culture assay, PBMCs were cultured with autologous PHA-activated cells to
stimulate the reactivation of memory cells, and the differentiation of precursor CTLs, without
inducing apoptosis. However, such a polyclonal stimulation would cause any non-HIV-1-
specific memory CTLs to expand as well, which could mask a low number of HIV-1-specific
CTLs. Therefore, a method which would be more HIV-1-specific was tried using peptides.
Short amino acid sequences in different HIV-1 proteins have been identified as CTL epitopes,
specific for particular MHC-class I molecules. Depending on affinity, these peptides would
bind to the class-I MHC-molecule, displacing the peptide already bound. This binding
mimics the expression of endogenously processed antigen, stimulating the expansion of HIV-
1-specific memory CTL populations. Using this method, the numbers of non-HIV-1 -specific
memory CTL cells would be reduced in culture, thus enabling a lower level of HIV-1 -specific
CTL responses to be detected.
All the HIV-1-infected children were tissue-typed by a PCR method (Krausa et al., 1995),
with the help of P. Krausa, (Institute of Molecular Medicine, Oxford). Peptides of 8-10
amino acids long, corresponding to defined CTL epitopes, were kindly donated by Dr. S.
Rowland-Jones (Institute of Molecular Medicine, Oxford). All the available peptides, specific
for the HLA-type of each child, were selected and pooled to stimulate PBMC effector cells
(as described in 2.6.1.2). These same peptides were used to pulse B-cells (peptide-pulsed
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(as described in 2.6.2.2). Vaccinia-HIV constructs were also used as target cells in the CTL
assay (as described in 2.6.2.1 and 2.6.3). The HLA-types of the children and the peptides
used to stimulate the cells are shown in table 4.4.
4.3.4.1 CTL-ve children
Pools of HIV-1-peptides were used to stimulate effector cells in three CTL-ve children (P69,
P125 and P132) to see if an HIV-1-specific CTL response could be elicited. Peptide
stimulated effector cells were used against the vaccinia-HIV construct infected targets as well
as peptide-pulsed target cells. The results are shown in figure 4.5.
PBMCs from P69 were tested on three occasions. From the first assay, at 126 months of age,
CTL activity was detected against pp 2 (corresponding to a nef peptide presented on HLA-
B18) but not to pp 1 (pol and gag peptides, presented on HLA-A2). On the second time of
testing, at 129 months of age, no CTL activity was seen at all. The third time of testing, at
132 months of age, showed a weak CTL response to pp 1 (pol and gag peptides, presented
on HLA-A2), but not to pp 2 (nef peptide, presented on HLA-B18). No CTL activity was
detected on any occasion against the vaccinia-HIV construct-infected target cells. The CTL
assays were carried out after the same time in culture of the effector cells (13 or 14 days),
but the E:T ratios varied (2:1, 44:1 and 11:1, respectively).
PBMCs from PI25 were tested once, but no CTL activity was detected to the peptides.
However, a weak CTL response was seen against target cells infected with the vaccinia-HIV-
pol construct.
PBMCs from P132 were tested on two occasions, but no CTL activity was detected to either
peptide-pulsed- or vaccinia-HIV construct-infected target cells.
4.3.4.2 CTL+ve children
Pools of HIV-1-peptides were also used to stimulate the PBMCs from four CTL+ve children
121
Table4.4
HLA-typeandpepti epoolsusedforstimulationfffect rc ll








































HIV-1-peptidesusedforthstimulationfCTLeffect rc llarshowccordingtHLA- ypef achh .






□gag □tat □pol □env □pp1 □PP2 □pp3
P125
P132
(P6 and P27 from group I, PI 10 from group II and P131 from group III). These experiments
were done separately (i.e. not at the same time as the bulk-culture method), to investigate
whether the different method of stimulation caused the specificity of the CTL response to
differ from that previously seen using the bulk-culture method. The results are shown in
figure 4.6 (a).
No CTL activity was seen for P6 (at 126 months of age), to either peptide-pulsed or vaccinia-
HIV-1 construct-infected target cells. This confirmed the observations from the two previous
assays using the bulk-culture method (not shown), that this child had lost CTL activity.
For P27, no CTL activity was seen when the effector cells were stimulated with peptides, at
111 months of age, although CTL activity to target cells infected with vaccinia-HIV-gag had
been seen three months previously, from the bulk culture method. For the ensuing sample
from this child, at 114 months, the PBMCs were stimulated using the bulk culture method
and assayed against peptide-pulsed and vaccinia-construct-infected target cells. No CTL
activity was detected to the peptide-pulsed target cells, but borderline CTL activity to target
cells infected with the vaccinia-HIV-po/ construct was seen (figure 4.6, P27, 114+).
However, CTL activity was absent when this was repeated at 117 months (see figure 4.6, P27
117++).
Peptide stimulation of PBMCs from PI 10, at 64 months of age, elicited a CTL response to
target cells pulsed with the peptides from pp 2 (gag, env, and nef, presented on HLA-A3).
CTL activity was also seen to target cells infected with the vaccinia-HIV-gag construct,
having previously shown no CTL activity to this target using the bulk-culture method.
Interleukin 7 (IL-7) was added to the peptide-stimulated cultures (described 2.6.1.2) on two
subsequent occasions, at 69 and 70 months, as this has been reported to enhance antigen-
specific CTL effector cell production (Carini and Essex, 1994). On the first time of testing
with IL-7 added (figure 4.6, PI 10, 69§), no CTL activity to peptide-pulsed target cells was
detected, but CTL activity to target cells infected with the vaccinia-HIV-po/ and -env
constructs was seen. On the second time of testing with IL-7 added, CTL activity to pp 1
(pol and gag peptides, presented on HLA-A2) was detected, as well as responses to target
cells infected with the vaccinia-HIV-gag, -pol and -env constructs (figure 4.6(a), PI 10, 70§).
There was a slight difference in culture time of the effector cells between these two occasions
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of testing (19 days compared to 14 days, respectively). However, for the peptide-stimulated
CTLs no activity to the target cells infected with the vaccinia-HIV-rar construct was seen, this
specificity having been seen previously using the bulk-culture method.
No CTL activity to peptide-pulsed target cells was seen from P131. However, a response to
target cells infected with the vaccinia-HIV-/;o/ construct was seen, this child not having
previously shown any responses to this target.
4.3.4.3 HIV-1-uninfected child
In a 15 month uninfected child (P140), the peptide assay was used to try to stimulate an HIV-
1-specific CTL response. This child had been consistently CTL-ve, apart from one response
to VtYW-gag at 9 months old. The results are shown in fig 4.6 (b). No CTL activity was
seen.
4.3.5 CD8 SUBPOPULATIONS IN EFFECTOR CELLS
Various studies in HIV-1-infected adults have described the phenotype of the CTL effector
cells as CD8 cells expressing combinations of HLA-DR, CD38, CD45RO or CDlla (Ho et
al., 1993; van Baalen et al., 1993; Watret et al., 1993). In whole blood, the proportion of
CD8 cells expressing these antigens is markedly increased in HIV-1-infected children (chapter
3). The marker expression on whole blood lymphocytes and on effector cells, from HIV-1-
infected children, was investigated to ascertain whether a specific phenotype on peripheral
blood lymphocytes or on effector cells was associated with CTL activity.
The surface markers of CD8 cells in whole blood, and in the effector cell population used
in the CTL assay, were measured (as described in 2.3.1). The levels of marker expression
were compared between the cultures which were CTL+ve (n = 16) and those which were
CTL-ve (n = 25), from HIV-1-infected children. The results for whole blood are shown in
figure 4.7 (a) and for effector cells in figure 4.7 (b). Pooled two-sample t-tests were used
to compare the levels of marker expression. In whole blood, no significant differences were
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Figure 4.7 Phenotypes of cells from CTL+ve and CTL-ve cultures
The percentage marker expression (mean ± sem) for the CTL+ve and CTL-ve
cultures are shown (y-axis). The markers are defined on the x-axis.
(a) in whole blood (i.e. cells put into culture).
(b) on effector cells used in the CTL assay.
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found in marker expression between the two groups. However, in the effector cell
populations a significant increase in CD8% (** p<0.01) and significant decrease in CD4%
(* p<0.05) was seen in CTL+ve compared to CTL-ve cultures. The proportion of CD8 cells
expressing CD45RO and HLA-DR was significantly increased (** p<0.01 respectively), while
the proportion of CD8 cells expressing CD38 was significantly decreased (* p<0.05) on the
CTL+ve effector cells, compared to the CTL-ve effector cells.
4.3.6 CYTOKINE PRODUCTION FROM CTL CULTURES
CTL activity has been reported to be associated with the production of Th-1 cytokines from
CD4 cells (Kemeny et al., 1994). It has been suggested that the loss of CTL activity is
related to a decrease in the production of Th-1 cytokines from CD4 cells in vivo (Clerici and
Shearer, 1993). Therefore the relationship between the production of Th-1 or Th-2 cytokines
and the presence of CTL effector cells was investigated.
CTL culture supernatants from HIV-1-infected and EU children taken at day 7 were analysed
for Th-1 cytokines (IL-2 and IFN-y) and Th-2 cytokines (IL-4 and IL-6), using commercial
kits (Genzyme) according to the manufacturers instructions. Results were obtained for IL-6,
but not for the other cytokines. The IL-6 levels from CTL+ve and CTL-ve cultures are
shown in figure 4.8 (a) and were compared by a Mann-Whitney statistical test. There was
no significant difference in the IL-6 level between the two groups (medians = 66.5 pg/ml and
156 pg/ml, respectively, p = 0.198). The levels of IL-6 in cultures from EU and HIV+ve
children are shown in figure 4.8 (b). Comparison of the groups by a Mann-Whitney
statistical test, showed that the supernatants of CTL cultures from HIV+ve children had
significantly less IL-6 than those from EU children (medians = 61 pg/ml and 358 pg/ml
respectively, p < 0.01).
44 DISCUSSION
HIV-1-specific CTL activity was studied in infected children to investigate how these
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Figure 4.8 IL-6 levels in supernatants
The levels of IL-6 (pg/ml) detected in culture supernatants are shown. The levels are
presented horizontally, and the vertical bars denote the median level in each group.
(a) CTL+ve and CTL-ve cultures
(b) HIV+ve and EU children
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responses changed longitudinally. The presence and specificity of the CTL response was
studied in relation to methodological differences and the clinical progression of the children.
The effect of stimulation with specific HIV-1-peptides was also investigated. In addition, the
phenotypes of the effector cells and the production of cytokines in the CTL cultures were
analysed. CTL responses were also studied in 20 EU children, to see whether HIV-1-specific
CTL responses developed after in utero or intrapartum exposure to HIV-1.
4.4.1 SPECIFICITY OF CTL RESPONSE FROM BULK-CULTURED
EFFECTOR CELLS
The main method used in this study was the bulk culture method to allow the expansion and
differentiation of memory CTL cells. The specificity of these secondary (restimulated) CTL
responses varied, both within and between children. This was not due to methodological
variation, such as the day of assay or the E:T ratio; these parameters were all comparable to
those used in other studies of children (Luzuriaga et al., 1995; Buseyne et al., 1993; Cheynier
et al., 1992; Luzuriaga et al., 1991; McFarland et al., 1994). Others have found in children,
that the primary CTL response (the CTL activity detected from freshly isolated, unstimulated
PBMCs) and the secondary CTL response from the same blood sample, do not show the
same specificity of target recognition (Buseyne et al., 1993; Cheynier et al., 1992; McFarland
et al., 1994). Therefore, the differences in specificity detected here are probably a reflection
of the expansion of different cell populations during culture; some populations may give
detectable killing before others, as different cell populations grow at different rates.
The most abundant proteins in the HIV-1 virion are those encoded by env and gag.
Therefore, it was expected that CTL responses to HIV-gag and HlV-env would predominate.
However, the most frequently recognised construct was HIV-po/, which was detected in all
but one, of the CTL+ve infected children. This indicates that pol contains major CTL
epitopes which are conserved across different HIV-1 variants in children, as has been shown
in adults (Walker et al., 1988; Lamhamedi-Cherradi et al., 1992; Lamhamedi-Cherradi et al.,
1995). CTL activity to pol has rarely been reported in children (McFarland et al., 1994;
Buseyne et al., 1993). In one study, this could be because the CTL activity was measured
early, on day 7 of culture (McFarland et al., 1994). In the children studied here, and from
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studies in adults (Lamhamedi-Cherradi et al., 1992; Lamhamedi-Cherradi et al., 1995), the
CTL activity was measured later, giving more time for the expansion of />o/-specific effector
cells.
CTL activity to HIV-gag was seen in five infected children, with a borderline response in
another child. CTL activity to HIV-env was seen in two infected children, and one of these
was a borderline response. This contrasts with published studies in both adults and children,
which have reported high frequencies of CTL activity to both gag (Ho et al., 1993; Walker
et al., 1987; Koup et al., 1989; Buseyne et al., 1993; McFarland et al., 1994) and env
(Hoffenbach et al., 1989; Koup et al., 1989; Luzuriaga et al., 1995; Cheynier et al., 1992).
Sequence variation between the virus used in the construct and that found in the children,
could be such that few cross-reactive epitopes are recognised by the effector cells, and may
explain the lower proportion of HIV-gag-specific responses seen in these children, compared
with that found in other cohorts (Buseyne et al., 1993; Cheynier et al., 1992; McFarland et
al., 1994). To verify this, the viral sequences in the children would have to be compared
with the construct sequence.
The vaccinia-HIV-gag construct used in this study encoded the p55 gag-precursor protein and
cells infected with this construct expressed p55 on the cell surface (Nixon et al., 1988;
Walker et al., 1987). Initial studies reported that this p55 precursor was not further processed
to produce mature HIV-1-gag proteins, p24, pl7 and pl5 (Nixon et al., 1988; Walker et al.,
1987), but has been successfully used in CTL assays in adults (Nixon et al., 1988). Whether
this lack of further processing of the p55 protein contributed to the non-recognition of the
target cells by the effector cells from children, is not clear, but could be investigated by
comparison with another vaccinia-HIV-gag construct (Gowda et al., 1989).
Differences in viral populations between individuals could affect CTL recognition,
particularly as there is more variation in env than in other parts of the HIV-1 virion
(Simmonds et al., 1991). A study by Robertson et al., (1994) compared env-specific
cytotoxic responses (CTL and ADCC) to HIV-1MN and HIV-1LAI in adults, and found some
degree of cross-reactivity between strains. In the infected children studied here, the frequency
of responses to HIV-e/tv was lower than that found in other cohorts. The reasons for this
require further investigation.
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CTL activity to HIV-tat has not been previously described in children. This response was
unexpected as, in adults, rat-specific CTLs have been detected, but at such a low frequency
that it was concluded that HIV-rar was not a major CTL epitope (Lamhamedi-Cherradi et al.,
1992). These results highlight the differences seen from studying CTL responses in children
as opposed to adults. The MHC restriction and possible epitope sequences specific to this
CTL response require further investigation.
4.4.2 CTL ACTIVITY AND CLINICAL PROGRESSION
The loss of CTL activity in progressors (Rinaldo et al., 1995; Klein et al., 1995; Ho et al.,
1993) and the relation of CTL to the control of primary viraemia (Borrow et al., 1994;
Lamhamedi-Cherradi et al., 1995; Koup etal., 1994) have been well documented and indicate
that CTL activity is beneficial in the HIV-1-infected individual. However the detection of
CTLs from lung (Plata et al., 1987), CSF (Sethi et al., 1988) and splenic tissue (Cheynier et
al., 1994) of patients with AIDS suggest that these may contribute to the tissue degradation
seen in HIV-1 infection (Pantaleo et al., 1993; Embretson et al., 1993). The ability of CTLs
to kill uninfected, activated CD4 cells in vitro has been described (Bienzle et al., 1996) and
is associated with CD4 depletion in vivo (Grant et al., 1994). It has also been reported that,
in vitro, CD8 cells can become infected with HIV-1 in the process of killing HIV-1-infected
target cells. These CD8 cells in turn, were able to infect CD4 cells, but were not recognised
as being infected themselves and therefore were not removed by any mechanism (de Maria
et al., 1994b). Furthermore, HIV-1-infected CD8 cells have been isolated from the lung
(Semenzato et al., 1995) and peripheral blood (Livingstone et al., 1996) of infected patients,
suggesting that CTLs could spread virus to different organs.
In the children studied here, all the CD4% groups contained CTL+ve and CTL-ve children,
but only one of the CTL-ve children the child (from group II) has progressed clinically. The
CTL+ve children who progressed, all showed CTL responses to HIV-tat from the bulk-culture
method. This was unexpected, as Torpey et al., (1993) postulated that CTL activity to HIV-
rar may be beneficial, as an attempt on the part of the immune system, to destroy HIV-1-
infected cells before the production of mature virions. However, these results indicate that
CTL activity to HIV-rar does not prevent disease progression. It is possible that in vitro
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detection of tor-specific CTL may indicate an increased level of HIV-1-replication in vivo,
therefore reflecting an increased likelihood of disease progression.
It could be postulated that CTL activity is beneficial up to a certain point in the natural
history of disease. In the children studied here, three lost CTL activity before the CD4%
showed any substantial decline, yet have remained clinically stable. Conversely, two other
children, continued to show CTL activity once the CD4% decline had started. These two,
and one other child who also showed vigorous CTL activity, have developed SI variants of
HIV-1, which have been claimed to be predictive for the onset of AIDS (Schuitemaker et al.,
1992). If these SI variants emerged as an attempt by the virus to evade recognition by CTLs
(Phillips et al., 1991), this suggests that CTL activity may contribute to the selective pressure
leading to the emergence of a more virulent viral strain.
4.4.3 NON-DETECTION OF CTL ACTIVITY
Four children were consistently CTL-ve using the bulk-culture method and the loss of CTL
activity was seen in five children. The expression of the HIV-gene products on the surface
of B cells infected with the vaccinia-HIV constructs, were comparable in two children, as
found elsewhere (Gowda et al., 1989). Therefore, the difference in CTL recognition must
be at the effector cell level. Joly et al., (1989) reported that a soluble factor released by
CD57+ CD8 cells could suppress CTL recognition of HIV-1-infected cells by an unknown
mechanism, and that this cell population expands with disease progression. However, in
these children, there was no increase in the proportion of CD57+ CD8 cells outwith normal
levels in whole blood (see chapter 3), nor in the effector cell population. Effros et al., (1996)
reported that, in HIV-1-infected individuals, a population of CD8 cells which did not express
CD28, were found to have become senescent, possibly due to persistent viral stimulation.
It was suggested that these senescent cells may be immunologically exhausted. It is possible
that in the children who lost CTL activity, that exhaustion of CTL clones had occurred.
A study by Wolinsky et al. (1996), suggested that a low level of diversity of viral sequence,
within an individual, is related to the loss or non-appearance of CTL responses and
subsequent progression to AIDS. This was seen in two children (P125 and P132), who were
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bora to the same mother. Viral sequences from the mother and the two children indicated
that these virus strains were more closely related than those found in the wider Edinburgh
IVDU cohort (~3% divergence as opposed to ~5% divergence, respectively). The intra-child
viral diversity was higher in P125 than that found in P132, (~2% as opposed to ~0.5%, C.M.
Wade, J Virol 1997, submitted). One child (P125) showed CTL activity, but only when the
cells were stimulated with HIV-1-peptides. The other child showed no CTL activity, thus
supporting the view that higher viral diversity and CTL activity are related. These children
differ from the individuals in Wolinsky's study, in that neither has progressed clinically.
As one of the CTL-ve children (PI 16) was born in central Africa, it is likely this child was
infected with a non-subtype B virus, but could be infected with a subtype A or D virus, these
being more prevalent (Myers, 1994). The subtype identification of this virus has not been
performed due to a lack of material. Differences in viral sequence at the CTL epitopes may
explain the non-recognition of B-subtype CTL targets in this child. A few cross-reactive
CTL epitopes between HIV-1 subtypes have been defined, corresponding to one of the childs'
HLA loci, B14 (Korber et al., 1995), but not the other loci, which could limit the generation
of a CTL response. This child was the only CTL-ve child to progress to AIDS, and has since
died.
A few studies in HIV-1-infected adults have associated the non-detection of CTL activity
with a low virus burden (Ferbas et al., 1995; Dalod et al., 1996). It was suggested that the
low virus load would be reflected by a lower proportion of cells expressing HIV-1-antigens,
which would be insufficient to stimulate a CD8 cell-mediated response. One child was
consistently CTL-ve using the bulk-culture method. Repeated attempts to culture virus from
PBMCs from this child have been unsuccessful. Plasma HIV-RNA, but not HIV-antigen
(p24), has been detected (Dr. M Arnott, personal communication), but there is also some
evidence that the plasma virus may have been neutralised by antibody (data not shown). In
the case described by Dalod et al., (1996) CTL activity was detected once the patient had
detectable virus levels. In the child in this study, CTL responses were detectable when the
cells were specifically stimulated using HLA-specific peptides, indicating that memory HIV-
1-specific CTLs do exist, but at a low level. If the viral levels increase in this child, a further
expansion of these CTLs could occur and CTL activity may then become detectable using
the bulk-culture method. As was found in the adult studies (Ferbas et al., 1995; Dalod et al.,
135
1996), this child has remained clinically stable, despite the lack of CTL activity.
4.4.4 SPECIFICITY OF CTL RESPONSE FROM PEPTIDE STIMULATED
EFFECTOR CELLS
Stimulation of effector cells by HIV-1-peptides in the CTL+ve children showed a change in
the specificity of response, from that observed previously by the bulk-culture method.
Ahearne et al., (1995) showed an increased CTL response to the target cells which expressed
the same proteins as those used for effector cell stimulation (Ahearne et al., 1995).
Therefore, an increased response to peptide-pulsed target cells was expected. However,
Buseyne et al., (1994) found that peptide-pulsed B cells were not lysed by the effector cells
as frequently as target cells infected with a vaccinia-HIV construct expressing the same
sequence. This was borne out in one child, where the vaccinia-HIV construct-infected target
cells were preferentially recognised over peptide-pulsed target cells. More interestingly, CTL
responses were seen, in two children, to the vaccinia-HIV-po/ construct, when peptides used
to stimulate the cells in those cultures had included those from the gag, env and nef regions,
but not the pol region of HIV-1. It is possible that /^/-specific CTL clones were stimulated
by endogenous HIV-1 expression during activation of the cells in culture. However, these
results indicate that the method of stimulation of the effector cells affect the specificity of the
response, indicating that studies using different methods may not be comparable.
The addition of IL-7 to the peptide-stimulated cultures of one child, enhanced the CTL
response to the vaccinia-HIV construct-infected target cells. It has been suggested that
addition of IL-7 allows the CTL precursors to mature faster than would occur without IL-7
(Carini and Essex, 1994; Ferrari et al., 1995). This could explain the difference in specificity
between these experiments, as the cells were cultured for different lengths of time.
4.4.5 CTL ACTIVITY, LYMPHOCYTE PHENOTYPES AND CYTOKINES
The phenotypes of blood and effector cells for all the CTL+ve and CTL-ve occasions in the
infected children were compared. The effector cells from the CTL+ve occasions contained
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an increased proportion of phenotypically activated and memory CD8 cells, supporting the
findings from studies in adults (Ho et al., 1993; Watret et al., 1993; van Baalen et al., 1993).
Non-detection of CTL activity was accompanied by a lack of expansion of HLA-DR+ CD8
cells, confirming other studies (Watret et al., 1993; Pantaleo et al., 1990b). This also fits
with the observations of Mahalingham et al., (1995), who showed, in HIV-1-infected adults,
that although cells may express different activation markers, only those which express HLA-
DR actively proliferate. The decreased CD38 expression on the CTL+ve effector cells was
surprising. In adults, circulating HIV-1-specific CTLs have been shown to be within the
CD38+ HLA-DR+ CD8 cell population (Ho et al., 1993). However, the expression of CD38
on CD8 cells in whole blood, is different in children from that in adults (see chapter 3) and
reflects the immaturity, rather than activation, of these cells. Therefore, the decrease in CD38
expression on the CTL+ve effector cells may be an indication of the maturation and
differentiation of these cells in culture. Alternatively, the increased expression of CD38 on
the CTL-ve effector cells may reflect an increased occurrence of circulating CD38+ CD8
cells, not expressing HLA-DR, which do not have CTL effector function in vivo (Ho et al.,
1993; Giorgi et al., 1994). Studies in adults also showed an increased expression of CD1 la+
(S6F1) CD8 cells within the effector population (Sohen et al., 1990; Watret et al., 1993),
which was not seen here. It is possible that, as the expression of this marker is very high in
the whole blood of children (see chapter 3), there is no further expression possible in culture.
CTL differentiation has been associated with the production of cytokines produced by the
CD4 cells during culture, with Th-1 cytokines enhancing and Th-2 cytokines inhibiting cell
mediated immunity (Clerici and Shearer, 1993). A significantly higher amount of IL-6 was
produced in the cultures from EU children, regardless of whether they were CTL+ve or not.
The serum levels of IL-6 have been shown to be raised in HIV-1-infected children (Rautonen
et al., 1991), and therefore it was expected that the cultures from the infected children would
produce more IL-6. Although IL-6 is a Th-2 cytokine, it is an inducer of T cell growth
(Kuhweide et al., 1990), and so would be produced and used, during CTL effector growth
in culture. As the cytokine levels were measured after day 7 in culture, the decreased level
of IL-6 in the cultures from HIV-1-infected children may indicate increased usage of this
cytokine, possibly by increased cell turnover, rather than lower production, as a higher
proportion of cells from infected children expressed activation markers (see chapter 3).
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4.4.6 CTL ACTIVITY IN EU CHILDREN
Anti-HIV-1 CTL activity was also detected in EU children. Unlike those found in the
infected children, most of the responses were to HIV-env, possibly reflecting the abundance
of this protein in the virion. Responses to HIV-1 proteins (gag, env, pol and nef) have been
detected in other studies of children born to HIV-1-infected mothers (Rowland-Jones et al.,
1993; Cheynier et al., 1992; de Maria et al., 1994a) and also other exposed uninfected
individuals, such as health care workers (Pinto et al., 1995), prostitutes (Rowland-Jones et
al., 1995) and the uninfected sexual partners in HIV-1-discordant couples (Langlade-Demoyen
et al., 1994). It was suggested that the CTL responses within all these individuals, were
induced from exposure to the virus and had a protective effect in the prevention of HIV-1
infection.
Previous results had identified two exposed uninfected children with CTL activity coinciding
with raised CD8 subpopulations in whole blood. Repetition of these assays, at a later date,
showed no CTL activity and CD8 subpopulations within normal ranges. Therefore, it was
suggested that these children had cleared virus and become uninfected (Rowland-Jones et al.,
1993; Aldhous et al., 1994b, appendix). The increased CD8 subpopulations indicated that
the cells involved in the immune response were activated. Similar observations have been
made in other viral infections, which were cleared by CTL activity and accompanied by a
transient increase in CD8 subpopulations (Miyawaki et al., 1991; Watret et al., 1993; Byrne
and Oldstone, 1984). Direct evidence that children can clear virus has come from Bryson et
al., (1995) who described a child infected with HIV-1, by being positive for virus culture and
PCR, who then became negative for PCR at a later date. No assays of immune function were
performed in this child, so the mechanisms by which clearance of HIV-1 took place, are not
known. The clearance of HIV-1 in children may be facilitated by a low viral load, or a
defective virus, together with an effective immune response. In the EU children studied here,
the lymphocyte surface markers in whole blood were all within the normal ranges shown in
chapter 3. Therefore, it is unlikely that these children were in the process of actively clearing
virus; rather that the CTL responses were from the restimulation of circulating, memory
CTLs. To induce a CTL response, CD8+ CTL precursor cells have to be stimulated by
another cell, which has endogenously processed virus and presented it on the cell surface
(Paul, 1993). This suggests that CTL responses are a result of exposure to, and possible
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clearance of, replicating virus, although CTL responses in mice have been elicited from
immunisation with purified HIV-1 proteins (Takahashi et al., 1990).
In summary, this longitudinal study followed the CTL activity to different HIV-1-proteins in
a cohort of HIV-1-infected children. Different specificities of target recognition by CTLs
were seen, although all but one, of the CTL+ve children recognised HIW-pol. There was no
association between the presence of CTL activity and disease progression. However, a
possible association between the specificity of responses and disease progression was seen,
with HI\-tat rather than HIV-gag, being recognised in the children who progressed clinically.
This would need to be confirmed in other cohorts of children. The method of stimulation
of CTLs has an effect on the specificity of response of the effector cells: stimulation of the
PBMCs in culture with HIV-1-peptides allowed a more HIV-1-specific cell population to
grow. The CTL response was found to be associated with the expansion of a population of
phenotypically activated, memory CD8 cells. However there was no phenotype in whole
blood which could predict the presence of CTLs in the child. CTL responses were not
associated with the levels of IL-6 in culture.
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The phenomenon of CD4 cell loss in HIV-1 infection has been well documented: indeed it
was part of the early descriptions of HIV-1 infection (Gallo et al., 1984; Barr6-Sinoussi et
al., 1983). The CD4 cell plays a central role in the induction of an immune response,
through recognition of foreign antigen and secretion of cytokines (see 1.2.2.3.1). In HIV-1
infection, it is possible that functional defects of CD4 cells may occur prior to cell death,
which would affect its ability to regulate the other aspects of the immune repertoire
(Romagnani, 1992; Kos and Engleman, 1996; Mosmann and Sad, 1996; Kemeny et al.,
1994).
Previous studies in HIV-1-infected adults have used lymphocyte proliferation to assess the
biological responses of T cells to various stimuli, including HIV-1. In these adult studies,
the CD4 cell depletion was preceded by a loss of T cell function, as shown by an inability
of lymphocytes to proliferate to antigens and mitogens (Clerici et al., 1989; Klimas et al.,
1991; Ranki et al., 1989). This reduction in proliferative responses was found to occur in
a specific pattern: the loss of responses to HIV-1 was seen first, then recall antigens followed
by allogenic antigens and finally by a loss of responses to mitogens (Clerici et al., 1989;
Ranki et al., 1989; Bentin et al., 1989).
Only a few studies have examined the T cell proliferative responses in HIV-1-infected
children. A decreased T cell responsiveness and decreased CD4 cell count have been
associated with an increased likelihood of onset of an AIDS-defming illness (Chirmule et al.,
1995). A similar pattern of loss of proliferative response to that seen in adults, has also been
described (Johnson et al., 1991).
Lymphocyte proliferation was studied in the Edinburgh cohort of children, to ascertain
whether the responses were associated with clinical progression in the infected children, and
also, if any loss of response was related to changes in specific lymphocyte populations. Due
to the small amount of material available from these children, the range of stimuli used was
limited to one mitogen, one recall antigen and a combination of recombinant HIV-1 proteins
(rHIV cocktail). Phytohaemagglutinin (PHA) was chosen as the mitogen, as this is a
polyclonal T cell mitogen acting through the T cell receptor and CD2 (Coligan et al., 1996).
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Tetanus toxoid (TT) was chosen as the recall antigen, as the children in the cohort were
immunised against this at 2, 3 and 4 months, with a booster between 4 and 5 years of age
(Department of Health, 1992). The recombinant HIV-1 proteins used in the cocktail were:
gpl20 from two different strains of HIV-1 (HIV-1SF2 and HIV-1MN), p24 (from HIV-1LAI), the
p66 protein of reverse transcriptase (RT) (from HIV-1lav), nef and tat (both from HIV-1IIIB).
There is some evidence that lymphoproliferative responses to HIV-1 also occur in HIV-1-
exposed but uninfected (EU) individuals. These have been interpreted as evidence of specific
immune responses to HIV-1, which may be involved in the prevention of HIV-1 infection in
these individuals (Kelker et al., 1992; Borkowsky et al., 1990; Clerici et al., 1994). The
proliferative responses in EU children were also studied, to see whether they showed any
responses to HIV-1, and if so, for how long these responses remained. As controls, blood
samples were obtained from healthy HIV-1-seronegative plasma donors (normal donors) and
from the umbilical cords of healthy newborn babies (cord bloods), with no risk factors for
HIV-1 infection.
52 METHODS
Proliferative responses were assayed using freshly separated PBMCs incubated with either
antigen or mitogen in quadruplicate, at a final concentration of 1x10s cells/well, in a 96 well
U-bottomed plate. To ascertain the sensitivity of the responses, the mitogen or antigens were
added at two concentrations, one within and one below the recommended optimum range
(between 1 and 10 pg/ml, Coligan et al., 1996). Control wells contained cells with medium
alone. The cells were incubated for 6 days, labelled with lpCi 3H-thymidine for a further 18
hours, harvested onto filtermats and counted (as described in 2.10).
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5.3 RESULTS
5.2.1 LYMPHOCYTE PROLIFERATION TO PHA
The proliferative responses to PHA at concentrations of 2.5pg/ml and 0.5pg/ml are presented
in figure 5.1. These are presented as the stimulation index (geometric mean cpm of
stimulant / geometric mean cpm of medium), as this corrects for the range of background
proliferation observed between individuals. The results for both mitogen concentrations are
shown for the cord bloods, normal donors, EU and HIV-1-infected children. The infected
children were further divided into groups according to age and CD4% profile as previously
described (see chapter 3).
Comparison of the responses at the higher (optimal) concentration, showed that the normal
donors had significantly higher stimulation index values than the other three groups (analysis
of variance on the log stimulation index values, p<0.01). None of these responses were at
stimulation index values of less than 100. Of thirteen assays in cord bloods, only one had
a stimulation index of less than 3 (i.e. a negative response). There was no significant
difference in the stimulation index values when comparing the HIV-1-infected and EU
children (by two-sample t-tests on log values). Three children (two EU and one HIV-1-
infected) had stimulation index values of less than 3.
At the lower (sub-optimal) concentration, a one way analysis of variance on the log values
showed that the normal donors still had significantly higher stimulation index values than the
other three groups (p<0.05). Of thirteen cord bloods, two had a stimulation index of less than
3. There was no significant difference when the HIV-1-infected and EU children were
compared, by a two-sample t-test on the log stimulation index values. Six children (four EU
and two infected) had stimulation index values of less than 3.
The proliferative responses, for the different subject groups, to tetanus toxoid (TT) at
concentrations of 2.5pg/ml and 0.5pg/ml are presented in figure 5.2. Comparison of the
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responses (by analysis of variance on the log stimulation index values) showed there was no
significant difference between the groups at the higher antigen concentration. At the lower
concentration, a difference was seen (p<0.05). The responses in the EU children were
significantly higher than those in the HIV-1-infected children (p<0.05, by two-sample t-test
on log stimulation index values).
5.3.2.1 Relationship of TT responses to age in EU children
The EU children, as a group, were younger in age than the HIV-1-infected children (mean
age = 31.4, range 1 - 156 months; mean age = 83.2, range 21 - 137 months, respectively).
To see whether there was an age-relation in these TT responses, and whether the lower
responses in the infected children could be due to their being older, the EU children were
divided into 3 groups: younger than 6 months, 6 - 18 months and older than 18 months. The
stimulation index values (geometric mean and range) are shown in table 5.1, together with
the numbers within each group with a positive proliferative response. Comparison of the age-
groups by analysis of variance (on the log stimulation index values) showed that the children
younger than 6 months had significantly reduced responses to tetanus toxoid at both
concentrations (p<0.05, table 5.1). This difference could reflect the age at which the children
were immunised against TT. The stimulation index values for all the children older than 6
months of age were combined and compared to the HIV-l-infected children (all of whom
were older than 6 months of age). This is shown in table 5.1, as geometric means and range.
The older EU children had significantly higher responses to TT than the HIV-l-infected
children (p<0.01 at 2.5 pg/ml and p<0.01 at 0.5 pg/ml, by two-sample t-tests on the log
stimulation index values).
5.3.3 LYMPHOCYTE PROLIFERATION TO RECOMBINANT HIV-1
COCKTAIL
The proliferative responses to the rHIV cocktail at concentrations of 1.25pg/ml and 0.25pg/ml
are shown in figure 5.3. Comparison of the subject groups by analysis of variance (on the
log stimulation index values) showed that the responses from the cord bloods were
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Table 5.1 Responses to Tetanus Toxoid
Child group Stimulation index Responses p value
geometric mean (range) SI > 3 (n)
TT at 2.5ug/ml
EU Children
< 6 months (n = 12) 2.07 (0.96 - 42.08) 4
6 - 18 months (n = 18) 13.43 (0.93 - 206) 12 0.029*
> 18 months (n = 14) 8.55 (0.58 - 358) 11
EU > 6 months (n = 32) 12.33 (0.58 - 358 23 0.0021§
HIV+ve (n = 21) 3.26 (0.75 - 538) 8
TT at 0.5pg/ml
EU children
< 6 months 1.61 (0.46 - 30.5) 1
6 - 18 months 9.84 (0.88 - 217) 10 0.024*
> 18 months 10.68 (0.80 - 387) 10
EU > 6 months 12.24 (0.80 - 387) 20 0.0018§
HIV+ve 2.59 (0.28 - 285) 6
The proliferative responses to tetanus toxoid (TT) are shown at two concentrations.
The geometric mean and range of the stimulation index values (SI) are shown for the
different age groups of the EU children, and for the EU and HIV-1 infected (HIV+ve)
children of over 6 months.
11 denotes the p value was obtained from the analysis of variance for these groups using
the log stimulation index values.
























significantly higher than those in the other subject groups, at both concentrations (p<0.01).
Comparison of the EU and infected children showed a slight decrease in responses in the
infected children, which was not significant at the higher concentration (p = 0.06), but was
significant at the lower concentration (p<0.01).
These unexpected results were further investigated by obtaining five more cord bloods, and
assaying for proliferation against the rHIV cocktail as before. The cells were also incubated
with each recombinant protein individually and with an alternative combination of the two
gpl20s and p24 (gpl20/p24), all at the same concentrations previously used. The results are
presented in figure 5.4, and show that proliferative responses were seen against the rHIV
cocktail as before, and also against the recombinant proteins tat, nef and RT (p66). These
three proteins had been expressed in Esherichia coli (E.coli). The gpl20/p24 combination
induced no proliferative response in cord bloods, and was, therefore, used in subsequent
proliferation assays.
Preliminary results using the gpl20/p24 at concentrations 1.25pg/ml and 0.5pg/ml in the cord
bloods, EU and HIV-1-infected children are presented in figure 5.5. None of the cord bloods
or the EU children showed any responses to these proteins, but two (of six) HIV-1-infected
children did show positive responses.
5.3.4 RELATIONSHIP BETWEEN PROLIFERATIVE RESPONSES AND
PBMC SUBPOPULATION
To see whether there was a relationship between proliferative responses and the proportions
of different lymphocyte populations in whole blood, these were compared for both PHA and
TT, for all the subject groups together. The lymphocyte populations measured were: the
percentage of total lymphocytes expressing CD3, CD4 or CD8; the percentage of CD4 cells
co-expressing either CD45RO or CD45RA, to see whether the proportion of (phenotypically)
memory and naive cells affected the responses; the percentage of CD3 cells co-expressing
CD28, to see whether the expression of this co-stimulatory molecule, required for antigen-
specific T cell responses (Linsley and Ledbetter, 1993), was related to proliferation to a











































































The proliferative responses for PHA and TT (log stimulation index) were compared with the
percentage of cells expressing the marker of interest.
The lymphocyte populations are defined as: the percentage of total lymphocytes expressing
CD3, CD4 or CD8; the percentage of CD4+ cells co-expressing either CD45RO or CD45RA
(CD45RA+ CD4); the percentage of CD3+ cells co-expressing CD28 (CD28+ CD3)
§ the correlation value (r) was obtained using Microsoft Excel
U denotes a significant correlation (p<0.05)
Table 5.2 Proliferative response and lymphocyte population
Stimulant Lymphocyte population correlation
(%) value (r)§
























of greater than 0.21 denotes a significant correlation (for n = 87 children, Wardlaw, 1985).
For PHA, there was no correlation between the log stimulation index and percentage of CD3,
CD4 or CD8 lymphocytes in PBMCs at either concentration (table 5.2). Correlations between
the log stimulation index and the percentages of CD45RO+ and CD45RA+ CD4 cells were
seen at the higher concentration (r = 0.473 and r = -0.433, respectively), indicating that the
proliferative responses increased as the proportion of CD45RO+ CD4 cells increased. There
was no correlation between the log stimulation index and any lymphocyte phenotype at the
lower concentration of PHA.
For TT, no lymphocyte population showed any correlation to the log stimulation index.
5.3.5 RESPONSES IN HIV-1-INFECTED CHILDREN
Data from the HIV-1-infected children were presented in figures 5.1 and 5.2 according to the
CD4% groups outlined in chapter 3: group I contains the older children who have not yet
progressed; group II contains the older children who have a decreased CD4%; group III
contains the younger children and includes one of the children classed as a fast progressor.
From figure 5.1 it can be seen that all except one group III child, responded to PHA at the
higher concentration. At the lower PHA concentration, the same child and a group II child
did not respond. The highest responses to PHA were seen in three children, one from each
group. There was no association between the level of response to PHA and the groups to
which the children belonged.
From figure 5.2 it can be seen that the highest responses to TT were seen in two children




The loss of CD4 cell function before the depletion of CD4 cell number has been documented
in HIV-1 infected adults. A consistent progressive pattern of loss of responses to HIV-1 and
recall antigens, followed by alloantigens and finally mitogens has been shown in a number
of studies in adults (Clerici et al., 1989; Bentin et al., 1989; Hoy et al., 1988; Ranki et al.,
1989). This study was undertaken to determine whether proliferative responses to PHA, TT
and HIV-1 were lost in a particular pattern in HIV-1-infected children.
The HIV-1-infected children showed similar PHA responses to those seen in EU children.
However, the responses to TT were significantly lower in the HIV-1-infected children,
compared with the EU children older than 6 months of age. This is consistent with results
of a previous study of infected adults, which showed that the loss of proliferative responses
to TT could identify early immune dysfunction (Hoy et al., 1988). HIV-1-infected children
from all the CD4% groups had reduced responses to TT, which supports the results of a
previous study (Chirmule et al., 1995). A study by Clerici et al., (1993a) suggested that age
affects the cytokine and proliferative responses to recall antigens in normal children. They
reported that PBMCs from cord bloods and children between 6 and 13 months of age did not
produce responses to flu, and only a few children showed weak responses to tetanus. In
contrast, the results from the EU children in this study, showed that responses to TT reached
adult levels by 6 months of age. However, markedly reduced responses to TT were seen in
the EU children of less than six months of age. The most likely explanation of this would
be that the recall response to this antigen after primary immunisation had not yet developed.
There is evidence indicating that the timing and extent of the PHA response are influenced
by the proportions of CD45RO+ and CD45RA+ cells in the culture; CD45RA+ cells respond
more readily to stimulation by PHA (Morimoto et al., 1985; Merkenschlager and Beverley,
1989; Akbar et al., 1991), whereas CD45RO+ cells respond readily to recall antigens and
more slowly to PHA (Merkenschlager et al., 1988; Merkenschlager and Beverley, 1989).
Thus, the kinetics of the proliferative response to PHA, from the CD45RA+ cells, would be
faster and would peak earlier, than that of the CD45RO+ cells; a slower response, which
would peak later, would be expected from the CD45RO+ cells. A positive correlation was
seen between the PHA response and the percentage of CD45RO+ CD4 cells, at the higher
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concentration of PHA. Conversely, a negative correlation was seen between the PHA
response and the percentage of CD45RA+ CD4 cells, i.e. a higher response to PHA was seen
with an increased proportion of CD45RO+ CD4 cells. The cultures from the normal donors
contained a higher proportion of CD45RO+ CD4 cells, in the initial cell populations, than
those of the other subject groups, and these showed the least variation and the highest
stimulation index values. As the cells were incubated for a period of time which was longer
than is optimal for this mitogen (3 - 4 days would have been better than 7 days), these higher
responses in the normal donors, therefore, could reflect a later peak of the PHA response, due
to the higher proportion of CD45RO+ CD4 cells.
Memory CD4 cells respond to recall antigens (Merkenschlager et al., 1988; Merkenschlager
and Beverley, 1989), and some studies have correlated the loss of CD4 function, in HIV-1-
infection, with the loss of the memory CD4 cell population (van Noesel et al., 1990;
Schnittman et al., 1990; Shearer and Clerici, 1991). However, this finding has not been
confirmed in all studies (Giorgi et al., 1987; Hoy et al., 1988). Other studies have shown
that the induction of a proliferative response to a recall antigen requires activation of the
CD28 moiety on the cell by interaction with the B7 antigen on the APC (Linsley and
Ledbetter, 1993). They have further suggested that the loss of recall response is due to the
loss of surface CD28 expression (Linsley and Ledbetter, 1993; Borthwick et al., 1994; Boise
et al., 1995). However, in this study, there was no correlation between recall response to TT
and the expression of the memory (CD45RO) marker or CD28 on lymphocytes.
In other studies of HIV-1-infected children, a correlation between proliferative responses and
absolute CD4 count has been seen (Chirmule et al., 1995; Johnson et al., 1991). However,
both these studies also reported a subset of children with a decrease in recall responses,
regardless of the CD4 count. There was no association between CD4% and responsiveness
to recall antigen in the HIV-1-infected children studied here, as all the CD4% groups
contained responders and non-responders. The highest responses to TT was seen in a group
II child, who was losing CD4 cells. This suggests that those circulating CD4 cells that were
present, may have had an 'over-reactive' response to antigen, which could lead to cell death
through apoptosis or other biochemical mechanisms (Katsikis et al., 1995; Bofill et al., 1995).
Another recent study has shown that the addition of intravenous immunoglobulin G (IVIgG)
preparations to cultures in vitro, can suppress the proliferative response (Andersson et al.,
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1996). IVIgG is used to prevent bacterial infections (de Martino et al., 1991; Mofenson and
Moye Jr, 1993). In the study here, two children in group I and one child in group II,
received regular IVIgG infusions every three weeks (Dr. J. Mok, personal communication).
The mechanism of IVIgG suppression of proliferation is unknown, but it may have some
residual effect on the PBMCs, despite their having been washed before culture.
Proliferative responses were seen to the HIV-1 proteins which had been expressed in E.coli
(nef, tat and the p66 moiety of reverse transcriptase). It is possible that during the extraction
or purification procedure, some of the E.coli proteins were also co-purified with the
recombinant HIV-1 proteins (Dr. H. Holmes, MRC AIDS Reagent Programme NIBSC,
personal communication). However, it was not possible to confirm this, as control extracts
were not available. The preparations were greater than 90% pure (MRC ADP Reagents
catalogue), and the concentrations of recombinant protein used were 1.25pg/ml and 0.5 pg/ml.
If 10% of the protein added to the culture was derived from bacteria, this would mean that
the concentration of the bacterial contaminant could be as much as 50ng/ml. One study of
proliferative responses to bacterial lipopolysaccharide (LPS), optimised the responses using
between 100 and 10,000 ng/ml of antigen, although responses were seen at lower
concentrations (Mattern et al., 1994). Therefore, it could be postulated that the concentration
of bacterial contaminant, which might be present in these cultures, would be enough to give
a measurable proliferative response. Small amounts of bacterial products can induce the
release of cytokines from cells which, in turn, could lead to the activation of these cells by
autocrine mechanisms (Mattern et al., 1994). Therefore, the responses seen to the rHIV
cocktail could be better interpreted as anti-bacterial responses, possibly occurring through
some mechanism which does not require prior priming by antigen (Zumia, 1992).
A study of responses to Cryptococcus neoformans, in adults without prior exposure, showed
that proliferative responses to this organism were seen in normal adults. In HIV-1-infected
individuals a loss of proliferative response to this antigen was associated with an increased
likelihood of progression to AIDS (Hoy et al., 1988). If the responses to rHIV cocktail, in
the children studied here, were interpreted as anti-bacterial responses, then the proliferative
responses of the cord bloods may indicate the available vigorous response to bacterial
antigens encountered perinatally, possibly by some innate mechanism (Pabst and Kreth,
1980). At the lower concentration of the rHIV cocktail, these responses were comparable in
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EU children and normal adults, but decreased in the HIV-1-infected children. This may
reflect a decreased proliferative capacity against bacterial antigens in the infected children,
which may explain the increased susceptibility to opportunistic bacterial infections observed
in other cohorts (Galli et al., 1995).
It is possible that the proteins themselves had an effect on the cells to increase their
proliferative activity. Studies have indicated that HIV-tat can act as a T-cell growth factor
(Rosen, 1992) and has some homology with snake neurotoxins (Garry and Koch, 1992).
However, there is also evidence that HIV-1-proteins may inhibit proliferation. HIV-tat has
been shown to inhibit antigen-specific T cell responses (Subramanyam et al., 1993), whereas
intracellular HIV-nef has been shown to inhibit activation pathways of PBMCs (Greenway
et al., 1995).
Proliferative responses to HIV-1 antigens have been reported in some HIV-1-infected children
and adults (Borkowsky et al., 1990; Pontesifli et al., 1995). In adults, responses have been
seen to a selection of HIV-1 proteins (gpl20, p24 and rev) in individuals with higher CD4
counts, but the specificity of response differed between individuals (Pontesilli et al., 1995).
The results presented here are consistent with this study, as proliferative responses to
gpl20/p24 were seen in two children, both of whom had stable CD4 percentages.
Preliminary results using the p24/gpl20 cocktail indicated that there was no substantial
proliferation to these antigens in the EU children. Any responses that may have been present
were masked by the responses to the probable contaminant in the antigen preparation. Some
studies of exposed uninfected individuals (EUs) have detected IL-2 production in response
to HIV-1 antigens but not proliferation (Clerici et al., 1992; Clerici et al., 1993b). In one
study of 23 cord bloods, from HIV-l-exposed children, IL-2 production in response to HIV-1
antigens was only found in a proportion (8/23). In the same study, 3 of the 15 non-IL-2-
producers (20%), but none of those who produced IL-2, were later found to be infected with
HIV-1. The authors suggested that exposure to HIV-1 in utero can stimulate anti-HIV-1
responses which is protective against HIV-1-infection (Clerici et al., 1993b). However, in
that study, the twelve non-IL-2 producers who did not become infected indicate that there
must be other mechanisms by which these children remained uninfected.
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In conclusion, this study shows that the responses to recall antigen in the HIV-1-infected
children were reduced compared to EU children, but that PHA responses were comparable.
There was no association between proliferative responses and clinical progression. A
correlation between the proliferative response to PHA and the proportion of CD45RO+ CD4
cells in whole blood was seen. Two (of six) infected children, both of whom with a stable
CD4% showed responses to recombinant gpl20/p24 proteins, indicating that these responses
may be associated with the maintenance of disease stability.
158
Chapter 6 DOWN REGULATION OF CD4 FROM THE
SURFACE OF T CELLS IN AN HIY-1-
INFECTED CHILD
6.1 INTRODUCTION AND OBJECTIVE
6.2 STRATEGY FOR INVESTIGATION AND CD4 RT-PCR METHOD
DEVELOPMENT
6.2.1 CD4 depletion of PBMCS
6.2.2 RNA extraction
6.2.3 Reverse transcription of mRNA to cDNA
6.2.4 Development of PCR method for CD4
CD4 RT-PCR using combined RT and PCR steps
Separate RT and PCR reactions
Titration of HeLa-CD4 RNA
6.2.5 PCR for B-Actin
6.2.6 PCR for HIV-1





6.1 INTRODUCTION AND OBJECTIVE
T lymphocytes are characterised by the expression of CD3 and the T cell receptor (TCR) on
the surface of the cells. They are divided, functionally, into those which have a helper
function and those which have a cytotoxic or suppressor function. T-helper cells usually
express CD4 on the surface of the cells, while cytotoxic/suppressor cells usually express CD8.
The CD4 molecule is a 60kD trans-membrane glycoprotein, which, in conjunction with the
TCR, recognises antigenic peptide presented on the MHC class II molecule on APCs (see
1.4.2.1 and figure 1.3). The recognition of antigen causes a signal to transduce into the cell,
through the cytoplasmic domain of the CD4 molecule. The CD4 molecule then associates
with p56'c* (a member of the src family of tyrosine kinases) within the cytosol (Ravichandran
and Burakoff, 1994). Tyrosine kinases are enzymes which phosphorylate proteins (on the
tyrosine moiety), and are part of the signal transduction mechanisms within the cell.
Intracellular signal transduction leads to the activation of the cell and production of cytokines.
These cytokines (small 'messenger' peptides), in turn, affect other cells to produce an
immune response (see figure 1.4) (Kemeny et al., 1994; Kos and Engleman, 1996; Mosmann
and Sad, 1996; Romagnani, 1992). In HIV-1 infection, progression of disease is characterised
by the loss of circulating lymphocytes expressing CD4 on the surface, leading to an increased
susceptibility of the individual to opportunistic infections.
The CD4 molecule has also been shown (together with the 8-chemokine receptors) to be the
main route for HIV-1 entry into cells. HIV-gpl20 binds to the CD4 molecule on the surface
of cells, causing a conformational change, followed by fusion of viral and cellular
membranes, allowing entry of the viral core into the cell (Antoni et al., 1994). Infection of
cells expressing CD4, by HIV-1, can affect the expression of CD4 on the cell surface.
Studies in T-cell lines have shown that CD4 expression at the cell surface is down-regulated
by HIV-1. The exact mechanisms by which this down-regulation occurs is not clear, but
HIV-nef, -vpu and -env have all been implicated. Some (thus far unclear) interaction of tief
with the cytoplasmic domain of the CD4 molecule (Garcia et al., 1993; Anderson et al.,
1994) has been shown to cause endocytosis of surface CD4 which accumulated within
endosomes in the cell (Schwartz et al., 1995). There is evidence that HIV-v/;« then promotes
the degradation of the CD4 molecule within these endosomes (Willey et al., 1994; Bour et
al., 1995). Crise et al., (1990) showed that, after synthesis of CD4 in HIV-1-infected cells,
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complexes of CD4 and gp 160 (the envelope precursor protein of HIV-1) were formed. These
CD4-gpl60 complexes were retained within the endoplasmic reticulum (ER), and thus CD4
was not expressed on the cell surface. However, CD4 molecules not complexed with gpl60,
were expressed normally at the cell surface (Crise et al., 1990). Chen et al., (1996) showed
that the tief, vpu, and env-mediated mechanisms of CD4 down-regulation occurred
independently and at different stages of HIV-1 infection within cells. They found that nef
down-regulated CD4 in the early stages of viral infection of the cell, while the actions of vpu
and env were seen later on in the viral life-cycle. However, maximal CD4 down-regulation
was seen when the actions of all three gene products occurred in the same cells. This down-
regulation could also occur in PBMCs, but was less efficient than that seen in T cell lines,
and was more dependent on the actions of nef than vpu and env (Chen et al., 1996).
However, these mechanisms of down-regulation do not affect the de novo biosynthesis of
CD4 (Schwartz et al., 1995; Sanfridson et al., 1994).
During the study of lymphocyte surface markers (chapter 3), one child was noted whose total
percentage of lymphocytes expressing CD3, was markedly greater than the sum of the
percentages of lymphocytes expressing CD4 or CD8. This was also seen in the routine
monitoring of the CD3, CD4 and CD8 expressing cells in this child using a different set of
antibodies (J.A. Whitelaw, personal communication, see table 6.1). Thus, it appeared that a
circulating population of T lymphocytes was present in this child which did not express either
CD4 or CD8. The child was born in Africa, had consistently shown no CTL activity to HIV-
1 (see chapter 4) and had progressed to AIDS by the age of 70 months.
Although, the down-regulation of CD4 has been shown in in vitro HIV-1-infected PBMCs,
this phenomenon has not been described in cells obtained from HIV-1-infected individuals.
Therefore, it was decided to investigate the T cells from this child, to determine whether they
were synthesising CD4, but not expressing it on the cell surface, and whether this loss of
surface CD4 was associated with HIV-1 infection of the cell.
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6.2 STRATEGY FOR INVESTIGATION AND CD4 RT-PCR
METHOD DEVELOPMENT
The strategy for investigation is shown in figure 6.1, with the modifications of the methods
outlined in italics, and described in detail below.
Freshly isolated PBMCs were separated into cells expressing surface CD4 (CD4+ve) and
those not expressing CD4 (CD4-ve) fractions. This was done by positive selection using anti-
CD4 antibodies and immunomagnetic beads. The CD4 expressing cells were retained on a
magnetic column, while the CD4-ve fraction was collected. The CD4+ve fraction was then
eluted and collected (described in detail in 2.11). The purity of the eluted fractions was
checked by flow cytometry (described in 2.3.1), to show that the CD4-ve fraction contained
only cells which were not expressing CD4 on the surface. Cells from the CD4+ve fraction
were not checked by flow cytometry, as the surface CD4 molecules were already complexed
to antibodies and beads.
Initially, DNA and RNA were co-extracted from cells (denoted DNA/RNA) using the method
described in 2.12.1. It was envisaged that, in the final experiment, total RNA (without DNA)
would be used, from which mRNA could be detected. Detection of mRNA would reflect the
cells which were actively synthesising the molecules of interest.
A DNAase step to remove DNA was tried, by incubating the DNA/RNA with DNAase at
37°C for 20 minutes. This was then heated to 80°C for 10 minutes to degrade the DNAase.
PCR using the DNAase-treated RNA gave no bands (see below). However, bands were seen
when DNA/RNA was used without a DNAase step (see below).
A Micro-RNA Isolation kit was tried from Stratagene, (described in 2.12.2) as this was
6.2.1 CD4 DEPLETION OF PBMCS
6.2.2 RNA EXTRACTION
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promoted as giving a more efficient extraction of small amounts of RNA. To compare the
extraction methods, PBMCs from normal donor cells were used, from which adherent cells
had been removed. These cells were 'snap' frozen (i.e. frozen quickly at -70°C, which helps
to break up the cells) in aliquots of 10-fold dilutions from 10' to 102 cells and extracted using
the Strategene kit or the phenol/chloroform method (described in 2.12). RT-PCR for B-Actin
was performed on the RNA or DNA/RNA (described in 2.13.2 and 2.13.3.1). The primary
PCR products for B-Actin, (lOpl) were visualised by electrophoresis on a 1.3% agarose gel
against molecular weight (pGEM) markers. (These are lengths of DNA of known sizes
against which the DNA bands of interest are sized, see 2.13.5). The gel was run at 150V for
1.5 hours.
The results are presented in figure 6.2. B-Actin bands were seen from cells extracted using
the Stratagene kit, but not the DNA/RNA from the phenol/chloroform method. This shows
that the Stratagene method is more efficient for RNA extraction. The initial PCR
experiments used extracted DNA and RNA (denoted DNA/RNA), whereas the later ones used
RNA extracted with the Stratagene method (denoted RNA).
6.2.3 REVERSE TRANSCRIPTION OF mRNA TO cDNA
For CD4, the initial method combined the reverse transcriptase (RT) and primary PCR steps
(see 6.2.4.1). When this was unsuccessful, it was decided to separate the RT and PCR steps,
as these could allow conditions which would be more optimal for the enzymes used. All
mRNA contains a 3'-poly-A tail (Alberts et al, 1989). Therefore, an oligo-dT primer was
used which annealed to the 3'-poly-A tail, and RT transcribed the RNA to cDNA (described
in 2.13.1).
For most of the experiments, the RT step was done using a reverse transcriptase enzyme
obtained from Promega (AMV-RT). However, a different reverse transcriptase enzyme,
Expand™-RT (from Boehringer), was also tried (described in 2.12.1.2). This enzyme was
engineered with a point mutation so that it has less RNase H activity, and so produces larger
amounts of cDNA. This enzyme was compared to AMV-RT, using RNA diluted out in 10-
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(described in 2.13.3.1). The primary PCR product (lOpl) was electrophoresed on a 1.2%
agarose gel, against pGEM markers at 150V for 1.5 hours.
Bands corresponding to the expected product size of B-Actin (661 bp) were seen from cDNA
from using both enzymes and are shown in figure 6.3. Those using the Expand™-RT were
brighter than those seen from using the AMV-RT. These results indicate that the Expand™-
RT is a more efficient enzyme than AMV-RT, for reverse transcription of RNA to cDNA.
6.2.4 DEVELOPMENT OF A PCR METHOD FOR CD4
6.2.4.1 CD4 RT-PCR using combined RT and PCR steps
A PCR method for CD4 was found in a study which had compared CD4 sequences between
humans and different monkey species (Fomsgaard et al., 1992). The primer sequences used
in that study were made from the conserved regions of human CD4, which were found to be
the same as another published sequence of human CD4 (Maddon et al., 1985). The primers
were synthesised (by Oswel DNA Services) and the sequences are given in 2.13.2.2. The
outer primers for the primary PCR are denoted CD4-1 (sense) and CD4-2 (antisense). These
give an expected product size of 1346bp. The inner (or nested) primers for the secondary
PCR are denoted as CD4-3 (sense) and CD4-4 (antisense). These gave an expected product
size of 1195bp. DNA/RNA was extracted from normal donor PBMCs (described in 2.12.1).
Although the sources of reagents were different, combined reverse transcription and PCR
steps were performed as described in the original paper (Fomsgaard et al., 1992). Briefly,
DNAase-treated RNA was incubated with the primary PCR primers (CD4-1 and CD4-2) in
a PCR buffer containing dNTPs and RNAsin, and both AMV Reverse Transcriptase (AMV-
RT) and Taq polymerase (Taq) in a lOOpl amplification reaction. The tubes were incubated
on a thermocycler at 42°C for 60 minutes (reverse transcription step), followed by 94°C for
4 minutes (to denature the cDNA) and then 30 cycles of 94°C for 1 minute, 50°C for 1.5
minutes (to anneal the primers to the cDNA) and 72°C for 2 minutes (extension step). A
secondary PCR was performed from the primary product (lOpl), using inner primers (CD4-3
and CD4-4) and the same PCR programme, omitting the initial 60 minute incubation
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agarose gel against pGEM markers. The gel was run at 75V for 2 hours. No bands were
seen. This experiment was repeated using DNA/RNA without DNAase treatment, and still
no bands were seen.
The primary and secondary PCR products from these primers were very large (1346bp and
1195bp respectively) as they were designed to be used to create cDNA libraries from low
quality RNA. In a nested PCR, which is driven by Taq polymerase, full length copies may
not be produced. Therefore, using a published sequence of CD4 (Maddon et al., 1985), and
keeping the two antisense primers from the original method (CD4-2 and CD4-4), two further
sense primers were designed (with the help of C.M Wade). This was done by choosing a
region in the CD4 gene which was approximately 500bp from CD4-2 (the outer anti-sense
primer). Sequences which were rich for C and G bases were chosen, as these are more stable
than A-T rich regions. The new primers were denoted CD4-5 (outer sense primer) and CD4-
6 (inner sense primer). These gave expected primary and secondary PCR product sizes of
579bp and 459bp respectively. The alignment positions of all the primers, both from the
original paper and those designed, are shown in figure 6.4, and the primer sequences are
described in 2.13.2.2. These primers were used in the same PCR reaction as used originally
(see above) for two attempts but no bands were seen.
6.2.4.2 Separate RT and PCR reactions
Resting PBMCs should contain mRNA for CD4, through a low level of cell turnover.
However, it was decided for these experiments, to use RNA extracted from human cell lines
which express CD4 and are actively replicating, as there would be more total, and CD4-
specific mRNA, available from these lines. The DNA/RNA used in this experiment was
prepared (by D. Innes, E. Harvey and A. Alonso) from the following cell lines: C8166 cells
(a human T-lymphoblastoid cell-line, which expresses CD4); HeLa cells (a human epithelial-
like cell line, which does not express CD4) and HeLa cells transfected with CD4 (HeLa-
CD4). Total RNA (lpg), from each cell line, was used in each AMV-RT reaction (described
in 2.13.1). The synthesised cDNA was used in PCRs for CD4, using both sets of primers
(i.e. to give both the larger (1195bp) and smaller (459bp) secondary PCR products), and the
original thermocycler programme (described in 2.13.2). The secondary PCR products (lOpl)
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Figure 6.4 Alignment of the CD4 primers
The 5' to 3' sequence of the DNA of human CD4 is represented by the red line. The
positioning of the primers for CD4 are shown by arrows, and the numbers above the
arrows indicate the position of the primer by the base number. Arrows pointing 5'
to 3' indicate the sense primers. Arrows pointing 3' to 5' indicate the anti-sense
primers. The primers from the original CD4 method (Fomsgaard et al., 1992) are
indicated as CD4-1 to CD4-4. The new primers synthesised are shown as CD4-5 and
CD4-6. The primer sequences are given in 2.13.2.
0 70 99 155 178
5'
CD4-1 CD4-3
(outer sense primer) (inner sense primer)
837 861 891 914
CD4-5 CD4-6








were separated by electorphoresis on a 1.3% agarose gel against pGEM markers, at 150V for
1.5 hours.
Results are shown in figure 6.5. Both sizes of CD4 products were seen from C8166 and
HeLa-CD4 cells but not HeLa cells, as expected. No bands were seen for RNA-ve, cDNA-ve
and primer-ve controls and only non-specific bands were seen for Taq-ve controls.
6.2.4.3 Titration of HeLa-CD4 RNA
As it was envisaged that only a small amount of RNA would be available in the final
experiment, and hence even less CD4-specific mRNA, the limits of detection were
investigated. The RT step was carried out using AMV-RT for the HeLa-CD4 DNA/RNA,
titrating the total DNA/RNA added from lpg to lpg, in 10-fold dilutions in DEPC-water.
PCR for CD4 was carried out using both primer sets to see which size of CD4 PCR product
would be easier to obtain from small amounts of RNA. The secondary PCR products (lOpl)
were run on a 1.3% agarose gel against pGEM markers, at 150V for 1.5 hours.
The results are presented in figure 6.6 and show that CD4 bands (1195bp and 459bp) were
seen at the dilutions down to lOOpg of total DNA/RNA in the RT step, but not below. For
the larger CD4 product, some bands were very faint. The primers for the smaller CD4
product (459bp) gave more consistent results, and therefore, were used for the rest of the
study. No specific bands were seen in the RNA-ve, cDNA-ve, Taq-ve and primer-ve
controls.
6.2.5 PCR FOR B-ACTIN
To show that the RNA had reverse transcribed, the cDNA from the above experiments was
also used in a PCR for P-Actin. p-Actin was used as a positive control as this protein is
constitutively expressed as part of the cell cytoskeleton. Therefore, every time a cell divides,









PCRgelafterRT-PCRforCD4usingb thprimers ts.HeLa- D4NAwastit a dutrol g( nan1d2)l 3 14)intheRT-reaction.cDNAwasus dnes ePCR.hs ondaryproductow .Ban sfortlarg rC 4r(ex t size1195bp)andthmallerCD4product(expect diz459rindicbyrrows.TGEMma k rssh nla M,andthenumbersonrighthsideef rot iz fesmark .L1521containn gativetrol :la s6 (noRNA),lanes17and8cDNA),920Taql e1primers).
1234567890Mil3147892
The primary PCR for P-Actin was carried out (described in 2.13.3), using primers and a
method obtained from Stratagene. The primer sequences are detailed in 2.13.3.1. Bands
corresponding to the expected product size (661 bp) of P-Actin are shown in figures 6.2 and
6.3.
A secondary primer was also obtained for the P-Actin PCR, in a nested reaction which gave
a secondary PCR product of 501bp. The primer was designed by A. Alonso, and synthesised
by Oswel DNA Services. Details of the primers are given in 2.13.1.2. The secondary PCR
for p-Actin was tried using the primary products obtained in 6.2.3 (comparison of the two
RT enzymes). The secondary products (20pl) were electrophoresed on a 1.2% agarose gel
against pGEM markers, at 150V for 1.5 hours.
The results are shown in figure 6.7. Bands for all the dilutions of RNA (described in 6.2.3,
and legend to figure 6.3) were seen from the secondary PCR of P-Actin. In the lanes
containing higher initial amounts of RNA, a second band was also seen with the secondary
PCR product. This band was the same size as the primary product for B-Actin, and was
probably residual primary product. As this was the last preliminary experiment, the
secondary PCR was only used for the final experiment.
6.2.6 PCR FOR HIV-1
A CD4 cell productively infected with HIV-1 would be more likely to show surface CD4
down-regulation, than a latently infected one. Therefore, as the detection of HIV-1 DNA
would not distinguish between latently and productively infected cells, the presence of HIV-1
mRNA was investigated to see whether the virus was actively replicating in the same cell
fractions.
This was done using primers for a region of the env gene, which produces spliced mRNA,
i.e. the regions in the HIV-1 genome are quite distant (the primary sense primer anneals at
173bp, and the antisense primer anneals at 5725bp). When mRNA is made, the exons within
the genomic DNA are removed and a small product is given (in this case a product of 215bp)
(Zack et al., 1990; Schwartz et al., 1990). A secondary primer was designed by A. Alonso.
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The primers and method are described in 2.13.4.
6.2.6.1 Analysis of subtype A/D strains of HIV-1
As the child to be studied was from central Africa, it was necessary to check whether the
HIV-1 primers were suitable for subtype A and subtype D viruses, as they had originally
been designed using a subtype B strain of HIV-1 (Zack et al., 1990; Schwartz et al., 1990).
Three different viruses were used, derived from Zairian patient strains. Two were subtype
D viruses (HIV-1ELI and HIV-1Z129) and the other a subtype A virus (HIV-1MAI ). Human T-
cell lines infected with these subtypes of HIV-1 were available (from the MRC AIDS
Reagent Programme): CEM cells infected with HIV-1ELI (called CEMeli here), H9 cells
infected with HIV-1Z129 (called H9Z129 here), or with HIV-1MAI (called H9MAL here). These
cells were snap-frozen and the RNA extracted (described in 2.12.2). The RT step was done
using AMV-RT and the resulting cDNA was used in nested PCRs for CD4, HIV-1 and a
primary PCR for |3-Actin. The PCR products (lOtil) were run on a 1.3% agarose gel against
pGEM markers, at 150V for 1.5 hours.
The results are shown in figure 6.8. Bands corresponding to the sizes of the expected PCR
products were seen for Actin (661bp), CD4 (459bp) and HIV-1 (179bp). PCR products were
seen for each of these HIV-1-infected cells lines indicating that the primers were appropriate
for recognition sequences from these HIV-1 subtypes.
63 EXPERIMENT
Although the phenomenon of the lymphocyte levels, had been seen over a period of 18
months, only one fresh blood sample was available from the index child.
The blood samples used were as follows:-
Sample P116§ the HIV-1-infected child under investigation (index child)
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an HIV-1-infected child with a steady CD4%, whose CD4% and
CD8% add up to the CD3%
an HIV-1-infected child with a very low CD4%, but whose CD4%
and CD8% add up to the CD3%
an HIV-1-uninfected child born to an HIV-1-infected mother
a cord blood as a 'thymocyte control'
)
) cells infected with African HIV-1 strains
)
§ For PI 16, P69 and P92, samples of diluted whole blood (diluted 1:3 in PBS) were
available as well as the separated PBMCs.
1 The cord blood was included as the earliest available source of CD3 lymphocytes
which would be newly emerging from the thymus. These may have residual mRNA
expression from the stage of development at which these cells co-express CD4 and
CD8 (Marodon and Rocha, 1994).
For each blood sample, the percentages of cells expressing CD3, CD4 and CD8, and the
percentage of cells expressing both CD4 and HLA-DR were measured (described in 2.3.1).
The expression of HLA-DR on CD4-expressing cells was measured as an indication of the
activation state of the cells. It has been suggested that, in HIV-1 infection, only those cells
which express HLA-DR are actively replicating (Malhalingham et al., 1995).
PBMCs were isolated from peripheral blood of the index and control children, and separated
into CD4+ve and CD4-ve cell fractions by magnetic beads (outlined in 6.2.1 and described
in detail in 2.11). The RNA from each cell fraction was extracted using the Stratagene RNA
Micro-Isolation kit (described in 2.12.2).
RNA preparations were screened on a Spectrophotometer at wavelengths of 260 and 280nm
to measure the amounts of RNA available (described in 2.12.3). The RT-step was done using
Expand™-RT (described in 2.12.2). The amount of total RNA put in the initial RT reaction
was adjusted to approximately 0.5pg. The nested PCR reactions for CD4, HIV-1 and 6-Actin
were carried out (described 2.13.2, 2.14.3 and 2.14.4). The secondary PCR products (20pl)










The percentages of cells expressing CD3 (CD3%), CD4 (CD4%) and CD8 (CD8%) from the
index child, over a period of time, are presented in table 6.1. The numbers in bold represent
the difference between the CD3% and the sum of the CD4% and CD8%. Results from two
flow cytometry systems, using antibodies from either Becton Dickinson (BD) or Ortho,
showed that approximately 20% of CD3 expressing cells did not express CD4 or CD8. For
comparison, the CD3%, CD4% and CD8% from an age-matched HIV-1-uninfected child
(P86) are also shown. The sample used in the experiment had a lower proportion of the cells
under investigation than that seen in previous blood samples. Using the BD antibodies, this
proportion was not much different from the population seen in the uninfected child.
However, a larger difference was seen from the using the Ortho antibodies.
The CD3%, CD4% and CD8% from the index and the control children are presented in table
6.2. Results using the Ortho antibodies are not presented as these were not available for all
the control samples used. The percentage of activated CD4 cells (expressing HLA-DR) are
also shown.
Two examples of the FACScan plots of the PBMC populations are shown in figure 6.9(a) and
(b), before (A and B), and after (C and D) CD4 cell depletion by immunomagnetic beads.
The results presented here are from the index case, PI 16, (figure 6.9(a)), and from one of the
HIV-1-infected control patients, P69 (figure 6.9(b)) and are representative of the separation
results for all the samples.
For the index child (PI 16) both before and after CD4 cell depletion, there were no cells
which expressed CD4 on the surface, detectable by flow cytometry (figure 6.9(a)). However,
approximately 10% of the gated lymphocytes expressed CD3 but not CD8. These were seen
both before and after the CD4 depletion, and are shown in the lower right quadrants of boxes
A and C.
For the HIV-1-infected control (P69) before CD4 cell depletion, approximately 50% of the
gated cells expressed CD8 figure 6.9(b), (A), and approximately 21% of the gated cells
expressed CD4 (B). After CD4 cell depletion, approximately 65% of the gated cells
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Table 6.1 Percentages of CD3, CD4 and CD8 lymphocytes in PI 16 over time
Sample date BD antibodies Ortho antibodies*
CD3 CD4 CD8 CD3+ DN CD3 CD4 CD8 CD3+ DN
26/11/93 79 11 49 19 - - - -
04/03/94 67 11 49 7 - - - -
17/06/94 72 18 45 9 - - - -
07/10/94 77 7 52 18 - - - -
28/10/94 76 5 53 18 72 3 34 35
18/11/94 - - - - 73 3 45 25
20/12/94 - - - - 74 1 49 24
03/03/95 70 1 52 17 72 1 43 28
03/05/95 64 1 47 16 61 1 37 23
#09/09/95 44 0 39 5 57 1 42 14
P86 80 47 29 4 80 48 27 5
Percentages of CD3, CD4 and CD8 lymphocytes are shown.
The results of an age-matched HIV-1-uninfected child (P86) are also shown.
CD3+ DN denotes the difference between the total CD3% and the sum of the CD4%
and the CD8% (i.e. CD3 positive, CD4 and CD8 (double) negative).
* The results using the Ortho antibodies were produced with permission of J.A.
Whitelaw, HIV Immunology Unit, Royal Infirmary, Edinburgh.
# Sample used for the index child in the final experiment.
Table 6.2 Lymphocyte percentages in the index and control children
Sample CD3 CD4 CD8 CD3+CD4-CD8- %DR+CDl
Index child (PI 16) 44 0 39 5 NA
HIV+ve control (P69) 82 25 54 3 13
HIV+ve control (P92) 64 2 64 0 NA
HIV-ve control (P144) 68 43 26 0 2
Thymocyte control (CB1) 61 43 16 2 4
Percentages of lymphocytes in the index and control children.
%DR+ denotes the percentage of activated CD4 cells (expressing HLA-DR).
NA denotes not available
Figure 6.9 Efficiency of the CD4 cell depletion
FACScan plots of the separations before (A and B) and after (C and D) CD4 cell
depletion.
The results shown are representative of the separation results for all the samples.
The combination of a-CD3 and a-CD8 antibodies are shown in boxes A and C.
Cells expressing CD3 are shown on FL-1 (x-axis) and those expressing CD8 are
shown on FL-2 (y-axis). Quadrant lines are those which were set from a control
tube, such that less than 1% of cells showed non-specific staining. The upper right
quadrant contains those cells which express both CD3 and CD8.
The combination of a-CD3 and a-CD4 antibodies are shown in boxes B and D.
Cells which express CD3 are shown on FL-1 (x-axis) and those expressing CD4 are
shown on FL-2 (y-axis). The upper right quadrant contains those cells which express
both CD3 and CD4. The number in each quadrant is the percentage of cells in the
lymphocyte gate which fall into that quadrant.
(a) Results for PI 16, the index child



















































expressed CD8 (C), and less than 1% of the gated cells expressed CD4 (D), showing that the
CD4 depletion efficiently removed the CD4-expressing cells. This child also had a small
proportion of CD3-expressing cells which did not express either CD4 or CD8 figure 6.9(b),
C (lower right quadrant).
Results of the RT-PCR for CD4, Actin and HIV-1 are shown in figure 6.10. These are
results of the second of two experiments. Similar results were obtained in both experiments
but the gel from the second was clearer.
In both experiments, bands corresponding to the product size of (3-Actin were detected in all
the samples from the children, and the HIV-1-infected cell lines. No bands were observed
in the negative controls (as expected). This shows that there was cDNA added to the PCRs
and that the RT step was successful.
In both experiments, bands corresponding to the product size of CD4 (459bp) were expected
and seen in the CD4+ve fractions for the cord blood (lane 50) and in the diluted whole blood
from the one of the HIV-1-infected control children (P69, lane 11) and two of the HIV-1-
infected cell lines (lanes 30 and 33). In the second experiment bands were also seen from
the CD4+ve fraction of the index child (lane 7) and the other HIV-1-infected control child
(P92, lane 21). The first experiment gave an additional band from the HIV-1-infected cell
line, CEMeli, which was absent from the second experiment, but had been seen previously
(figure 6.8).
In both experiments, bands for CD4 were expected but not seen, from the diluted whole
blood sample from the index child (lane 1), and the CD4+ve fractions of the control HIV-1-
infected and uninfected children (lanes 16, 27 and 44).
In both experiments, bands corresponding to the product size for CD4 were seen in the CD4-
ve fractions from the index child (lane 4) and the cord blood (lane 47). These results indicate
that there is mRNA for CD4 present within these cells.
In both experiments, bands corresponding to the product size of HIV-1 (179bp) were
expected and seen from the whole blood sample of one of the HIV-1-infected control children
182
Figure 6.10 PCR results for CD4, HIV-1 and Actin
The PCR gel is shown in three sections. At each end of each section, the pGEM markers are
shown to size the bands. The sizes of the pGEM bands are shown beside each section.
The expected product sizes are 459bp for CD4, 179bp for HIV-1 and 501 bp for Actin.
The lane numbers are above each lane on the gel, and are described below:-
Lanes Sample
1 - 3 PI 16 diluted whole blood CD4 / HIV-1 / Actin
4 - 6 PI 16 CD4-ve fraction CD4 / HIV-1 / Actin
7 - 9 PI 16 CD4+ve fraction CD4 / HIV-1 / Actin
10 - 12 P69 diluted whole blood HIV-1 / CD4 / Actin
13 - 15 P69 CD4-ve fraction CD4 / HIV-1 / Actin
16 - 18 P69 CD4+ve fraction CD4 / HIV-1 / Actin
19 II9mal CD4 Taq -ve control
20 H9Z129 HIV-1 Taq -ve control
21 - 23 P92 diluted whole blood CD4 / HIV-1 / Actin
24 - 25 P92 CD4-ve fraction CD4 / HIV-1 / Actin
27 - 29 P92 CD4+ve fraction CD4 / HIV-1 / Actin
30 - 32 H9MAL CD4 / HIV-1 / Actin
33 - 35 H9z129 CD4 / HIV-1 / Actin
36 - 38 CEMELi CD4 / HIV-1 / Actin
39 CEMeli Primer -ve control
40 Empty
41 - 43 PI44 CD4-ve fraction CD4 / HIV-1 / Actin
44 - 46 PI44 CD4+ve fraction CD4 / HIV-1 / Actin
47 - 49 CB1 CD4-ve fraction CD4 / HIV-1 / Actin
50 - 52 CB1 CD4+ve fraction CD4 / HIV-1 / Actin
53 - 55 RNA -ve control CD4 / HIV-1 / Actin
56 - 58 cDNA -ve control CD4 / HIV-1 / Actin
59 CB1 CD4-ve Actin Taq -ve control
60 CB1 CD4+ve Primer -ve control
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
P116WB P1164- P1164+ P69WB P694- P694+
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 3 8 39 40
P92WB P924- P924+ H9MAL H9zm CEMEL[
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
P1444- P144 4+ CB14- CB14+ RNA-ve cDNA-ve
(P69, lane 10) and from two of the three HIV-1-infected cell lines (lanes 34 and 37).
In both experiments, bands for HIV-1 were expected, but not seen, from the whole blood
samples of the index child (PI 16) and the other HIV-1-infected control child (P92, lanes 2
and 22, respectively); from the CD4+ve fractions of all three HIV-1-infected children (lanes
8, 17 and 28) and from the third HIV-1-infected cell line (lane 31), although this band had
been seen previously (figure 6.8).
In both experiments, a band corresponding to the expected product size of HIV-1 was seen
in the CD4-ve fraction of one of the HIV-1-infected control children (lane 14). These results
indicate that HIV-1 is present and actively replicating within these cells.
65 DISCUSSION
A significant proportion of T cells expressing surface CD3, but not CD4 nor CD8, was noted
in an HIV-1-infected child. The aim of this study was to see whether these cells were
synthesising, but not expressing, the CD4 molecule, and whether this was associated with
HIV-1 replication within the same cell population. Down-regulation of surface CD4 by HIV-
1 has been reported in T cell lines and in in vitro HIV-1-infected PBMCs (Chen et al., 1996),
but thus far, not in HIV-1-infected individuals. Therefore, a strategy was developed which
would identify any cells which were actively synthesising CD4, but not expressing the protein
at the cell surface.
Cells expressing CD4 were positively depleted using anti-CD4 antibodies and
immunomagnetic beads. Positive depletion was used (i.e. the CD4 expressing cells were
removed) as this would remove monocytes as well as T cells. The remaining CD4-ve
fraction should not include any cells expressing CD4 and the flow cytometry results
confirmed that the CD4 expressing cells were effectively removed. It was decided not to
deplete the PBMCs for CD8 cells as well as CD4 cells, as the cell yield after a second
manipulation with magnetic beads could be so low as to be undetectable. Therefore
throughout these experiments the CD4-ve fraction includes cells expressing CD3 and CD8,
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as well as the cells of interest. Other experiments using cells which were positively depleted
for CD8 (i.e. CD8+ve fractions), from normal donor PBMCs did not shown any CD4 mRNA
(not shown), nor did the CD4-ve fractions from the HIV-1-infected controls, which shows
that there is no cross-reaction with genomic DNA for CD4.
Total RNA from the cells was initially extracted using a phenol/chloroform method which
isolated all the nucleic acids from cells. As it was thought, initially, that the amounts of
DNA in the preparation may interfere with the RT-PCR, either by increasing the amounts of
non-specific sequences or by cross-reaction with genomic DNA, a DNAase step was included.
However, the enzyme may not have been efficiently degraded by heating at 80°C for 10
minutes, such that, during reverse transcription, any cDNA could have been removed by
residual DNAase activity. An alternative approach, such as re-extracting the RNA by the
chloroform/phenol method, was likely to decrease the yield of RNA. Therefore, the Micro-
Isolation kit was deemed to be the most efficient method and was shown to give a better
yield of PCR product when compared with the phenol/chloroform extracted DNA/RNA.
The reverse transcription of mRNA by an oligo-dT primer annealing to the 3'-poly-A tail,
allowed all the available mRNA to be transcribed to cDNA. As this step is not very efficient,
the Expand™-RT enzyme was used, which was promoted as giving a better yield of cDNA.
The results showed that it gave PCR products from smaller starting amounts of total RNA,
than did the AMV-RT. The limiting factor in the final experiment was the small number of
cells from an end-stage HIV-l-infected child, when only a very small amount of mRNA
would be available. The limit of detection of the CD4 PCR was found to be a starting
amount of 100 pg (O.lng) of total RNA from a CD4-expressing T cell line (HeLa-CD4 cells).
However, these HeLa-CD4 cells were actively dividing, and about a third of them expressed
surface CD4 (data not shown). As a higher proportion of the total RNA from these cells,
would be CD4-specific mRNA than that found in PBMCs from an individual, the starting
amount of total RNA was adjusted to approximately 500ng for each sample in the final
experiment, to try to ensure that the mRNA levels were above the limit of detection.
The CD4 RT-PCR was adapted from a published method (Fomsgaard et al„ 1992), which
combined reverse transcription with a primary PCR step, to amplify the specific CD4
sequences directly from mRNA. The initial difficulties encountered could have been due to
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the very low level of CD4 mRNA in normal, resting PBMCs. In retrospect it would have
been better to start with DNA/RNA from a CD4-expressing cell line. The separation of the
RT and PCR steps, the acquisition of new primers and the use of RNA from CD4-expressing
cell lines gave bands on a gel of the expected size for CD4. The separation of the RT and
PCR steps also allowed the cDNA to be probed for (3-Actin as a positive control for the
presence of cDNA, and HIV-1, to see whether HIV-1 was replicating in the cells which did
not express CD4.
Bands of the same size as the expected product for CD4 were detected in both the CD4+ve
and CD4-ve fractions from the index child (PI 16), indicating that CD4 mRNA was present.
However, CD4 mRNA was not detected in the diluted whole blood sample from this child.
For the other two HIV-1-infected children, CD4-PCR products were detected in the diluted
whole blood, but not the separated cell fractions. The same amount of RNA from the whole
blood samples from each HIV-l-infected child was used. The differences between these
children, could be because the whole blood for the index child (PI 16) contained a lower
proportion of total lymphocytes (approximately 5%), and the amount of mRNA for CD4 may
have been below the limits of detection. The proportions of lymphocytes in the whole blood
of the other two HIV-l-infected children were much higher (41% in P92 and 37% in P69).
In addition, whole blood contains inhibitors of PCRs, which may have had a proportionally
larger effect on the lymphocytes of the index child as there were fewer of them, than in the
HIV-l-infected control children.
Despite the low numbers of cells available from the index child, CD4 mRNA was detected
in the CD4-ve fraction, showing that these cells were synthesising CD4. The presence of
CD4 mRNA may be due to some type of "feed-back mechanisms" of the cell which may
detect the non-expression of CD4 at the cell surface, and therefore, direct the cell to increase
biosynthesis of CD4. In the other two HIV-l-infected children these feedback mechanisms
may not be used to the same extent, as, from the phenotype results, the CD3-expressing cells
also expressed either CD4 or CD8. The absence of CD4 mRNA in the CD4+ve fraction of
one of the other two HIV-l-infected children (P92) could be due to very low levels of CD4
cells (1% of lymphocytes). For the other HIV-l-infected child (P69), the absence of mRNA
for CD4 could be explained by the low proportion of activated CD4 cells, as only the
activated cells would be undergoing mRNA synthesis (Malhalingham et al.} 1995). Likewise,
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the uninfected child (P144) did not show any CD4 mRNA in the separated fractions of the
PBMCs. In this child, an even smaller proportion of those cells were activated, compared
to the infected children, so most of the cells would not be undergoing mRNA synthesis. The
cord blood showed CD4 mRNA in both the CD4+ve and CD4-ve fractions, which was
confirmed when the experiment was repeated. This was unexpected as the flow cytometry
plots were similar to those shown in figure 6.9 (data not shown). Repetition of the
experiment with another cord blood and the RNA from P144 gave similar results (data not
shown).
T cells, expressing CD4 or CD8, arise from the same stem-cell population in the thymus,
which expresses both antigens on the cell surface (double positive). These cells then mature
and become either CD4- or CD8-single positive. Different mechanisms are involved in the
control of CD4 gene expression in immature (double positive) and mature (single positive)
thymocytes (Hanna et al., 1994) and the down-regulation of CD4 or CD8 expression occurs
at different stages of thymocyte development (Marodon and Rocha, 1994). The results from
the cord bloods suggest that there may be some residual CD4 mRNA expression in CD8-
single positive lymphocytes, which have newly emerged from the thymus. The contribution
of the thymus in the production of new CD4-expressing T cells, in older HIV-1-infected
children is not clear. However, studies in SCID-Hu mice (Aldrovandi et al., 1993) have
shown that HIV-1 infection of foetal thymic tissue, leads to a depletion in the number of
CD4-expressing T cells emerging from the thymus (Bonyhadi et al., 1993; Aldrovandi et al.,
1993; Su et al., 1995). The infection of a human foetal thymocyte cell line not expressing
CD4, with HIV-1 in vitro, has also been reported (Hatch et al., 1992). These studies have
implications for the HIV-1 infection of the foetus in utero and has been discussed previously
(see 3.4.3). In HIV-1-infected adults, thymic regeneration has been suggested as being
unlikely (Ho et al., 1995; Wei et al., 1995). The CD4 mRNA in the CD4-ve fraction from
the index child, may be from newly emerged cells from the thymus expressing surface CD8.
However, evidence from studies in lymph nodes from HIV-l-infected adults showed the
pathogenic effects of HIV-1 infection in the destruction of lymphoid tissue long before the
levels of circulating, peripheral CD4 expressing lymphocytes were decreased (Pantaleo et al.,
1993; Embretson et al., 1993). The assumption that the same pathogenic effects of HIV-1
in lymphoid tissue of children also occurs, suggests that it is unlikely for the thymus be
producing functional cells. Therefore, the detection of CD4 mRNA in the CD4-ve fraction
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from the index child, is more likely to be due to the down-regulation of surface CD4.
It is possible that the sequence of the CD4 molecule on the surface of the cells could have
changed, such that the CD4 molecule was not recognised by the antibodies used.
Polymorphisms within the CD4 molecule have been reported (Dean et al., 1994). It has been
previously reported, that the anti-CD4 antibody obtained from Ortho (clone OKT4) does not
recognise the CD4 molecule in a small number of individuals. However, in these same
individuals, the CD4 molecule was recognised by the anti-CD4 antibody obtained from BD
(clone Leu 3a, Levy et al., 1988). Previous results from the Edinburgh cohort have also
found that CD4-expressing cells not detectable using the Ortho antibodies, were detectable
using the BD antibodies (J.A. Whitelaw and M.C. Aldhous, unpublished observations).
Comparison of the results from the index child, using both antibody sets, showed that there
was a slight difference in the percentages of lymphocytes expressing the different surface
molecules. However, cells expressing CD3, but lacking CD4 and CD8 in the index child,
were detected using both sets of antibodies, indicating that the non-expression of surface CD4
is a more probable explanation.
Studies in HIV-1-infected adults have indicated that the turnover of CD4 cells is much higher
than was previously thought, with approximately 2 x 109 cells being produced and destroyed
per day (Ho et al., 1995; Wei et al., 1995). They suggest that this high cell turnover is
driven by the high level of HIV-1 infection and production from these same cells. The
detection of CD4 mRNA in whole blood or separated cells from the infected children studied
here, indicates that some proportion of the CD4 cells are indeed actively replicating.
Conversely, the non-detection of CD4 mRNA from the uninfected child, indicates that CD4
cell turnover could be much less. This was assumed in the studies previously mentioned (Ho
et al., 1995; Wei et al., 1995), but the actual rate of cell turnover within an uninfected
individual is not known.
Whether the non-expression of CD4 at the cell surface was associated with HIV-1 infection
of the cell, is not clear, as HIV-1 was not detected. The non-detection of HIV-1 in the index
child (PI 16) may be due to a low rate of HIV-1 replication. Using in situ hybridisation
techniques it has been found that as few as 1 in 104 or 105 cells actively express HIV-1 in
PBMCs (Harper et al., 1986) and, as only a small number of cells were available from this
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child, this could explain the non-detection of HIV-1. A few unidentified bands appeared on
the gels, particularly from the HIV-1 PCR. One possibility is that reduced selectivity of the
priming occurred, due to the other mRNAs which would have been made into cDNA. There
is also the possibility of different HIV-1 transcripts being given, as the annealing site for the
antisense primer encodes for some of the regulatory proteins, such as vpr and vpu, and these
may, or may not, be transcribed depending on which part of the life-cycle the virus was
going through (Zack et al., 1990; Schwartz et al., 1990). Bands corresponding to the
expected product size of HIV-1 was identified from one of the HIV-1-infected controls (P69),
in the diluted whole blood sample and in the CD4-ve population, but not the CD4+ve
population and was seen in both experiments. This was unexpected and an explanation for
this is not clear. The HIV-1 detected could be from some cell population that does not
require CD4 for entry of virus, e.g. B-cells (Monroe et al., 1988). In late-stage HIV-1-
infected patients (with CD4 counts under 200 cells/pl), CD8 cells infected with HIV-1 have
been described (Livingstone et al., 1996). However, as this child still has a CD4 count of
approximately 700 cells/pl, this was deemed unlikely.
The down-regulation of surface CD4 expression has been previously observed in PBMCs and
T-cell lines infected with HIV-1 in vitro (Chen et al., 19%), but has not been reported from
HIV-1-infected individuals. It is possible that a similar population of cells has occurred in
other HIV-1-infected individuals. However, this observation may have been missed, due to
the emphasis on the routine monitoring of the CD4 count alone (Margolick et al., 1992;
Aledort et al., 1992), rather than within the context of the levels of total T lymphocytes and
those expressing surface CD8.
Cells expressing CD3 but not CD4 nor CD8 were not seen in any other child. The most
obvious difference between the index child and the rest of the cohort, is that this child was
born in Africa and is unlikely to be infected with a subtype B virus. It is possible that the
down-regulation of CD4 in vivo may only occur with non-subtype B viruses. However, the
effects of different viral subtypes on immune responses have not been widely studied. There
is evidence that different subtypes have different tropism for Langerhans cells (Soto-Ramirez
et al., 1996) and that different subtypes may be transmitted more easily by different routes
(Kunanusont et al., 1995).
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The loss of surface CD4 would have similar effects on immune function, as does the actual
loss of T helper cells. Without the CD4-MHC class II interaction, the T helper cell would
not be able to recognise the presence of exogenous antigen and, as with the loss of CD4 cells,
the individual becomes more susceptible to opportunistic infections. Similarly, the T helper
cells could not be activated in response to antigen recognition, so the production of cytokines
is dysfunctional, which, in turn, leads to dysfunctional immune responses.
The preliminary results shown here indicate that the down-regulation of CD4 from the surface
of the cell can take place in vivo, and therefore could contribute to CD4 cell dysfunction in
HIV-1-infected patients.
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7.1 T-CELL MEDIATED IMMUNE RESPONSES IN HIV-1-
INFECTED CHILDREN
This thesis presents the results of the studies of different T-cell mediated immune responses
which may be at work in HIV-1-infected children. The lymphocyte surface marker analysis
showed that a sustained increase in the proportion of activated and memory CD8 cells
occurred soon after birth, and that these can be used as indicators of HIV-1 infection in
exposed children (chapter 3). The study of these surface markers in relation to functional
assays indicated that the expression of the different antigens on the cell surface in whole
blood bore no relation to their functional capacity. The study of CTL responses showed that
the presence and specificity of target recognition varied, both within and between children.
There was also evidence to suggest that the presence and specificity of the CTL response may
contribute to disease progression (chapter 4). The study of proliferative responses showed
that, as a group, HIV-1-infected children had reduced responses to TT, but maintained
responses to PHA. There was no association between the responses to any antigen and
clinical progression (chapter 5). Finally, the down-regulation of CD4 expression on the
surface of cells was seen in one child (chapter 6).
There was no correlation between expression of surface markers on T cells and functional
activity. This is not entirely surprising as there is still some debate as to the relationship
between phenotype and function (Westermann and Pabst, 1996). An increase in the
percentage of CD8 lymphocytes expressing activation and memory markers has been seen in
newly infected adults (Zaunders et al., 1995), which was associated with CTL responses to
the virus (Pontesilli et al., 1994; Hoffman et al., 1989). Therefore, the increased expression
of activation and memory markers on CD8 cells, indicate that some immune activation was
occurring in these children.
7.2 T-CELL MEDIATED IMMUNE RESPONSES AND LOSS
OF CD4 CELLS
Although recent studies of the turnover of CD4 cells in vivo indicate that cell killing occurs
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rapidly (Ho et al., 1995; Wei et al., 1995), HIV-1 is not classed as a directly cytopathic virus
(Zinkernagel, 1995). Therefore other mechanisms must be at work to produce CD4 cell loss.
In these children, the different types and extent of the immune responses suggest that
different mechanisms are implicated, such as CTL activity (chapter 4), dysfunctional
proliferative responses (chapter 5) or surface CD4 down-regulation (chapter 6).
Reports have been published to suggest that HIV-1 preferentially infects CD4 cells with a
memory phenotype (Schnittman et al., 1990; Cayota et al., 1990). In some adults, the loss
of proliferative responses has been related to a loss of memory CD4 cells (Shearer and
Clerici, 1991; van Noesel et al., 1990). In the children studied here, antigen-specific
proliferative responses were not related to any phenotype (chapter 5), and an increase in
expression of memory or activation markers on CD4 cells was only seen much later in HIV-1
disease, as the CD4% started to decrease (chapter 3). This increase in activation or memory
markers may reflect an increased incidence of HIV-infected CD4 cells in the periphery, later
on in disease. It has been shown that the CD4 cells in lymph nodes are infected while the
numbers of circulating CD4 cells are still steady (Pantaleo et al., 1993; Embretson et al.,
1993). Therefore, in measuring the surface markers of lymphocytes in peripheral blood, it
has to be remembered that these cells do not necessarily reflect the changes occurring in the
tissues. Although there is cell trafficking, only approximately 2% of the total lymphocyte
pool are circulating in the periphery at any one time, and the compartments are not in
equilibrium (Ho et al., 1995; Wei et al., 1995). Therefore, a decrease in CD4% in peripheral
blood may be an indication that the pathological effects of HIV-1 infection (direct or indirect)
have already destroyed other lymphoid tissue. From the peripheral circulation, the virus can
lodge in other areas of the body. In post-mortem AIDS patients, HIV-1 has been isolated
from many different tissues which are not normally associated with lymphoid function, and
some are sequestered from immune surveillance (Donaldson et al., 1994).
There was no association between CTL activity and proliferative responses to HIV-1 in
individual children. Two children did not respond to HIV-1 at all (i.e. consistently showed
no CTL activity and did not proliferate to HIV-1 proteins), while two other children showed
both CTL activity and proliferation to HIV-1 proteins. All the other children, for whom data
were available, showed CTL activity, but not proliferation, to HIV-1. This suggests that the
CTL responses are longer lived than proliferative responses in children. Similarly, the
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proliferative responses to other stimuli (TT and PHA) did not correlate with CTL responses,
as the responses to TT were reduced while the responses to PHA were retained in most
children, regardless of their CTL responses.
One such child showed vigorous CTL activity to HlV-mr and -pol and a strong proliferative
response to TT and PHA, but not HIV-1, despite the strong CTL response. These responses
occurred in the context of a rapidly declining CD4% (a drop from 23% to 9% in 6 months).
In this child, it is possible that the CTLs are actively killing both infected and uninfected
'bystander' CD4 cells, and hence, are contributing to the loss of CD4 cells. There is
evidence that activated CD4 cells are more likely to be killed in this 'bystander' fashion
(Grant et al., 1994; Bienzle et al., 1996). The high proliferative responses may be an
indication of the ease with which these cells can be activated by other pathogens or stimuli
in vivo, as if the cells were in some 'hyperactive' state. These antigen-specific responses may
activate HIV-1 replication in vivo, and hence contribute to disease progression.
Conversely, another child showed an anti-HIV-1 proliferative response, which, although was
not high, was above that seen in the controls. This child has consistently appeared to 'ignore'
the virus, with a CTL response only induced after peptide stimulation, a lower proportion of
(phenotypically) activated CD8 cells than that seen in other children, and a very slow decline
in CD4 cells. Other cases of patients with similar non-responsiveness have been described
(Dalod et al., 1996; Ferbas et al., 1995). However at some point, the virus levels in these
other patients has increased, the immunological responses have become detectable, and an
increased rate of CD4 cell loss was seen. The mechanism which causes increased virus
levels, and hence the immune responses, in these other patients, was not clear. Whether this
child will follow this pattern remains to be seen.
The finding that the down-regulation of surface CD4 expression can occur in vivo indicates
another mechanism by which CD4 cell depletion occurs (as measured by the decreased
proportion of T cells expressing CD4 on the cell surface). This child consistently showed
no CTL responses during the study, which was initially assumed to be due to infection with
a non-subtype B strain of HIV-1. It was speculated that this child may have CTL activity
in vivo, even if it was undetectable in vitro, due to differences between the viral strains found
in the child and those used in the CTL assay. However, the down-regulation of surface CD4
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expression indicates that this may have had an impact on the generation of CTLs, due to a
decreased T-helper function. If no CD4 is expressed on the cell surface, then this cell cannot
interact with APCs via MHC class II and the CD4/T-cell receptor ceomplex (Paul, 1993).
Therefore, the cell would be unable to activate cell signalling pathways to produce cytokines
(Ravichandran and Burakoff, 1994; Kemeny et al., 1994; Romagnani, 1992; Kos and
Engleman, 1996; Mosmann and Sad, 1996), and so no other cells could be induced to provide
an immune response to HIV or any other antigen.
7.3 OTHER FACTORS AFFECTING DISEASE
PROGRESSION
These studies did not take into account other factors which may influence disease
progression, such as maternal virus strain, HLA-type (Just et al., 1995) and presence of the
32bp 6-chemokine receptor mutation (Dean et al., 1996; Huang et al., 1996). Whether there
is a difference in the virus strains transmitted to the mothers by different routes, is not clear.
Mucosal barriers and mucosal immune responses, may imply that a more virulent strain is
required for successful transmission of infection by a sexual route rather than parentally.
Indeed, in Thailand, where two epidemics appeared at the same time in almost exclusive risk
populations, there are indications that the more virulent virus strain is transmitted sexually
(Kunanusont et al., 1995). For eight children, for whom information was available, born to
seven HIV-l-infected mothers from the Edinburgh cohort, six mothers had intravenous drug
use as their risk group, while one had been a partner of an intravenous drug user. The child
whose mother had been infected sexually, did not have remarkably different responses from
those observed in the other children. The influence of the maternal immune responses on the
selection of the variants transmitted vertically is not clear, though there is evidence that
selection occurs as, a minor, monocytotropic variant is often transmitted (Wolinsky et al.,
1992).
There have been reports that the rate of disease progression in children is related to the rate
of disease progression in their mothers (Tovo et al., 1994). Although the information is
limited, this does not seem to be borne out in these children. The older children who did not
progress were born in the mid-1980s, soon after their mothers became infected. These
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women were part of the original Edinburgh cohort (Mok et al., 1989a; Mok et al., 1989b)
and two of three of these mothers have died, after having been infected for several years.
For the older children who did progress, born to mothers who were presumed to have been
infected at the same time as those in the original cohort, two of three mothers have died,
again after having been infected for several years. The younger children were born in the
1990s and all their mothers are still alive, including the mothers of the two children classed
as fast progressors, despite one of the children having died. Some of these younger children
were born after their mothers had been infected for several years. This could reflect the
underlying disease progression in the mothers, which, in turn, increased the likelihood of
transmission of HIV-1 (European Collaborative Study, 1991). There were also those who
transmitted virus relatively soon after infection, which is similar to the scenario of the
original cohort (Mok et al., 1989a; Mok et al., 1989b). However, there may be slight but
important differences in the virus strains transmitted (C.M Wade et al., J Virol 1997,
submitted), which could account for any differences in clinical disease progression and
immune responses in these children. To ascertain this, the virus populations in all the
children would have to be isolated and the DNA sequences analysed.
Although the HLA-types for the children are known, the data set is too small for any
influence to be seen (Just et al., 1995). Preliminary data for the P-chemokine receptor CCR5
32bp deletion (Samson et al., 1996; Liu et al., 1996), showed that three of the infected
children are heterozygous for this mutation, which has been claimed to influence the rate of
disease progression in adults (Dean et al., 1996; Huang et al., 1996). However, these three
children fall into each of the groups, defined in chapter 3, according to age and CD4%, and
two children have also developed an SI variant of the virus, which is associated with disease
progression (Schuitemaker et al., 1992). The anti-HIV-specific responses differed in these
children, as one showed CTL activity alone, but the other two had both proliferative and CTL
responses to HIV-1.
In other viral systems such as lymphocytic choriomeningitis virus (LCMV), the level of the
immune response was directly related to the dose of pathogen: i.e. a higher dose of LCMV
produced a vigorous CTL response, which cleared virus but led to severe immunodeficiency,
whereas a lower dose led to a chronic viral infection, without pathogenic effects
(Moskophidis et al., 1993). Other reports of studies of neonatal mice also indicate that a
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different dose of pathogen can lead to either induction of tolerance, a Th-1 or a Th-2
response (Ridge et al., 1996; Sarzotti et al., 1996; Forsthuber et al., 1996), all of which
would affect the cell mediated-immune responses to that pathogen. In the children studied
here, the dose of infecting virus from the mother may vary, according to the stage of her
disease. However, the different responses to HIV-1 seen in these children, may indeed be
due to the different levels of virus in each child.
7 4 HIV-SPECIFIC IMMUNE RESPONSES IN HIV-EXPOSED
UNINFECTED CHIUDREN
The detection of HIV-1-specific responses in the EU children, highlights the non-availability
of control subjects, as it is considered unethical to take blood samples from children for
studies from which they will not directly benefit. Therefore, whether the responses seen in
the EU children are truly due to exposure to the virus, or whether some cross-reactive
mechanisms have been at work, has not been verified. In a study of HIV-1-exposed adults,
CTL responses to HIV-gag were seen in seronegative blood donors with no risk factors for
infection (Langlade-Demoyen et al., 1994).
Cell-mediated responses to HIV-1 were seen in the EU children, but these were confined to
CTL responses, and not proliferation. This may be purely methodological: some studies have
indicated that anti-HIV-1 proliferation can only be detected by measuring cytokine
production, and that using 3H-thymidine incorporation is not sensitive enough (Clerici et al.,
1992; Clerici et al., 1993b), but this is not the case in other studies (Borkowsky et al., 1990;
Pontesilli et al., 1995). Efficient CD4 recognition of HIV-1 produces cytokines, enabling the
generation of CTLs, which, in turn, recognise endogenously processed antigen presented on
the MHC-class I molecule. Some of the HIV-l-exposed children did recognise processed
HIV-proteins in the CTL assay, as has been seen in other studies of exposed but uninfected
individuals (Rowland-Jones et al., 1993; Cheynier et al., 1992; de Maria et al., 1994a; Pinto
et al., 1995; Rowland-Jones et al., 1995; Langlade-Demoyen et al., 1994). This indicates that
these children do have efficient CD4 responses to HIV-1 antigens, despite the lack of
proliferation. These results also suggest that these children may have previously actively
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processed antigen, either through a low dose exposure, or through an inefficient or abortive
infection with HIV-1. Cases of children clearing HIV-1 have been described (Rowland-Jones
et al., 1993; Bryson et al., 1995; Roques et al., 1995; Aldhous et al., 1994b). There are also
cases described of children from whom HIV-1 has been transiently detected (by PCR or
culture), without concomitant clinical infection (European Collaborative Study, 1991; de
Rossi et al., 1991; Rogers et al., 1989).
The study of several different immune mechanisms in the same children has not been done
before. There have been separate studies of surface markers, CTL activity and proliferation
in different cohorts of children, but none trying to relate all these together in the same cohort.
The information gained from these children suggests that no one immune mechanism is at
work in mediating anti-HIV-1 responses, and that in some cases the anti-HIV-1 responses
may contribute to pathogenesis. Therefore, to focus in on one specific set of responses, could
be limiting. These results also suggest that no single immune response is responsible for the
maintenance of clinical stability, or the induction of clinical progression in these children.
These results need to be confirmed in a larger group of children. In addition, although these
children have been monitored for a period of up to four years, the differences in responses
show that one cannot extrapolate from one child to the next. Therefore all the children
should be studied from birth to death to obtain a clearer picture of the changes and
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The expression of markers defining functional subpopula-
tions on the surface of CD4 and CD8 cells changes with
disease. To monitor these changes in children, it is impor¬
tant to establish the age-related normal changes in marker
expression due to maturation of the immune system. We
have studied the expression of several functionally impor¬
tant molecules on both CD4 and CD8 cells in 168 children
(aged 0-122 months) using monoclonal antibodies and flow
cytometry. Our results show that the percentage of CD4
cells decreases with age, while the CDS percentage in¬
creases, resulting in a decrease in the CD4/CD8 ratio. The
expression of CD45RO and CD29 increases with age, while
CD45RA expression decreases, both on CD4 and CD8 cells.
The expression of HLA-DR on both CD4 and CDS cells,
and of CDlla and CD57 on CD8 cells, is less clearly age
dependent. The relationships between the marker percent¬
ages and age were not straightforward; the standard devia¬
tions and the skewness, as well as their mean values, varied
as a function of age. The changes were modeled for each
marker and age-specific centiles are presented.
KEY WORDS: Lymphocyte surface markers; normal children;
age-related expression.
INTRODUCTION
The use of monoclonal antibodies (MAbs) and flow
cytometry to monitor the CD4 and CD8 T-lympho-
cyte populations in peripheral blood is well estab¬
lished (1). Molecules defining subpopulations of
CD4 and CD8 cells are associated with particular
'HIV Immunology Unit, University Department of Medicine,
Level 2, Lauriston Building, Royal Infirmary, Edinburgh EH3
9HB, Scotland.
2MRC Biostatistics Initiative for AIDS and HIV in Scotland,
Centre for HIV Research, Division of Biological Sciences,
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Scotland.
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functions, and monitoring these subpopulations can
help in understanding the immunopathogenesis of
cellular immune responses.
The expression of subpopulation markers on CD4
and CD8 cells has been shown to be abnormal in a
number of diseases. Increased expression of
CD45RO, a marker of memory (2), on CD8 cells has
been shown in infectious mononucleosis (3), in
some DNA viral infections (T. Miyawaki, personal
communication), and in HIV infection (4, 5), with a
decrease in the reciprocal CD45RA "naive" marker
(6). In contrast, CD29, also a marker of memory (7),
has been shown by some groups to be lost in HIV
infection (8, 9), although not confirmed by others (5,
10). CD8 lymphocytes show increased expression
of the activation marker, HLA-DR, in infectious
mononucleosis (3), and in HIV (5, 10, 11), which,
together with an increased expression of CD57, a
marker of natural killer activity (12), can be related
to cell dysfunction (13, 14). An increase in CDlla,
a marker which differentiates between suppressor
and cytotoxic CD8 cells (15), has also been seen in
HIV infection (16). The further evaluation of CD4
and CDS subpopulations, both cross-sectionally
and longitudinally, are potentially important in the
study of cellular immune response mechanisms in
both adults and children.
Children are born with immature immune sys¬
tems (17) and studies of cellular phenotypes in
disease states need to take into account the changes
in marker expression with age. A number of studies
of lymphocytes in normal children have concen¬
trated on T and B cells (18-20), while others have
included some CD4 and CDS subpopulations (21-
25). These studies, however, covered only a small
number of markers over a limited age range.
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0271-9142/94/0900-0289$07.00/0 © 1994 Plenum Publishing Corporation
290 ALDHOUS ETAL.
Table I. Details of the Children Studied
Age
Mean age Range
Group Number (mo) (mo)
HIV positive mother 60 39.0 0-81
Premature 15 1.4 0-6
Preoperative" 18 29.7 4-76
Outpatients'" 75 44.1 0-122
"Patients undergoing cardiac catheterization and/or surgery.
''Children with noninfectious or nonimmunological diagnoses.
The European Collaborative Study (ECS) (19)
has provided age-specific centiles for the CD4 and
CD8 cell numbers and percentages, up to 4 years of
age in HIV-uninfected children born to HIV-
infected mothers. The study presented here extends
the age range and, also, defines the age-related
expression of immunologically important CD4 and
CD8 subpopulations in children.
One problem in determining normal ranges is
access to blood from healthy children. We have
used residual blood samples obtained from 108
children attending outpatient clinics, with known
nonimmunological or infectious diagnoses, and 60
HIV-uninfected children born to infected mothers.
METHODS
Subjects. Residual heparinized peripheral blood
samples were obtained from 168 children. Children
were excluded whose diagnoses had evidence of
immunological involvement such as pyrexia, infec¬
tions, jaundice, or burns. The diagnoses of those
studied, together with numbers and ages, are shown
in Table I. The samples were stored at room tem¬
perature and processed on the same day as vene¬
section.
Immunofluorescence Analysis. Blood phenotypes
were analyzed using standard dual-color flow cytom¬
etry with the following monoclonal antibodies: anti-




FITC (Coulter), and anti-CD45RO(UCHLl)-FITC
(DAKO Ltd). All antibody mixes were diluted 1:2,
except for CDlla, which was used at 1:16. Briefly,
diluted blood was added to the antibody pair and
incubated for 15 min at room temperature. The red
cells were lysed using Facslyse (Becton-Dickinson).
The samples were centrifuged, washed in saline, fixed
in 1% formaldehyde/phosphate-buffered saline, and
stored at 4°C until analyzed on a FACScan (Becton-
Dickinson). Results are expressed as the percentage
of CD4 or CD8 cells coexpressing the antigen studied:
(CD4+ CDX+/CD4) x 100.
Statistical Analysis of Results. Each child con¬
tributed only one sample to the data set. Results
below the level of detection of the assay were
assigned a value of 1%, which was the detection
limit for all markers. Age-related centiles were
calculated for each marker by the method described
in the appendix. All values beyond three standard
deviations from their age-specific mean were
checked and/or recalculated from the stored FAC¬
Scan data.
For all the markers the age centiles allow the data
to be transformed to Z scores, which measure the
deviation of a value from its age-specific median in
standard deviation units. These Z scores were then
compared across subgroups to check for any differ¬
ences.
RESULTS
Our results are presented throughout as centiles,
over an age range of 0-100 months. These show the
median and ranges (the values between the upper
and the lower centiles) within which a defined
proportion of the results lie.
The fitted centiles for the CD4 percentage
(CD4%), CD8 percentage (CD8%), and CD4/CD8
ratio (dotted lines) are compared to the results for
the ECS (solid lines) in Fig. 1. The lines illustrated
are the 5th, 25th, 50th (median), 75th, and 95 th
centiles for each case. Figure 2 shows the data and
the fitted centiles for the other 10 subpopulations
measured. The predicted values of the age-specific
medians are given in Table AI (Appendix).
CD4 and CD8 Populations
In the first 20 months of life, the CD4% decreased
with age (the range between the 3rd and the 97th
centiles decreased from 34-67 to 25-57%) and then
remained fairly steady, while the range became
slightly narrower (26-52% at 100 months). The
CD8% decreased slightly during the first 20 months
(from 15-38 to 14-34%) and then increased steadily
with age (25-43% at 100 months). Consequently,
the CD4/CD8 ratio also decreased steadily, with the
range also becoming narrower with age (from 1.0-
3.8 at birth to 0.8-1.8 at 100 months).
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Fig. 1. Centiles for percentage of CD4 and CD8 cells and CD4/CD8 ratio compared to the ECS (19). Solid lines denote results for
the ECS. Dotted lines denote our centiles. Lines illustrated are the 5th, 25th, 50th (median), 75th, and 95th centiles.
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Fig. 2. Data and fitted centiles for marker coexpression. Lines illustrated are the 3rd, 5th, 10th, 25th, 50th (median), 75th, 90th, 95th, and
97th centiles. Axes are percentage coexpression of marker on CD4 or CD8 cells against age in months.
Memory Cell Markers
CD45RO expression on CD4 and CD8 cells in¬
creased with age (3-21% at birth to 18-58% at 100
months on CD4 cells and from 3-27% at birth to
10-52% at 100 months on CD8 cells), with the range
also increasing, especially on CD4, where there was
a lower and narrower range at birth. CD29 expres¬
sion also increased markedly with age (from 3-24%
at birth to 13-48% at 100 months on CD4 cells and
from 1-41% at birth to 14-78% at 100 months on
CD8 cells), with the rise being steepest in the first 2
years. In contrast, CD45RA expression on CD4 and
CD8 cells was high at birth (59-93% on CD4 cells
and 69-99% on CD8 cells) and decreased steadily,
leveling off at approximately 60 months, and any
further decrease was more gradual. The range in¬
creased over this time (42-83% on CD4 cells and
44-92% on CD8 cells at 100 months).
Activation Markers
There was no clear relationship of HLA-DR
expression on T cells with age. The range from the
3rd to the 97th centiles at birth was 0-10 and 0-17%
for CD4 and CD8 cells, respectively. Thereafter the
lower centiles were still around zero, but the upper
centiles rose to 16% on CD4 cells and 23% on CD8
cells at 100 months. The expression of HLA-DR on
CD8 cells seemed to peak during the third year and
subsequently leveled off.
Cytotoxic Markers
CDlla expression on CD8 cells showed little
relationship with age. A wide scatter occurred at all
ages (2-40% at birth, 5-48% at 48 months, and
5-39% at 100 months), and a peak of higher values
0 20 40 60 80 100
CD8.CD45RO
o J—j , 1 1 , ,—
0 20 40 60 BO 100
CD8.HLA.DR
0 20 40 60 80 100
CD8.CD57
0 20 4 0 60 BO 100
CD8.CD45RA CD8.CD29
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Table II. Correlations Between Z Scores for Different Markers
(a) Correlations among CD4%, CD8%, ratio, and CD4 subpopulations
CD4 CD8 Ratio CD4 CD45RO + CD4 CD45RA+ CD4 CD29+ CD4 HLA-DR+
CD4 *
CD8 -0.39 *
Ratio 0.79 -0.86 *
CD4 CD45RO+ -0.39 0.20 -0.36 *
CD4 CD45RA+ a — — -0.51 *
CD4 CD29+ -0.34 0.22 -0.33 0.65 -0.50 *
CD4 HLA-DR+ -0.21 — -0.20 0.20 — 0.23 *
(b) Correlations between CD8 subpopulations
CD8 CD8 CD8 CD8
CD45RO+ CD45RA+ CD8 CD29+ HLA-DR+ CDlla+ CD8 CD57+
CD8 CD45RO+ *
CD8 CD45RA+ -0.46 *
CD8 CD29+ 0.30 -0.20 *
CD8 HLA-DR+ 0.46 -0.21 0.27 *
CD8 CDlla-t- — — — 0.22 *
CD8 CD57+ — — 0.26 — 0.38 *
"Denotes a correlation <0.2 in absolute value.
at about 48 months, with a subsequent decline in the
upper centiles was seen. CD57 expression on CD8
cells also had a wide range, with unmeasurable
values (i.e., <1%) being common at all ages. The
range here was narrower at birth (1-17%) and
widened steadily with age (1-46% at 100 months).
Between-Group Analysis of Variance
We carried out an analysis of variance to assess
whether the age-corrected values differed by the
group of children. All the measurements were trans¬
formed into Z scores, which give the number of
standard deviations above or below the median.
The assumption of a normal distribution was rea¬
sonable for all markers except for the three which
had a substantial number of undetectable results
(HLA-DR on CD4 and CD8 cells and CD57 on CD8
cells). For these three markers the analysis of
variance was checked against a nonparametric test
(Kruskall-Wallis test), but the results were very
similar. In two cases (CD8 CDlla+ and CD8
CD45RA+) the P value for the test of significance
was less than 0.01 (data not shown). However,
there was no clear pattern of differences between
groups and the actual differences were small. The
mean Z score for the uninfected children of HIV-
infected mothers was never more than 0.5 of a
standard deviation away from the overall mean of
zero. Data from the groups were therefore pooled
for subsequent analysis.
Correlations Between Lymphocyte Subpopulations
Correlations between the Z scores, which are
above 0.2 are given in Table Ila, for CD4%, CD8%,
CD4/CD8 ratio, and CD4 cell subpopulations, and
in Table lib, for CD8 cell subpopulations. These
correlations, since they are between Z scores, are
corrected for the age of the child. The only corre¬
lations between subpopulations and the CD4% and
CD8% are for CD4 expression of CD45RO and
CD29. Within the CD4 population, the "memory
markers" CD45RO and CD29 are positively corre¬
lated (r = 0.65); both correlate negatively with the
"naive marker" CD45RA (r = —0.51 and r =
-0.50, respectively). On CD8 cells, the negative
correlation between CD45RO and CD45RA expres¬
sion persists (r = -0.46), but the correlation with
CD29 and CD45RO is much weaker (r = 0.30), as is
the negative correlation between CD29 and
CD45RA (r = -0.20). CD45RO expression also
correlates with HLA-DR expression (r = 0.46).
DISCUSSION
The phenotypic characterization of CD4 and CD8
subpopulations in peripheral blood is potentially
useful in the understanding of the complex relation¬
ships between cell types and pathogenic processes
(1). It is particularly relevant in diseases of children,
when little blood is available for functional studies.
Because of the maturation of the immune system
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with age, it is important to establish the normal
patterns of marker expression in children and to
distinguish changes found in disease processes from
those which occur naturally. Here we present age-
related normal centiles for surface markers which
are particularly relevant to immune function.
Previous studies have tended to concentrate on
CD4 subpopulations and have a limited range of
markers; some have also been limited by the age
range of the subjects studied. Because of the in¬
creased awareness of the role of CD8 cells in the
immune response to diseases, we have included the
phenotyping of both CD4 and CD8 subsets. Our
results are presented throughout as percentages,
rather than absolute counts, as these are subject to
less fluctuation and, therefore, give more consistent
results longitudinally (26). Error in measuring white
counts, from which absolute values are calculated,
has been shown to increase significantly the error of
reported values (27). It must be noted, however,
that for all the subsets studied, double staining of
CD8 cells tends to exaggerate the percentage
change due to the relatively low number of CD8
cells compared to CD4 cells. This could explain the
greater scatter found in the CD8 compared to CD4
populations.
Our results for CD4% and CD8% across the
comparable age ranges are consistent with other
groups (18-23). The values for CD8%, in this study,
are slightly higher but have a narrower standard
deviation than in the ECS, especially at the young¬
est ages, which is reflected in the lower values of
the ratio in the first few months of life. However,
the ECS showed evidence of considerable between-
lab variance for this measurement, which was pos¬
sibly due to different methods used. The CD4%
results show reasonable agreement with the ECS
over most of the range. Overall, the agreement
between the two sets of centiles is very close,
considering the differences in numbers, and this
agreement validates the subsequent results of this
study.
Our studies have found that the CD4% and abso¬
lute counts are high at birth and decrease with age,
while the CD8 levels, which are lower at birth than
in adults, increase over the same period of time,
thus resulting in a net decrease in the CD4/CD8
ratio with age (18-23). We found that the CD4% fell
more sharply in the first 20 months than later, after
which it declined more slowly. The CD8% fell
slightly in the first 18 months and then a steady rise
was seen. The combination of these changes re¬
sulted in a steady decline in the CD4/CD8 ratio,
initially because of the steeper decline in CD4%,
relative to CD8%, and subsequently due to the
steady rise in CD8%, with a corresponding steady
CD4%. In our premature children there were no
significant differences in CD4 and CD8 percentages
compared to full-term children. This agrees with the
findings of Thomas and Linch (28), who studied
premature babies and found that those which were
normal size for gestational age had no significant
differences in their T-lymphocyte populations com¬
pared to full-term babies, while babies that were
small for gestational age had a significant deficiency
in T and B lymphocytes. Wilson et al. (29) found
that children who were stressed at birth had lym¬
phocyte abnormalities, but these were confined to
the B-cell population.
Most other studies of memory markers have
focused on CD4 cells and have found that CD29 or
CD45RO expression increases with age, with a
reciprocal decrease in CD45RA expression (23-25,
30). Our results confirm these findings for CD4
cells, as the expression of both CD45RO and CD29
follows a similar pattern, and the two subpopula¬
tions are strongly correlated. However, on CD8
cells, the expression of these markers is different.
The percentage of CD8 cells coexpressing CD29 is
consistently higher than that coexpressing
CD45RO, and there is a weak correlation between
the two subpopulations. CD29 and CD45RO have
been cited interchangeably as markers of memory
or primed cells (31); however our results show that,
on CD8 cells, CD29 and CD45RO identify different
populations, which only partially overlap and are
therefore not interchangeable (32, 33). The expres¬
sion of CD45RA decreases with age in an approxi¬
mately reciprocal manner to the increase in
CD45RO expression, particularly in the CD8 popu¬
lation, which is consistent with the observations
that cells that are CD45RA+ CD45RO— switch to
CD45RA- CD45RO+ on maturation or priming
(34-36). The decrease in CD45RA expression with
age is also consistent with other studies, although
the percentage of CD45RA+ CD4 cells neonatally
was slightly lower here than in other studies which
used cord blood samples (—80% compared with
—91%) (23, 24). We used samples taken during the
first few days of life, which may explain the differ¬
ences and suggests that, even within a very short
period of life, lymphocyte maturation events are
taking place.
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Our results show a slight age relationship in the
coexpression of HLA-DR on CD4 and CD8 cells.
This is in agreement with Erkeller-Yuksel et al.
(23), who found an age-related increase in HLA-DR
expression on CD3 cells, but not with Parker et al.
(25), who found no significant age relationship of
HLA-DR expression on CD8 cells. We have also
shown that the high-density expression of CDlla on
CD8 cells is not age related in children. This sup¬
ports the findings of Morimoto et al. (15), who
suggested that CDlla is induced or up-regulated on
cytotoxic effector cells. Natural killer cytotoxicity,
mediated by CD57+ CD8 cells, is thought to be an
important means of immune defense against viral
infections in children (12). Our results confirm those
of other groups, showing an age-related increase in
CD57 expression on CD8 cells, with an increase in
spread of values with age (12, 21-23). The transient
rise in expression of CD29, HLA-DR, and CD57 on
CD8 cells at about 30 months is difficult to explain
and requires further investigation. It appears ap¬
proximately 10 months after a slight trough in the
CD8 percentage and may be an expression of nor¬
mal maturational changes, or may reflect subclinical
infectious events, such as infection with viruses,
e.g., cytomegalovirus (CMV). A recent report sug¬
gests that individuals who express high levels of
CD57+ CD8 cells are also infected with CMV (37).
The use of hospitalized children raises the possi¬
bility that pathological factors would affect lympho¬
cyte subpopulation expression. However, our sam¬
ples were selected for nonimmunological and
noninfectious diagnoses, and any differences found
between the groups of children were small, with no
group consistently different. Any effect of trauma of
hospital attendance and venesection would affect all
of the control groups equally and, also, children
being monitored for disease.
In conclusion, this study has established normal,
age-related values for a number of lymphocyte
subpopulations against which children with patho¬
logical conditions can be compared. Lymphocyte
subset phenotyping is particularly relevant in the
monitoring of pediatric HIV infection, where the
centiles shown in Fig. 2 can be used to compare the
tracks of markers in children at risk and provide
diagnostic and prognostic indicators (M.C.A., in
preparation). Charts suitable for clinical use, based
on Fig. 1, can be obtained from the authors. Alter¬
natively, the Appendix gives information from
which charts or Z scores could be calculated.
APPENDIX: DETAILS OF THE METHOD OF
CALCULATION OF CENTILE CURVES
Introduction
The method used to fit the centiles to the data in
the European Collaborative study (19) was based on
the method of Cole (38). This method proceeds by
dividing the data into bands by age group, estimat¬
ing the mean (M), standard deviation (S), and
skewness (L) for each band and then fitting
smoothed curves to the L, M, and S values. The
method used in this paper is very similar but pro¬
ceeds to estimate the LMS curves directly from the
raw data, rather than by dividing them into bands.
A similar, but distinct, approach has been adopted
by Cole and Green (39).
The Model
For each marker we have a set of n measure¬
ments (denoted by y) at a series of ages (x). We
model the distribution of y, given x, as follows.
L: At a given age (x) the values of the box-cox
transformation of y, with parameter X, are as¬
sumed to be normally distributed. The box-cox
transformation is given by
bc(y) = (yx - l)/\ or bc(y) = ln(y) when X=0
A value of 1 for X corresponds to a symmetric
distribution of y; values less than 1 are posi¬
tively skewed, with the percentiles farther apart
at high values of y, and values greater than 1
correspond to a negatively skewed distribution
where the percentiles are farther apart at low
values of y. In all cases a single value of X was
found to model the data adequately.
M: The mean of the distribution of bc(y) as a
function of x was modeled using a locally
weighted regression which produces a
smoothed fit to the data [the loess procedure in
Splus described by Chambers and Hastie (40,
Chap. 8)]. The smoothness of the fit can be
adjusted by choosing a locally linear or a locally
quadratic fit and by adjusting the smoothing
parameter.
S: The standard deviation was allowed to vary as a
function of the age x according to the function
sd(x) = cr exp(l + bx). Positive values of b
correspond to a standard deviation which in¬
creases with age, and negative values to one
that decreases with age.
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Table AI. Predicted Values of the Age-Specific Median (Expressed as Percentages)
CD45RO CD45RA CD29 HLA-DR
Age




CD8CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8
0 51.58 24.24 2.12 9.97 9.01 77.46 87.12 12.30 16.46 3.31 3.83 NA 2.81
6 47.26 23.12 2.01 11.69 9.72 76.08 86.14 14.26 23.01 3.41 4.67 13.20 3.29
12 43.99 22.50 1.91 13.57 10.46 74.68 85.15 16.22 28.45 3.52 5.56 14.02 3.79
18 41.80 22.33 1.84 15.62 11.24 73.31 84.16 18.16 32.53 3.62 6.51 14.95 4.31
24 40.95 22.70 1.78 17.88 12.08 71.95 83.16 20.18 35.36 3.73 7.57 15.69 4.94
30 41.06 23.56 1.73 20.11 12.94 70.60 82.15 21.81 36.87 3.84 8.37 16.45 5.46
36 40.82 24.71 1.65 21.73 13.85 69.22 81.14 22.67 36.25 3.94 8.23 17.15 5.62
42 40.70 25.97 1.57 23.12 14.81 68.04 80.13 23.37 34.81 4.05 7.83 17.75 5.72
48 40.62 26.99 1.51 24.57 15.81 67.01 79.16 24.05 34.47 4.14 7.58 18.21 5.80
54 40.59 28.09 1.44 25.87 16.80 66.30 78.28 24.84 34.05 4.21 7.49 18.14 5.94
60 40.51 29.08 1.38 27.14 17.74 65.69 77.68 25.63 34.12 4.26 7.37 18.15 6.07
66 40.42 29.75 1.35 28.11 18.66 65.26 77.53 26.06 35.00 4.30 7.28 17.86 6.15
72 40.27 30.32 1.32 28.91 19.59 65.09 77.59 26.34 36.07 4.33 7.27 17.46 6.21
78 39.90 31.03 1.28 29.99 20.56 64.72 77.49 26.89 37.21 4.37 7.26 17.15 6.33
84 39.36 31.77 1.23 31.13 21.55 64.50 77.38 27.45 38.54 4.41 7.40 16.71 6.49
90 38.65 32.54 1.18 32.32 22.57 64.39 77.34 28.00 40.07 4.45 7.67 16.16 6.70
96 37.74 33.35 1.13 33.55 23.63 64.36 77.35 28.56 41.79 4.49 8.02 15.55 6.93
102 36.63 34.21 1.07 34.81 24.72 64.39 77.39 29.11 43.72 4.54 8.44 14.92 7.18
108 35.29 35.15 1.00 36.11 25.86 64.43 77.44 29.67 45.85 4.58 8.89 14.30 7.44
114 33.70 36.17 0.94 37.43 27.05 64.45 77.48 30.2 48.18 4.63 9.33 13.71 7.70
120 31.83 37.29 0.86 38.77 28.29 64.41 77.48 30.79 50.72 4.67 9.72 13.18 7.94
The parameters X, b, and tr and the parameters of
the loess fit were fitted by maximum likelihood with
the package Splus. The smoothness of the fit was
chosen by comparing the extra variance explained
between models and by examining the smoothed
curves.
Results
For all the markers locally linear fits were com¬
pared to locally quadratic fits. Locally linear fits
were found to be adequate for all markers except
CD4%, CD4 CD29+, CDS CD29+, CD4 HLA-
DR + , and CD8 CD57+. However, the fits to CD4
CD29+, CD4 HLA-DR+, and CD8 CD57+, all of
which gave a rather sharp local peak at about 30
months appeared implausible, and the linear fits
have been presented. Thus linear fits were used
except for CD4%, CD8 CD29+, and (for consist¬
ency) CD8% and CD4/CD8 ratio. The fit to the data
was not changed greatly by the choice of the band
width for the locally linear regression except for
very small values which produced irregular fits. It
was increased in some instances to make the plots
look smoother.
The fitted values for the median (shown in Figs. 1
and 2) are tabulated in Table AI for six monthly
ages.
The values of a, b, and X for each marker are
given in Table AIL Most of the markers have
positively skew distributions. The exceptions are
CD4% and (especially) CD45RA on CD4 and CD8
cells, where the upper limit of 100% produces
negatively skew distributions. The values of X for
CD4%, CD8%, and their ratios are similar to those
found in the ECS.
The values of b are more difficult to interpret,
because they refer to the standard deviation of
bc(y), which will vary with the mean level of y.
Thus, for example, the standard deviation of CD4
CD45RO+ clearly increases withx (Fig. 2), but the
b estimate for this marker is negative. This comes
about because the levels ofy are increasing with x,
and a constant increment in bc(y), which in this case
is proportional to y0'28, will correspond to a larger
Table All. Fitted Values of the Parameters for Each Marker
cr b X
CD4% 1.700e+01 -6.917e--03 1.40
CD8% 4.990c-02 -6.109e--03 -0.22
CD4/CD8 1.904c-01 -5.515e--03 0.41
CD4 CD45RO+ 2.898c-01 -1.106e--03 0.25
CD8 CD45RO + 3.794c-01 -2.291e--03 0.20
CD4 CD45RA+ 9.924c+01 3.047e--04 1.78
CD8 CD45RA+ 3.262c+05 -5.963e--05 3.62
CD4 CD29+ 6.854e-01 2.067e--03 0.58
CD8 CD29+ 2.493e+00 2.039c--03 0.80
CD4 HLA-DR+ 2.353e-01 1.220c--03 0.05
CD8 HLA-DR+ 5.811e-01 -2.93 le--03 0.31
CD8 CDlla + 6.343e-01 -2.087e--03 0.33
CD8 CD57+ 4.127e—01 1.797e--03 0.10
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increment in the corresponding raw values, at
higher values ofy.
To obtain a Z score for a value Y of a marker
measured at age X, one must first read the median
value (M) for X from Table AI. The Z score is then
calculated as
[bc(Y) - bc(M)]/orexp(l + bX)
where the appropriate X in be and the values of b
and cr are taken from Table AIL The percentile can
then be obtained by referring Z to tables of the
normal distribution.
Similarly, to obtain a percentile point for a
marker at a given age, one first obtains the appro¬
priate Z statistic from the normal distribution ta¬
bles. The value of bc(y) is then calculated as
k = bc(M) + Zcrexp(l + bX)
and the corresponding raw value for the percentile
point calculated as (1 + Xk)1/\
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SUMMARY
HIV-specific cytotoxic T lymphocytes (CTL) are thought to play a major role in viral control in
HIV-infected adults. Changes in the relative proportions of CD8 lymphocyte subpopulations are
also thought to be associated with disease progression. Less is known about the relative
effectiveness of CTL against different HIV targets, or about the relationship, if any, between
CTL activity and CD8 subpopulations. We have measured CTL activity against four HIV gene
products (gag, tat, pol and env) and expression of CD45RO, CD45RA, HLA-DR, CD29, S6F1,
and CD57 surface markers on CD8 cells from nine HIV-infected and 11 HIV-uninfected children.
Of nine HIV-infected children, six showed antigen-specific CTL activity on at least one occasion:
4/6 directed against tat, 6/6 against pol, 1/6 against env, and 1/6 against gag. However, the
specificity of the CTL activity varied between children and within individual children with time.
Furthermore, two uninfected children showed CTL activity, one to HIV-gag, -pol and -tat, and the
other to HIV-po/. All the HIV-infected and two uninfected children had abnormal proportions of
CD8 subpopulations in whole blood compared with age-matched ^controls. There was no
correlation between CTL activity and CD8 subsets in whole blood. Five children changed from
CTL-positive to CTL-negative (or vice versa) during the study. In these, the occasions when CTL
activity was detected coincided with an increase in CD8 cells, an expansion of HLA-DR* CD8
cells and a loss of CD45RA* CD8 cells.
Keywords cytotoxic T lymphocytes CD8 subpopulations CD8 effector cells
paediatric HIV infection clinical significance
INTRODUCTION
CD8+ cytotoxic T lymphocytes (CTL) are thought to play a
major role in the immune control of HIV infection. High levels
of HIV-specific CTL have been demonstrated in asymptomatic
infected adults, which, in some studies, have been shown to be
lost with disease progression. Others have suggested that HIV-
specific CTL may have a pathogenic or deleterious effect
(reviewed in [1-3]).
Children infected by mother-child transmission are an
important group of patients to study. Since they are newly
infected, they may reveal the specificity of early cellular immune
responses, which would be important in the design of vaccines.
The clinical course of HIV disease in these children appears to
follow one of two routes—fast progressors who progress
rapidly and die within 1-2 years, and slow progressors who
Correspondence: Dr Karin S. Froebel, HIV Immunology Unit,
University Department of Medicine, Royal Infirmary, Edinburgh
EH3 9HB, UK.
remain clinically stable for a number of years [4,5], It is
important to establish whether cellular, specifically CTL
responses, have any role in favouring either of these clinical
outcomes. While CTL responses to HIV have been reported in
a number of studies of HIV-infected children [6-8], HIV-
specific CTL have also been described in children who subse¬
quently became antibody-negative [9], and it is important to
determine whether these children have successfully cleared
virus and become naturally immunized. In neonates, HIV
infection, and the immune response to it, takes place in the
context of a developing immune system, and the time at which
infection occurs may be relevant in determining the ability of
the child to resist infection, or to contain the virus.
A previous study in adults has suggested that it may be
possible to indirectly identify CTL by means of CD8 subset
markers in the cultured effector cells, in particular CD45RO,
HLA-DR and S6F1 [10]. We and others have shown in HIV-
infected children that CD8+ lymphocytes and specific subpo¬
pulations are present in abnormally high proportions [11,12].
We have also previously shown that the loss of CTL activity in
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an uninfected child was accompanied by a normalization of
CD8 subpopulations [9]. The aim of this study was to investi¬
gate CTL activity directed against a number of HIV gene
products, CD8 subsets in both peripheral blood and cultured
effector cells, and clinical status over 18 months in HIV-
infected, and in exposed but presumed uninfected children.
MATERIALS AND METHODS
Subjects
Altogether, 20 children were studied. Seventeen of these are
being monitored in Edinburgh, and are also included in the
European Collaborative Study [13-15]. Three more are from
Glasgow or Dundee. They are all seen at regular intervals, and
venesection is performed as part of routine follow up.
The study group comprised nine HIV-infected children
(mean age at start of study 43 months, range 3-88 months),
and 11 children who have lost maternal HIV antibody, have no
other indications of HIV infection, and so are presumed to be
HIV uninfected (mean age at start of study 27 months, range 1-
73 months). Eighteen of the children are known to be born to
HIV-infected women; two were adopted, and as no maternal
information is available the route of infection is unknown. The
clinical classifications of the infected children were determined
using criteria from the Centres of Disease Control (CDC) [16],
and. together with details of clinical symptoms, are presented in
Table 1.
Table 1. Clinical data of the children studied at each time of testing
Age Clinical CDC*
Child (months) symptoms stage
HIV infected
1 79-93 Ear/throat infections/PGL/well P2A
2 71-84 Well/well/PGL/well P2C,F
3 53-59 Well PI B
4 28-45 Well PI B
5 21-31 Fever/chest infection/well P2A
6 88-90 Well/chest infection P2A
7 40-43 Schistosoma haematobium/chest/vira\
infections P2A,C
8 4-6 Chest infection P2A
9 3-6 Candidiasis/PGL P2A
HIV uninfected
10 73 Well —
11 70 Well —
12 36 Viral illness —
13 30 Well —
14 25 Diarrhoea and vomiting —
15 15 Well —
16 1 Candidiasis —
17 10 Well —
18 17 Well —
19 6 Well —
20 17-25 Tapeworms/Diarrhoea —
*CDC classification for paediatric HIV.
PGL, Persistent generalized lymphadenopathy.
CTL assay
The method was based on that of Nixon et al. [17] using bulk
cultured effector cells in a 4-h 51Cr-release assay.
Effector cells. Peripheral blood lymphocytes (PBL) were
isolated from heparinized blood, and stimulated with phyto-
haemagglutinin (PHA) (2-5/rg/ml; Wellcome, Beckenham,
UK). For the HIV-infected samples, 10% of PBL were stimu¬
lated with PHA for 2 days, washed once, and then added
back to the remaining cells in 24-well tissue culture plates.
For the HIV-uninfected samples, all the cells were stimulated
with PHA, this having been shown to give a better outgrowth
of cells (unpublished observation). All cultures were main¬
tained at 37°C in RPMI 1640 medium containing 10% fetal
calf serum (FCS) for 7 days, and subsequently in medium
containing IL-2 (5% Lymphocult, Biotest, Solihull, UK).
Fifty percent of culture supernatant was changed every 3-4
days until assayed. Assays were carried out between day 9
and day 23 of culture, when there were deemed to be suffi¬
cient cells.
Target cells. Autologous Epstein-Barr virus (EBV)-trans-
formed B cell lines were infected overnight with 106 PFU of
either a vaccinia-HIV construct (gag, tat, pol or env), or a
vaccinia control. The constructs used were: vaccinia control
(Vac-Vsc8WR) and vac-gag (MRC, AIDS Directed Pro¬
gramme), tat (VVTG3196), pol (VVTG3167) and env
(VVTG1132) (Transgene, Strasbourg, France). A tube contain¬
ing EBV cells not infected with vaccinia constructs was set up as
a 'medium' control.
Assay. Given the variable number of cells available, the
effector cells were always used at the highest effector: target
ratios possible, which was generally between 10:1 and 50: 1.
The per cent lysis of the target cells was measured after 4 h in
culture, by release of 51Cr into the supernatant, and calculated
using:
specific lysis — spontaneous lysis
total lysis — spontaneous lysis
where total and spontaneous lysis were determined by incubat¬
ing the target cells in 5% Triton-X and in medium, respectively.
Immunofluorescence analysis
Blood or effector cell phenotypes were analysed using standard
dual-colour flow cytometry with the following MoAbs: anti-
CD^ Leu-3a)-FITC, anti-CD8(Leu-2a)-PE, anti-HLA-DR-FITC,
anti-CD45RA(Leu-18)-FITC (Becton Dickinson, Oxford,
UK), anti-S6F 1 -RD l/anti-CD8-FITC, anti-CD29(4B4)-FITC
(Coulter, Luton, UK) and anti-CD45RO(UCHLl)-FITC
(Dako Ltd, High Wycombe, UK). All antibody mixes were
diluted 1:2, except for S6F1 which was used at 1:16. Briefly,
diluted blood or effector cells were added to the antibody pair
and incubated for 15 min at room temperature. The erythro¬
cytes in whole blood samples were lysed using Facslyse (Becton
Dickinson). The samples were centrifuged, washed in saline,
fixed in 1% formaldehyde/PBS and stored at 4°C until
analysed on a FACScan (Becton Dickinson). Results are
expressed as the percentage of CD8 cells co-expressing the
antigen studied.
Analysis of results
CD8 lymphocyte subpopulation percentages in blood were
compared with age-related normal ranges previously estab-
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ished (M. C. Aldhous, submitted for publication). The percen-
ages were converted to 'Z-scores', a measure of the number of
standard deviations an individual is from the age-matched
nean value. The Z-scores of children who showed CTL
ictivity (CTL + ) were then compared with those who were
ETL , using the two-sample t-test.
The percentage of CD8 effector cells co-expressing the




CTL activity against HIV-gag, tat, pot and env is shown in Figs
1 and 2 for HIV-infected (nos 1-9) and uninfected (nos 11-20)
children, respectively. Results are presented as the per cent
specific lysis net of medium and vaccinia controls, with values
greater than 10% above controls being regarded as positive.
Each infected child was tested between two and four times, and
the uninfected children once, except for one child (no. 20)
assayed twice.
HIV infected children. Six of the nine HIV-infected children
showed CTL activity on at least one occasion. The most
commonly recognized target was pot, followed by tat (six and
four children respectively). Gag was recognized by only one
infected child. In four cases the CTL activity was directed
against a single target (children 1, 2, 3 and 4), and in two
cases it was directed against two targets {tat and pol in children
5 and 9).
The specificity of the CTL response changed on successive
tests. In the two youngest children who had CTL (children 9
and 5, aged 6 and 21-31 months, respectively) the response was
against both tat and pol. In two older children (children 3 and 4,
aged 53-59 and 28-45 months, respectively) the specificity of
the response changed from tat to pol, and in the two oldest
children, the specificity changed from pol to gag in child 1 (aged
79-93 months), and from pol to a weak env response in child 2
(aged 71-84 months).
Two children (children 2 and 4) lost CTL activity, and two
children (nos 1 and 5) lost and regained CTL activity during the
period of follow up. Three children (nos 6, 7 and 8) were CTL-
throughout the study.
Child
Fig. 1. HIV-specific cytotoxic T lymphocyte (CTL) activity on sequen¬
tial samples in HIV-infected children. 0, gag; 0, tar, ■, pol; □, env.
Child
Fig. 2. HIV-specific cytotoxic T lymphocyte (CTL) activity in HIV-
uninfected children. *Activity measured after day 11 and day 18 in
culture. 0, gag; 0, tat; ■, pol; □, env.
HIV-uninfected children. CTL activity was detected in two
HIV-uninfected children. A further two had borderline activity.
Child 20 showed significant levels of anti-gag, anti-rat and weak
anti-pol activity when first assayed at 17 months of age. On this
occasion, the effector cells were used at two different time
points, days 11 and 18 after stimulation, and the specificity
was shown to change from gag and pol on day 11 to tat on day
18. At 25 months, this child showed high non-specific killing
(data not shown), but no HIV-specific lysis. Child 19 showed
anti-pol activity at 6 months of age. Children 11 and 13 had
borderline (i.e. 10% lysis) anti-gag responses at 70 and 30
months, respectively.
CD8 subpopulations in whole blood
CD8 subpopulations were determined using the same blood
samples as the CTL assay, and were compared with the age-
related values determined for normal children (M. C. Aldhous,
submitted for publication). Levels were regarded as being
raised or decreased if they were above the 97th, or below the
3rd centiles, respectively.
HIV-infected children. All nine had raised (>97th centile)
levels of S6F1 + CD8 cells, on both CTL ' and CTL - occasions.
Eight had raised HLA-DR+ CD8 cells, the one child (no. 6)
with no raised HLA-DR levels being CTL . Six children (nos 1,
2, 3, 5, 8 and 9) had raised CD45RO+ CD8 cells and
correspondingly decreased (<3rd centile) CD45RA CD8
cells. These were observed on both CTL+ and CTL occasions
in all except one child (no. 8), who was consistently CTL-
against the constructs used. Conversely, child 4, who was
CTL+ on 2/3 occasions tested, had normal CD45RO expres¬
sion on CD8 cells. Children 5, 7 and 8 had raised CD29+ CD8
cells, which corresponded to CTL activity in only one child (no.
5), and only on one occasion. Child 7 was the only child who
showed raised CD57+ CD8 cells, and this did not correspond
to CTL activity. The S6F1 and CD45RO levels were raised
persistently, whereas the HLA-DR, CD29 and CD57 levels
were raised sporadically.
HIV-uninfected children. Children 13 and 20 had abnormal
CD8 subpopulations in whole blood. In child 13, the abnormal
phenotype levels corresponded to borderline CTL activity. The
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next sample received showed lymphocyte markers within
normal ranges for age (data not shown). In child 20, abnor¬
mally raised CD45RO + , HLA-DR + and S6F1+ CD8 cells in
whole blood corresponded to CTL activity against HIV gag,
tat, and poi, 8 months later no HIV-specific CTL activity was
detected and the CD8 phenotypes had returned to normal. The
anti-pol CTL activity of child 19 did not correspond to any
raised CD8 subpopulations. All other uninfected children had
CD8 subpopulations which were within the normal ranges for
age.
CD8 subpopulations in effector cells
The percentages of the various CD8 subpopulations in the
effector cell cultures were compared with those in the corre¬
sponding sample of blood. All children showed an increase in
HLA-DR+ CD8 cells and, apart from three infected children,
who already had very high levels in blood, there was also an
increase in CD45RO+ CD8 cells. All samples showed a
corresponding decrease in CD45RA+ CD8 cells, findings
which are consistent with immune activation. The percentage
of CD29+ CD8 cells decreased on effector cells, contrary to
expectation as both CD29 and CD45RO are memory markers.
S6F1 expression increased on the CD8 effector cells of unin¬
fected children, and was maintained, but did not increase
further, on the cells of the infected children, in whom expres¬
























Fig. 3. CD8 subpopulations in children who changed cytotoxic T
lymphocyte (CTL) activity. Comparison of CTL+ (■) and CTL" (T1)
occasions in (a) whole blood, (b) effector cells. Graphs are mean ± s.e.m.
*Significant difference between CTL+ and CTL" results (P < 0-05).
Analysis of CD8 subpopulations in CTL+ and CTLT children
Statistical comparisons of CDS subpopulations in blood were
made using Z-scores, and of effector cells using the percentage
values. There were no significant differences between the levels
of CD8 subpopulations in whole blood or effector cells between
those children who had CTL activity on any occasion and those
who did not.
We then analysed the results of the five children who
changed CTL activity during the study period. CD8 subpopu-
lation levels of blood (Fig. 3a) and effector cells (Fig. 3b) on
the CTL+ and CTL" occasions were compared. There was
no difference in whole blood, but in the effector cells the
percentage of CD8 cells was significantly increased (P = 0 05)
on the CTL+ occasions, as was that of the HLA-DR +
subpopulation (P<0 05). The increase in CD45RO+ CD8
cells was not significant, but the percentage of CD45RAT
CD8 cells was significantly decreased (P<0 05) on the CTL +
occasions.
CTL activity and clinical status
The clinical details are shown in Table 1. Five of the six infected
children with CTL activity were generally well (children 1-5)
during the period of follow up. The sixth (child 9) was
symptomatic throughout. The three CTL" children (nos 6, 7
and 8) all had infections during the study period.
DISCUSSION
There is increasing interest in the role of CD8 cells in suppres¬
sing HIV replication and in maintaining the asymptomatic
phase of the disease. In particular cytotoxic T cells are believed
to play an important part in the immune response to HIV [1-3].
CD8 subpopulations are increased in the peripheral circulation
of HIV-infected individuals at all stages of infection [18-21],
but their functional significance still needs clarification [22]. In
this study we have investigated the CTL activity against HIV
antigens in nine HIV-infected and 11 uninfected children,
studying possible associations between CTL activity, CD8
subsets and clinical disease.
Because of the small samples of blood obtained (approxi¬
mately 3 ml), all assays were performed using PHA-stimu-
lated, bulk cultured lymphocytes as effector cells. The killing
has been shown to be blocked by anti-CD8 antibody and to
be MHC restricted (data not shown) [17]. The most com¬
monly recognized antigen was pol, followed by tat, then gag
and env. While six of the nine HIV-infected children showed
CTL activity on at least one occasion, the specificity varied,
both between children and within individual children with
time, suggesting a possible sequential pattern of CTL specifi¬
city, with epitopes on tat and pol stimulating an early CTL
response. This observation requires confirmation by further
longitudinal data.
Our results are consistent with those of Luzuriaga et al. [23],
who found anti-gag and -env activity in only a proportion of
vertically infected children, but differ from those of Cheynier et
al. [7], who found CTL activity to HIV-gag, -env and -nef in a
high proportion of children tested, as did Buseyne et al. [8]
against HIV-gag, -env and -pol. The reasons for these differ¬
ences are unclear. Technical differences relating to alternative
methods used to stimulate effector cells may be important—in
this study, effector cells from one child (no. 20), maintained for
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different lengths of time, had different specificities, which
suggests that CTL precursors differentiated into separate
dominant clones during culture. Different viral sequences
used in the vaccinia constructs, or different strains of virus
—infecting the groups of children, may also account for incon¬
sistencies seen between studies.
Apart from HYW-nef, the regulatory proteins have not
generally been thought to be immunogenic [7,24-26]. Our
results show that HIV-tat is strongly immunogenic and,
together with pot, may stimulate important early responses,
particularly in children. The tat gene product is one of the early
regulatory proteins involved in the initiation of RNA transcrip¬
tion and elongation [27], and appears to be of great importance
in up-regulating gene expression and HIV replication. Thus,
rat-directed cytotoxicity may remove sites of high viral replica¬
tion and limit the extent of further viral transmission, or
potential for genomic variation. Increased expression of pot
would be expected to occur during active intracellular viral
replication [28], and cytotoxicity directed against these cells
would also limit virus production and viral load. In cross-
sectional studies of infected adults, CTL activity to both HIV-
tat and pot has been detected (K. C. Watret, unpublished data)
[26,29] but, for tat, less frequently compared with other HIV
gene products [26], Further longitudinal monitoring is needed
to establish whether the pattern of response suggested by this
group of children at different ages applies also to individual
children, and whether other regulatory proteins such as HIV-v;/
and rev are also immunogenic. If it is confirmed that HIV-tat
and pot induce an early CTL response, this may have implica¬
tions for the design of vaccines for children.
Evidence of cellular immune responsiveness to HIV in
uninfected individuals has been reported by a number of
groups [7,9,30]. This study has shown two of 11 presumed
uninfected children to have strong CTL activity on one occa¬
sion and a further two to have borderline levels. The intracel¬
lular processing and presentation of viral peptide to CTL is
thought to require infection of the target cell, implying that
these children have been exposed to live, though possibly non-
replicating, virus. Recent evidence from vaccine trials has
shown that CTL can be induced by non-replicating viral
proteins if presented with appropriate adjuvants [31]. Of
interest is the transient nature of the CTL response. Child 20,
who was assayed twice, lost the response on the second
occasion, suggesting that CTL precursors were no longer
present in the circulation, and raising the question of whether
this child is immunologically sensitized to HIV. Other labora¬
tory tests, including HIV antibody, antigen culture and poly¬
merase chain reaction (PCR) were consistently negative (data
not shown), and this child was therefore diagnosed as unin¬
fected. During the early stages of disease, HIV accumulates in
the lymphoid organs, even when there is little or no evidence of
infection in peripheral blood [32,33]. It may be possible that
some virus is still present in the lymphoid tissues of these
children, capable of emerging at a later date, as occurred in
one child studied by Luzuriaga et at. [6], PCR on lymphoid
tissue would be necessary to determine whether the children are
truly HIV-uninfected.
We examined whether any of the CD8 subpopulations,
known to be raised in paediatric HIV infection, correlated
with CTL activity, as phenotype monitoring of the numbers
or proportions of the relevant effector or precursor cells would
be a much easier method of following CD8 functional
responses. We also wished to see whether any particular
subpopulation was consistently different on comparing CTL +
and CTL- occasions, which may correspond to a CTL pre¬
cursor population. A previous study of a child who had
transient CTL activity suggested that raised CD8 subpopula¬
tions correspond to CTL activity [9], an observation which was
repeated in this study (child 20). However, the CTL activity
without raised CD8 subpopulations in whole blood from one
child (no 19), and the converse in another (child 8), indicate that
this is not universal. Furthermore, all of the infected children
had raised S6F1+ CD8 cells, including those who were
consistently CTL", and although six of the nine children had
raised CD45RO+ CD8 cells, these did not all correspond to the
six who had CTL activity. There is no evidence, therefore, for a
precursor phenotype in the whole blood for the populations
studied here, even when the children who changed CTL activity
during the study were analysed alone. However, it may be that
a precursor phenotype is one that was not included in this
study, or that those children who changed CTL activity still had
CTL, but to an antigen not included, and did not truly lose the
CTL activity altogether.
We have previously reported that loss of CTL activity in
adults was associated with a failure to expand of the
CD45RO + , S6F1 + and HLA-DR+ subpopulations of CD8
cells in bulk cultured effector cells [10]. In this study, to allow
for the possibility that the CTL" children may have CTL
against target antigens not studied here, we limited the analysis
of effector cell subpopulations to the five children who changed
CTL activity during the study. In these children there was a rise
in the proportion of HLA-DR + CD8 cells, and a decrease in
the proportion of CD45RA+ CD8 cells on the CTL+ occa¬
sions, which is consistent with immune activation. However,
there was no further expansion of S6F1+ CD8 cells, probably
due to the very high levels already present in the blood (a
phenomenon not seen to the same extent in adults [10]), giving
little room for further expansion. On the CTL occasions,
however, there was a lack of expansion of CD8 cells, and in
particular a lack of increased expression of HLA-DR on CD8
cells, which was statistically significant. This study therefore
confirms our previous findings that CTL activity is a conse¬
quence of the ability of particular CD8 subpopulations to
expand in culture.
CD57+ CD8 cells which suppress CTL activity have been
described in peripheral blood and in alveolar fluid [34,35], Here,
there were no consistent changes in the expression of CD57 on
CD8 cells, in either whole blood or effector cells, to explain the
lack of CTL activity in any child, or to account for an increased
lysis through natural killer function [36,37]. We were also
unable to confirm the results of Sohen et at. [38], who defined
CD8+ cytotoxic T cells as CD29+ S6F1+ CD45RA". Our
results showed a decrease in CD45RA+ expression and the
maintenance of S6F1+ expression, but a decrease in the
expression of CD29 on CD8 effector cells compared with
corresponding blood samples.
It is still not clear whether CTL activity is universally
beneficial to the individual infected with HIV. Loss of CTL
activity in asymptomatic individuals occurs before clinical
disease progression [34], suggesting that CTL activity is an
important mechanism in viral control. However, the finding of
CTL in bronchial lavage [39] and cerebrospinal fluid [40]
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indicates that CTL may contribute to the pathological mani¬
festations of HIV disease. In this study, CTL activity did not
always correlate with clinically stable disease. Five of the six
children who had CTL activity were, on the whole, clinically
well, and the preliminary evidence that child 20 may have
cleared HIV infection through CTL activity supports the
theory that CTL activity is beneficial. No CTL activity was
detected in three children who are still clinically stable. Con¬
versely, a newborn child 9, who is a fast progressor, developed
CTL activity at 6 months. All these children need to be
monitored further, to determine whether any direct associa¬
tion between CTL activity and clinical disease can be shown.
In conclusion, our results show that CTL activity in
children follows a sequential pattern of responses to different
antigens. This needs to be confirmed in a larger cohort of
children, and in newly infected adults, to determine whether a
similar pattern of responses holds. CTL activity is not directly
related to CD8 subpopulation in whole blood, but is associated
with the ability of certain CD8 cell populations to expand in
culture. CTL are not consistently associated with clinically
stable disease, and further study in a larger cohort of children
is required to show the relationship between CTL activity and
disease activity.
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Abstract
Vertical infection with human immunodeficiency
virus-1 (HIV-1) causes profound changes in the pro-
—portions of subpopulations of lymphocytes in the pe-
Iripheral circulation. In this study the percentages in
whole blood of CD4 and CD8 cells, and of im¬
munologically important subpopulations, were mea¬
sured in 19 HIV-infected children over periods of up
to 4 years and compared to our recently published
ranges for normal children of various ages.1 The rate
jof CD4 decline and of CD8 increase differed be¬
tween clinically fast and slow progressors. On CDS
cells, cytotoxic, memory (CD1 l abnght and CD45R0),
and activation (HLA-DR) markers were raised soon
after birth to levels outside the normal range, and
compared favorably with HIV culture as a method
for early diagnosis of HIV infection. Mean levels of
naive (CD45RA) and memory (CD45R0, CD29)
markers on CD4 cells became significantly altered
after 48 months of age, suggesting that these are
markers of more advanced disease. Despite different
ages of enrollment into the study, in the cohort as a
whole, the levels of the lymphocyte subpopulations
studied changed consistently. Thus, their measure¬
ment could be useful both in the diagnosis and prog¬
nosis of HIV infection in individual children. This
ps the first report showing that lymphocyte subpop-
Llation analysis can play a major role in the diagno¬
sis of pediatric HIV i fection.
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Introduction
Although much has been learned about the immune
responses of adults following HIV infection, less is
known about the ability of neonates or children to re¬
spond immunologically to HIV. A significant pro¬
portion of infants born to HIV-infected women is in¬
fected in utero or at birth, when the immune system
is still immature.2 Recent work with rhesus macaque
monkeys has shown that neonates differ from adults
in their susceptibility to infection with attenuated
simian immunodeficiency virus (SIV),3 suggesting
that conclusions drawn from studies of adult patients
cannot necessarily be extrapolated to neonates.
Furthermore, different routes of infection can influ¬
ence whether the immune response is predominantly
T-helper type 1, leading to cell-mediated immunity
mediated by interleukin 2 (IL-2) and gamma inter¬
feron, or T-helper type 2, leading to a predominantly
humoral immune response mediated by release of IL-
4, IL-6, and IL-10.4 Thus both the route of infection
and the stage of gestation at which it occurs may af¬
fect the type and degree of immune response that an
infant makes to HIV.
Flow cytometric analysis of lymphocyte subpopu¬
lations has been widely used in clinical staging of adult
HIV infection and to elucidate possible immunologi¬
cal responses.5 Similar analysis in children is compli¬
cated by the substantial changes that take place as part
of normal maturation. Recent studies by ourselves and
others have established age-related normal ranges for
CD4 and CD8 subsets, and for a number of immuno¬
logically important subpopulations.'-6'7 In HIV-in¬
fected children, previous studies have shown changes
in the levels of some of these subpopulations,8"" but
to our knowledge no previous studies have related lym¬
phocyte subpopulation analysis to diagnosis or to HIV
disease progression. In this study we prospectively fol¬
lowed the levels of CD4 and CD8 cells, and of CD4
and CD8 cell subpopulations expressing activation,
l
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memory, and cytotoxicity markers in a cohort of in¬
fected children and compared them with our recently
—published ranges for normal children of different ages1
and with clinical disease progression.
MMethods
Subjects
Children born to HIV-infected women were en¬
rolled in a perinatal transmission study and seen at
regular intervals.12'13 Venesection is performed as
part of routine clinical follow-up. A diagnosis of HIV
infection is made on the basis of two positive labo¬
ratory results indicating the presence of HIV, viz
virus culture, HIV-specific polymerase chain reac¬
tion (PCR), and plasma p24 antigen. Clinical signs
md symptoms were categorized according to the
dinical staging system proposed by Tovo et al.14
hildren were classified as fast progressors on the
iasis of the appearance of the following signs and
ymptoms before the age of 1 year: specific sec¬
ondary infectious diseases, severe bacterial infec¬
tions, progressive neurological disease, anemia,
fever, growth failure, persistent oral candidiasis, he¬
patitis, or cardiomyopathy.
Nineteen HIV-infected children aged from birth to
108 months were followed for a median of 27 months
(range 2-55 months). Sixteen were vertically in¬
fected, one by blood transfusion, and the route of in¬
fection for the remaining two was unknown. Four
children were defined as fast progressors, two of
whom had been followed from birth, whereas the
other two were enrolled at 10 and 13 months re¬
spectively. One of these children (no. 17) subse¬
quently stabilized clinically. Of the fifteen slow pro¬
gressors, four were followed from birth, whereas the
remainder were enrolled between 23 and 80 months
of age. Six children died during the study, but de¬
tailed lymphocyte subpopulation data were available
on only two. Clinical details of the children studied
are summarized in Table 1.
Age related normal ranges for lymphocyte sub-
populations for children aged 0-110 months, were
Table 1. Clinical Details of Children
Age (months)
at venesection
No. times CDC stage3
Child First Last tested at start of study HIV-related clinical events during study
Slow progressorsb
Nonspecific signs and symptoms1 49 102 34 A2
2 38 93 34 B2 Thrombocytopenia
3 55 107 25 Al Nonspecific signs and symptoms
4 29 77 21 Al Nonspecific signs and symptoms
5 3 42 16 A Al Nonspecific signs and symptoms
6 23 59 17 Al Recurrent respiratory infections, presumed
lymphocytic interstitial pneumonia
7 24 53 11 Al Nonspecific signs and symptoms
8 1 21 11 Al Recurrent upper respiratory infections
0 80 107 18 B3 Salmonella meningitis and septicemia, failure
to thrive, diarrhea
1 55 89 4 B2 Lymphocytic interstitial pneumonia
2 65 91 10 B3 Nonspecific symptoms, Ewing's sarcoma, died
5 66 82 9 B2 Nonspecific symptoms, cardiomyopathy, died
6 73 108 20 B3 Thrombocytopenia, HIV encephalopathy,
disseminated herpes zoster, died
8 1 6 4 N1 Clinically well
9 1 4 2 N1 Clinically well
9 1 13 13 CI HIV encephalopathy, cerebral toxoplasmosis, died
13 10 12 2 CI Septicemia, failure to thrive, died
14 13 20 4 C3 Recurrent abscesses, failure to thrive, died
17 2 8 4 B2 Thrush, pneumonia, nonspecific symptoms
aThe CDC stage was determined using the percentage of CD4 cells.48
bSlow and fast progressors were classified according to the system of Tovo et al.14
I
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calculated from 168 control samples, analyzed con¬
currently with the patients, as previously described.1
Immunofluorescence Analysis
Cell surface phenotypes were analyzed in whole
blood, by dual-color flow cytometry as previously
described,1 using monoclonal antibodies conjugated
with fluoro-isothiocyanate (FITC), phyco-erythrin
(PE) or rhodamine (RD1) as follows: anti-CD4(Leu
3a)-FITC, anti CD8(Leu2a)-PE, anti-HLA-DR-
FITC, anti-CD45RA(Leul 8)-FITC (Becton Dickin¬
son, Oxford, UK), anti-CDl la(S6Fl)-RDl/anti-
CD8-FITC, anti-CD29(4B4)-FITC(Coulter, Futon,
UK), and anti-CD45R0(UCHFl)-FITC (DAKO Ftd,
High Wycombe, UK). Pairs of appropriately diluted
antibodies were added to 100 /xl of heparinized blood
and incubated at room temperature for 15 min, be¬
fore lysis, washing, and fixation in 1% formalde¬
hyde/phosphate-buffered saline. The samples were
analyzed on a FACScan (Becton-Dickinson) using
Simulset software. Lymphocytes were labeled with
anti-CD 14/CD45 ("Leucogate," Becton-Dickinson)
and gated using forward and side light scatter. Gating
of total CDS cells, and of the CD45RA and CD45R0-
subpopulations, included both bright and dimly flu¬
orescing cells as positive; gating of CD1 la cells in¬
cluded only the brightly staining cells as positive
(CD1 labnght). Expression of phenotyping results as
percentages rather than absolute counts has been
shown to be less variable because of the natural vari¬
ation in blood lymphocyte counts,15'16 and, in our
experience, is more consistent longitudinally. The re¬
sults are therefore expressed as the percentage of
CD4 or CD8 cells coexpressing the antigen studied
(CD4+CDX+/CD4+ X 100).
Table 2. Age Dependent Levels of Lymphocyte Subpopulations in HIV Infected Children
Age (months)
0-24 25-48 49-60 61-110
Progression rate Fast Slow Slow
No. children 4 5 5 9 9
CD4 29 42 29 25 18
(-1.5**) (-0.43) (-1.30**) (-2.19**) (-3.06**)
CD8 45 27 43 51 56
(+2.34**) (+0.47) (+2.18**) (+3.17**) (+3.19**)
CD4 subpopulations
CD45R0 15 12 26 32 48
(+0.22) (-0.22) (+0.29) (+0.86**) (+1.31**)
CD45RA 76 78 67 57 46
(+0.08) (+0.26) (-0.09) (-1.08**) (-1.27**)
CD29 16 15 24 36 43
(+0.16) (+0.05) (+0.05) (+0.87**) (+1.31**)
HLA-DR 7 5 10 13 19
(+1.07*) (+0.63) (+1.40**) (+1.83**) (+1.73**)
CD8 subpopulations
CD45R0 28 25 37 46 61
(+1.67**) (+1.28**) (+1.68**) (+2.31**) (+2.68**)
CD45RA 57 67 53 47 35
(-2.22**) (-1.48**) (-1.77**) (-1.91**) (-1.94**)
CD29 54 41 54 55 53
(+2.12**) (+1.26**) (+1.19**) (+0.98**) (+0.66)
HLA-DR 30 21 32 38 42
(+2.47**) (+1.67**) (+2.17**) (+2.80**) (+3.30**
CD57 18 6 21 21 20
(+1.27*) (+0.10) (+1.06**) (+1.03**) (+0.97**)
CDlla 63 45 74 81 79
(+2.68**) (+2.06**) (+2.90**) (+3.21**) (+3.56**)
Results are expressed as the mean percent (and age-standardized Z scores) for each marker, for each age band. * p<0.05, **p<0.01:
results significantly different from age matched normal children.
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Figure 1. (A) The percentage of CD4+ lymphocytes in individual patients.
100 120
Statistical Analysis
Because both the absolute levels and proportions
of lymphocyte subpopulations change with age in
tormal children, the individual results for each pa¬
tent were converted to age-standardized z-scores, or
standard deviation units, relative to the age-related
nean for normal children.1 These were calculated by
subtracting from each individual measurement the
;orresponding specific mean for normal children, and
-dividing by the age-specific standard deviation for no
children. Thus, the z-scores for normal children
vould have a mean value of zero and a standard de¬
viation of 1. The z-scores for the HIV-infected chil¬
dren were compared with those of normal children in
24-month age bands between 0-71 months, and a 36-
month band between 72-108 months, as follows:
within each age band, the mean of the individual re¬
sults for each child was calculated (the child-specific
mean z-score). The means of the child-specific mean
z-scores were then calculated for each age band.
Children in the first 24-month age band were subdi¬
vided into fast and slow progressors. Differences be¬
tween the mean z-scores for HIV-infected children
and the normal reference range were assessed by test¬
ing for a difference from a normal distribution with
mean 0 and standard deviation of 1.
Results
The results, expressed both as the mean percentage
and the mean z-score for each lymphocyte subpopula-
tion, in each age band are shown in Table 2. For those
subpopulations where patient results fall substantially
outside the normal range, the results from individual
children are shown, plotted against age (Figs. 1 and 2).
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CD8 cells
Age in months
Figure 1. (B) The percentage of CD8~ lymphocytes in individual patients. The numbers refer to patients 1-19 as in Table
1. The solid lines show the 3rd and 97th percentiles respectively of the normal ranges for CD4 and CD8 cells.
CD4 and CD8 Cells
The composite results show a fall over time in the
percentage of CD4 cells and a rise in the percentage
of CD8 cells. The rise in CD8 cells occurred faster
and was more pronounced than the fall in CD4 cells,
indicating that this is not simply a reciprocal of the
CD4 percentage fall (Fig. 1 and z-scores in Table 2).
Apart from one child whose level fell after 80
months, CD8 cell levels were at or above the 97th
percentile for age-matched normal children by 45
months (Fig. IB), whereas CD4 cell levels in sev¬
eral children remained between the 3rd and 10th per¬
centile (Fig. 1A). Three of the four progressors (child
9, 14, and 17) showed a more rapid fall in CD4 cell
loss, and all four (nos. 9, 13, 14, and 17) showed a
more rapid rise in CD8 cells than the slow progres¬
sors. The differences between the infected and un¬
infected children reached statistical significance ir
the first age band (0-23 months) for fast progressors
and in the second age band (24-47 months) for the
slow progressors (Table 2). In two slow progressors
clinical disease progression to CDC stage B3 wa:
accompanied by a fall in both CD4 and CD8 cell:
(nos. 10 and 16, Fig. 1).
CD4 Subpopulations
Apart from HLA-DR+ CD4 cells, the mean per
centages of all the CD4 cell subpopulations stud¬
ied became significantly different from age
matched uninfected children in the 48-71-montl
age group (p < 0.01, Table 2). HLA-DR+ CD4 eel
numbers were elevated by 24 months in the fast
progressors and by 48 months in the slow progres¬
sors (Table 2).
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Figure 2A. Percentages of CDS cell subpopulations in individual patients: CDlla + . Line numbers are as for Fig. 1. The solid
lines show the 97th percentiles of each normal range.
CD8 Subpopulations
The mean percentages of all the CD8 cell sub-
populations studied were significantly altered by 24
months of age, except for CD57 + CD8 cells, which
were increased by 48 months (p < 0.01, Table 2).
The CDlla+bnght and HLA-DR+ subpopulations
showed the largest increases (z-scores: 2.68 and 2.47,
•espectively, by 24 months in the fast progressors,
-Table 2). Individual levels of CD1 la+bnght,
2D45R0+, and HLA-DR+ CD8 cells were outside
—he normal range for most of the children tested (Fig.
2). In particular the individual levels of CD1 la+bnght
CD8 cells were above the 97th percentile in all chil¬
dren by 12 months of age. The increase in CD29 +
=CD8 cells, seen in the first 24 months, lessened over
time, and levels returned to normal after 72 months
of age.
Relationship between Lymphocyte
Subpopulations and Virus Culture
The ages at which CD1 la+bnght, CD45R0+, and
HLA-DR+ CD8 subpopulations became elevated
above the 97th percentile were compared with the
ages at which virus culture was first positive in six
children followed from birth. The results are shown
in Table 3. Two children who were virus-culture pos¬
itive in the neonatal period also had raised levels of
these CD8 subpopulations at the time of their initial
lymphocyte analysis at 3 weeks and 2 months of age
respectively. Two additional children had elevated
CD8 subpopulations at the time that they were first
virus-culture positive, at 2 and 3 months respec¬
tively. Both had previously been virus-culture neg¬
ative, and one had previously had normal CD8 sub-
population levels. A fifth child had elevated CD8
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Figure 2B. Percentages of CDS cell subpopulations in individual patients: CD45R0 + . Line numbers are as for Fig. 1. The solid"
lines show the 97th percentiles of each normal range.
subpopulations at 1 month of age, 5 months prior to
positive-virus culture, and a sixth child was virus-
culture negative at 1 week, culture positive at 1
month, but did not show elevated CD8 subpopula¬
tions until the subsequent testing, 3 months later.
Discussion
This study has shown substantial and consistent
differences in the expression of CD4 and CD8 cell
markers in HIV-infected children compared to age-
matched uninfected children and to HIV-infected
adults. By expressing the results as z-scores, a de¬
rived statistic expressing units of standard deviation,
we were able to analyze differences of expression
over and above the changes due to normal matura¬
tion. The most surprising results were the rapid rate
of increase of total CD8 cells in the four fast pro-
gressors, compared to slow progressors. and the lev¬
els in all the children of CD8 subpopulations ex
pressing CDllabri§ht, CD45R0, and HLA-DI*
markers.
The loss of CD4 cells and the differential rate o
loss in the fast and slow progressors has been de
scribed previously in studies by Plaeger-Marshall e
al.11 and Shearer et al.17 The European Collaborative
Study18 has shown that the rate of fall of CD4 num
bers is a better predictor of Pneumocystis carini
pneumonia (PCP) than the absolute count; this i
consistent with our results. The Italian pediatric co
hort study also reported an increased rate of loss ii
CD4 cells, but did not show an increase in CD1
cells.19 Our study has shown that an increase in the
percentage of CD8 cells occurs, which is more rapic
than the loss of CD4 cells and of greater magnitude.
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Figure 2C. Percentages of CDS cell subpopulations in individual patients: HLA-DR + . Line numbers are as for Fig. 1. The
solid lines show the 97th percentiles of each normal range.
The absolute values of the z-scores were consistently
greater for the CD8% than for the CD4%, indicating
that the CD8% increase was not simply the recipro¬
cal of the CD4% decrease. Because of the relatively
small number of subjects, statistical analysis was car¬
ried out only at 24 months; however, it is likely that
with increased numbers, the changes in CD4 and
CD8 subsets in fast progressors will be shown to be
significant earlier than 24 months. An increase in
CD8 cells is also seen in HIV-infected adults, par¬
ticularly at seroconversion,20 and may indicate an ac¬
tive immune response.21 We and others have shown
that HIV infected children have effective CDS me¬
diated immunity against HIV,9-21-25 although in our
studies, an elevated number of CD8 cells is not al¬
ways associated with HIV-specific cytotoxicity.22
The more rapid rate of increase of CD8 cells in the
fast progressors may be a consequence of their hav¬
ing been infected in utero and, therefore, exposed to
HIV for longer than the children who were infected
at birth.2 A third possibility is that the level of CD8
cells may be indicative of active disease, or perhaps
higher viral burden, and may not necessarily repre¬
sent an effective immune response to HIV.
There was no overall trend in CD4 or CD8 cells
associated with progression to symptomatic disease
or death. Of the two children who showed substan¬
tial loss of both CD4 and CD8 cells (no. 10 and 16),
one has died and one has progressed to AIDS.
However, similar changes were not seen in the other
five children who died during the study. Larger co¬
hort studies will be required to determine whether
changes in lymphocyte populations can predict clin¬
ical progression.
Despite the different ages of recruitment, the
changes in CD4 and CD8 subpopulations were re-
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cord 1 2 3 1 2 3 4 6
5 CD8 subpops t T
virus culture neg pos pos
8 CD8 subpops norm norm T T T
virus culture neg pos pos pos
9* CDS subpops T T T T
virus culture pos pos pos pos
17* CDS subpops T T
virus culture pos pos pos
18 CD8 subpops norm T t T T
virus culture neg neg neg pos
19 CDS subpops norm norm t
virus culture neg pos pos
a*, clinically fast progressor; neg, negative virus culture after 4 weeks; pos, positive virus culture after 4 weeks; norm, all CD8 sub-
populations in normal ranges; f , one or more CDS subpopulation (CD I labnght, CD45R0, or HLA-DR) outside the normal range.
markably consistent, with the levels of three of the
CD8 subpopulations showing particularly rapid
and sustained increases. The levels of HLA-DR+ ,
CD45R0 + , and CD1 la+bnght CD8 cells increased
soon after birth, with most individual patient's re¬
sults crossing, and remaining above the 97th per¬
centile. This observation suggested to us that these
measurements may be useful in diagnosis. As HIV
polymerase chain reaction (PCR) was not per¬
formed routinely during this study, the results were
compared with the time that diagnosis was con¬
firmed by a positive virus culture. In five out of
six children followed from birth, HLA-DR+ ,
CD45R0 + , and CD1 la + bnght CD8 cell subpopu¬
lations were elevated above the 97th percentile at
the same time as or before they were virus-culture
positive. We reported previously that the levels of
these three CD8 subpopulations vary indepen¬
dently.1 Thus, in a child born to an HIV-infected
woman, an increase of one or more of these sub-
populations, especially CDlla + bnght CD8 cells
and one of the other two, is suggestive of HIV in¬
fection. CD45R0 and HLA-DR expression have
been shown to be elevated in other infections, in¬
cluding intrauterine infection, and are not specific
to HIV.26-27 Our unpublished studies, however,
suggest that high levels of CD8 subpopulations are
transitory in other viral infections, whereas they
persist in HIV infection. Further studies are re¬
quired, however, to distinguish the changes in CD8
subpopulations in HIV from other pediatric viral
infections, and to determine their validity as a di¬
agnostic marker.
The immunological functions associated with
these three CD8 subpopulations have been explored
in a number of studies. CD1 la+bnght and CD45R0+
CD8 cells have both been associated with both cy¬
totoxic and memory cell functions.28'30 In our stud¬
ies, however, we found a predominance of CD8 cells
with both of these markers in both cytotoxic-posi-
tive and -negative cultures;22 thus there appears not
to be a simple association between surface marker
expression and immune function. More recently,
CDlla+bnght CD8 cells have been associated with
increased spontaneous Ig production in HIV-infected
adults.31 Polyclonal hypergammaglobulinemia is al¬
most invariably seen in children with HIV,32 which
would be consistent with increased CD1 labnght ex¬
pression. In a recent study, Okumura et al. showed
that memory cell activity in the CD8 population re¬
sides in both CD45R0+ cells and in a subset of
CD45RA cells expressing the CD1 labnght marker.33
It has been suggested that elimination of the stimu¬
lating antigen allows CD45R0 cells to revert to
CD45RA cells, while retaining memory for the anti¬
gen.34 If this is the case, the continuously elevated
CD45R0 expression seen in this study may be an in¬
dication of continuous restimulation by HIV anti¬
gens. CD8 + CD57+ cells have been shown to sup¬
press MHC-restricted cytotoxic T cells (CTLs).35'36
CTLs are thought to be an important means of sup¬
pressing HIV replication in vivo and maintaining
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tsymptomatic disease.37 In this study the fast pro-
ressors had higher levels of CD8 + CD57+ cells
than the slow progressors, which would be consis¬
tent with the view that increased CD8 + CD57+ cells
inhibit the beneficial effect of HIV-specific CTLs,
and permit more rapid disease progression.
Changes in the CD4 subpopulations studied were
also consistent but showed a different pattern than
the CD8 subpopulations. Differences in the levels of
the putative memory and naive markers, CD45R0
CD29 and CD45RA, on CD4 cells became statisti¬
cally significant after 48 months, and were not as
marked as in the CD8 subpopulations. This is in con¬
trast to studies in HIV-infected adults, which have
shown CD45R0 + and CD29+ CD4 cells to be ei¬
ther decreased38'39 or unchanged.40 Occurring later,
these changes may be a result of altered immune
function, reflecting later stage disease, rather than a
response to virus expression as suggested for the
-CD8 subpopulations. It has been suggested that
-CD45R0+CD4+ cells in neonates41 or CD45R0+
-CD45RA+ double staining CD4 cells in cord
-blood42 may represent an embryonic population of
T cells that are functionally anergic. We do not be¬
lieve that this accounts for the increase of
-CD45R0 + CD4+ cells seen here, because the per¬
centages at birth were similar in the HIV-infected
and normal children. In the infected children,
changes induced by HIV and CD4 cell regeneration
as described recently by Ho et al. and others,43^5
superimposed on changes due to natural maturation,
will all contribute to the altered levels. Further stud¬
ies are required to determine whether the increase of
the CD45R0 marker on CD4 cells is a consequence
of accelerated maturation due to HIV infection, or
whether it is related to HIV pathogenesis, and there¬
fore useful as a marker of disease progression. The
activation marker, HLA-DR, increased earlier on
CD4 cells, becomes significantly elevated in the fast
arogressors by 24 months and in the slow progres-
>ors by 48 months. Thus, increased numbers of ac-
ivated CD4 cells may be more indicative of active
disease than either the CD45RA or CD45R0 cell
narkers.
In conclusion, we have shown that children in-
"ected vertically with HIV show progressive and
consistent changes in their levels of CD4 and CD8
ymphocytes, and in various subpopulations, which
exceed the changes taking place as part of normal
maturation. The rates at which some of these changes
occur distinguish clinically slow and fast progres¬
sors. The degree of change in the CD8 subpopula¬
tions is such that these measurements could be used
to aid the diagnosis of HIV infection in individual
children, and may be particularly useful as a screen¬
ing test where virus or DNA-based assays are not
available. Changes in CD8 subpopulations may also
identify children who have made an immune response
to HIV without becoming infected.46 Changes in the
levels of some of the subpopulations studied are as¬
sociated with early, active disease and others with
later disease. Recent work using three-color staining
suggests that more detailed surface marker analysis
may further segregate different clinical groups (M.
Aldhous, unpublished results and 47). Longitudinal
studies with larger cohorts are required to determine
possible associations between changes in subpopula-
tion levels and disease progression. Also, the associ¬
ations between surface markers, immune function,
and the immune mechanisms that determine clinical
progression need to be further explored.
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Cytotoxic T Lymphocyte Activity in Children Infected with HIV
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ABSTRACT
Of the Edinburgh cohort of approximately 130 children born to HIV-infected women, 9 are infected and alive.
This article describes results from the first 18 months of a natural history study of seven of these, and two
adopted children, studying the CD8 T cell-mediated cytotoxicity against HIV proteins (Gag, Tat, Pol, and
Env), over time, and relating it to clinical progression and viral activity. Autologous EBV cell lines infected
with vaccinia-HIV constructs were used as target cells, and bulk-cultured peripheral blood mononuclear cells
as effector cells. The children ranged in age from 0 to 93 months, with six of the nine showing CTL activity to
one or more HIV proteins. The specificity of the response was directed against Tat in the younger children,
switching to Pol, then Gag or Env. Preliminary analysis of virological data showed no association between CTL
and virus activity. The children with CTLs tended to be well clinically, but the cohort needs to be studied
longer before conclusions can be made about CTL activity and HIV disease progression. Cytotoxic T lympho¬
cyte activity has also been observed in two children diagnosed as HIV uninfected. These results show the im¬
portance of looking at CTL specificity, and may have implications in vaccine design.
INTRODUCTION
Cytotoxic T lymphocytes (CTLs) are thought to be an im¬portant part of the immune response against HIV in
adults.1 HIV-specific CTLs develop after the burst of viral
replication associated with acute infection, and are thought to
suppress disease progression by killing infected cells. In chil¬
dren born to infected women, CTLs have been less well charac¬
terized. Vertical infection can take place in utero before the im¬
mune system is mature and able to distinguish self from
nonself, at birth,2 in association with an infusion of maternal
IgG, which includes anti-HIV antibody, or after birth by the in¬
gestion of infected breast milk.3 Thus both the primary target
cell for infection, and the nature of the immune response, could
differ, depending on the timing and route of infection.
Scotland has the same incidence of HIV infection per head
of population as the United Kingdom, but has two major differ¬
ences. First, half of the 2000 Scottish cases, reported on
September 30, 1993, are in the Edinburgh region, although the
region has only one-tenth of the Scottish population. Thus, with
1000 cases, the city has a disproportionate concentration of
HIV-infected people. Second, a much higher proportion (27%,
or 270) of cases are women, who have been infected either
through intravenous drug injection or through sex (Scottish
Centre for Infection and Environmental Health, Glasgow, UK,
personal communication, 1994). A further difference in
Edinburgh is that the vertical transmission rate of HIV, at ap¬
proximately 10%, is one of the lowest global rates reported.4
The Edinburgh Paediatric HIV Clinic follows all children who
are born to HIV-infected women in the area from birth, plus any
children who are referred because of clinical symptoms. To
date this numbers approximately 130, of whom 9 are infected
and still alive. Seven of these, and two adopted children, in
whom the route of infection is unknown, are included in this
study. The children range in age from birth to 93 months. As
most were above 2 years of age at enrollment they were se¬
lected for "slow" clinical progression.
In preliminary experiments, we found an absence of HIV
Gag-specific CTL activity in children, despite a high incidence
in adults from the same cohort.5 In Edinburgh most of the HIV-
infected drug-taking community are thought to have been in¬
fected by recognizably similar viruses6 and we therefore rea-
'HIV Immunology Unit, Department of Medicine, University of Edinburgh, Edinburgh EH3 9HB, United Kingdom.
'Regional Infectious Diseases Unit, City Hospital, Greenbank Drive, Edinburgh EH 10 5SB, United Kingdom.
'Department of Medical Microbiology, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, United Kingdom.
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soned that the lack of a Gag response in the children was un¬
likely to be due to nonrecognition of the viral sequence used in
the target construct, but may reflect a difference in the nature of
the immune response. The present study was undertaken to de¬
termine whether HIV-infected children had CTL activity to
HIV antigens other than Gag and, if so, how these related to vi¬
ral activity and disease progression. In this article we report the
preliminary results of CTL activity against HIV tat, pol, gag,
and env gene products in 9 infected and 11 uninfected children,
tested over an 18-month period.
MATERIALS AND METHODS
Patients
The study group comprised 9 HIV-infected children (mean
age at start of study, 43 months; range, 3-88 months), and 11
children who had lost maternal HIV antibody, had no other in¬
dications of HIV infection, and so were presumed to be HIV
uninfected (mean age at start of study, 27 months; range, 1-73
months). Eighteen of the children were known to be born to
HIV-infected women; 2 were adopted and, as no maternal in¬
formation was available, the route of infection was unknown.
The clinical classifications of the infected children were deter¬
mined using criteria from the Centers of Disease Control (CDC;
Atlanta, GA),7 and, together with details of clinical symptoms,
treatment, and laboratory results, are presented in Table 1.
Cytotoxic T lymphocyte assay
The method was based on that of Nixon et al,,8 and used
bulk-cultured effector cells in a 4-hr 5lCr-release assay. The
majority of effector cells were phenotypically CD45R0- and
CD 1 la-expressing CD8 cells and killing was completely
blocked by anti-CD8 antibody5 (M.C. Aldhous, unpublished
observation, 1994). Effector cells were peripheral blood
mononuclear cells (PBMCs), isolated from heparinized blood,
and stimulated with phytohemagglutinin (PHA, 2.5 pg/ml;
Wellcome, Research Triangle Park, NC). All cultures were
maintained at 37°C in RPMI-1640 medium supplemented with
penicillin (100 IU/ml), streptomycin (100 pg/ml), 1 mM
sodium pyruvate, 0.5 mM l-glutamine, and 10% fetal calf
serum (FCS) ("RPMI medium") for 7 days, and subsequently in
medium containing 5% interleukin 2 (IL-2) (Lymphocult,
Biotest, Solihull, United Kingdom) replacing 50% of the cul¬
ture supernatant every 3^4 days. Assays were carried out after
9-23 days of culture, when there were deemed to be sufficient
cells. Target cells were autologous Epstein-Barr virus (EBV)-
transformed B cell lines, infected overnight with 106 plaque-
forming units (PFU) of either a vaccinia-HIV construct (gag,
tat, pol, or env), or a vaccinia control. The constructs used were
as follows: a vaccinia control (Vac-Vsc8WR) and vac-gag
(from HIV-IIIB; MRC, AIDS Directed Programme, National
Institute for Biological Standards and Control, Hertfordshire,
United Kingdom), vac-tat (VVTG3196), vac-pol (VVTG3167),
and vac-env (VVTG1132) (from HIV-LAI (Transgene,
Strasbourg, France). A culture tube containing EBV cells not
Table 1. Clinical and Laboratory Data of Children Studied at Each Time of Testing
Child
Age
(months) Clinical symptoms Treatment CDC" CTL
Virus
culture PCR
1 79 Ear infection Amoxil P2A Pol
82 Mild throat infection — + ■ ■
87 - - -
93 Well — Gag - +
2 71 Well — P2C, F Pol + -
75 Well — + - -
78 + nd -
84 Well — - - -
3 53 Well - PI B Tat + +
59 Well — Pol + +
4 28 Well — PI B Tat - -
35 Well - Pol - -
45 Well — - - -
5 21 Pyrexia Erythromycin P2A Tat/Pol + -
24 Chest infection Augmentin - + -
31 Tat/Pol - -
6 88 Well — P2A - - -
90 URTI — - - -
7 40 Schistosoma haematobium — P2A, C - + +
43 URTI, herpes simplex Acyclovir - + +
8 4 Chest infection Amoxil P2A - + -
6 Mild URTI — - + -
9 3 Candidiasis — P2A - + -
6 PGL — Tat/Pol + +
"CDC classification for pediatric HIV.
URTI, Upper respiratory tract infection; PGL, Persistent generalized lymphadenopathy.
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infected with vaccinia constructs was set up as a "medium"
control. Given the variable number of cells available, the effec¬
tor cells were used at the highest effector-to-target ratios possi¬
ble, generally between 10:1 and 50:1. The percent lysis of the
target cells was measured after 4 hr in culture, by release of 51Cr
into the supernatant. Total and spontaneous lysis were deter¬
mined by incubating target cells in 5% Triton X-100 and in
medium respectively.
Virus isolation by culture
Peripheral blood mononuclear cells were isolated from eth-
ylenediaminetetraacetic acid (EDTA)-anti-coagulated blood by
separation over Ficoll-Hypaque (Nyegaard, Oslo, Norway) at
800 x g for 20-25 min. The lymphocyte fraction was washed
and resuspended in 10 ml of RPMI medium supplemented with
amphotericin B (1.25 pg/ml; GIBCO, Paisley, United
Kingdom), (10 IU/ml; MRC AIDS Directed Programme
National Institute for Biological Standards and Control,
Hertfordshire, UK), PHA (3 jig/ml), and containing 2 x 106
PHA-stimulated PBMCs from uninfected donors. Virus pro¬
duction was assayed, using a p24 antigen kit (Coulter, Hialeah,
FL), every 7 days for 28 days. At each time of antigen testing, 1
x 106 uninfected donor PBMCs were added to the culture.
Polymerase chain reaction
A two-stage (nested) polymerase chain reaction (PCR) was
performed using the method of Simmonds et al.9 An outer
primer pair complementary to the pol region of the HIV
genome was used in the first PCR reaction. An aliquot of the
product from this reaction was reamplified using an inner
primer pair complementary to a region within the first PCR
product. The product from the second PCR reaction was visual¬
ized by electrophoresis on a 2% agarose gel containing ethid-
ium bromide.
RESULTS
Cytotoxic T lymphocyte activity against HIV Gag, Tat, Pol,
and Env is shown in Figs. 1 and 2 for the HIV-infected and un¬
infected children, respectively. The results are presented as the
percent specific lysis, net of medium and vaccinia controls,
with values greater than 10% above controls being regarded as
positive. Each infected child was assayed from two to four
times, and the uninfected children once, except for one child
(No. 20) who was assayed twice.
HIV-infected children
Six of the nine HIV-infected children showed CTL activity
on at least one occasion (Fig. 1). The most commonly recog¬
nized target was Pol, followed by Tat (six and four children, re¬
spectively), with Gag being recognized by only one infected
child. In four cases the CTL activity was directed against a sin¬
gle target (children Nos. 1, 2, 3, and 4) and in two cases it was
directed against two targets (Tat and Pol in children Nos. 5 and
9). The specificity of the CTL response changed on successive
tests. In the two youngest children who had CTLs (children
Nos. 9 and 5, aged 6 and 21-31 months, respectively) the re-
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FIG. 1. Cytotoxic T lymphocyte activity against constructs of vaccinia and HIV gag, tat, pol, and env of sequential samples from
HIV-infected children. The ages of the children at the time of testing are shown in Table 1.
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FIG. 2. Cytotoxic T lymphocyte activity against constructs of vaccinia and HIV gag, tat, pol, and env of HIV-uninfected chil¬
dren. *, Denotes activity measured after 11 and 18 days in culture.
sponse was against both Tat and Pol. Two children in the mid¬
dle of the age range (children Nos. 3 and 4, aged 53-59 and
28^15 months, respectively) lost their response to Tat, but re¬
tained that to Pol; in the two oldest children, the specificity
changed from Pol to a Gag in one (child No. 1, aged 79-93
months), and from Pol to a weak Env response in the second
(child No. 2, aged 71-84 months). Two children (Nos. 2 and 4)
lost CTL activity, and two children (Nos. 1 and 5) lost and re¬
gained activity during the study period. Three children (Nos. 6,
7, and 8) were CTL negative throughout the study.
HIV-uninfected children
Strongly positive CTL activity was detected in two HlV-un-
infected children, and a further two had borderline activity.
Child No. 20 showed significant levels of anti-Gag, anti-Tat,
and weak anti-Pol activity when first assayed at 17 months of
age. On this occasion, the effector cells were used at two differ¬
ent time points, days 11 and 18 after stimulation, and the speci¬
ficity was shown to change from Tat and Pol on day 11 to Gag
on day 18. At 25 months, this child showed high nonspecific
killing, but no HIV-specific lysis (data not shown). Child No.
19 showed anti-Pol activity at 6 months of age. Children Nos.
11 and 13 had borderline (i.e., 10% lysis) anti-Gag responses.
Cytotoxic T lymphocyte activity and clinical progression
The clinical records of the infected children were examined
for evidence of intercurrent infection and for other indications
of HIV disease progression, at the times they were tested for
CTL activity. Eight of the nine children are "slow" progressors
with regard to HIV disease, and showed no clinical progression
during the study period. The results, summarized in Table 1,
show that five of the six children with CTL activity remained
well during the period of follow-up. The sixth (child No. 9) was
clinically a fast progressor and, despite developing CTLs at 6
months, had persistent generalized lymphadenopathy. This
child lost CTL activity at 9 months, and developed toxoplasmo¬
sis at 10 months (data not shown). The three children in whom
no CTL activity was detected tended to have intercurrent infec¬
tions during the study period.
Cytotoxic T lymphocyte activity and viral activity
The results of virus culture and plasma PCR assays carried
out during the study period were compared with the CTL re¬
sponses (Table 1). There was no relationship between CTL ac¬
tivity and the ability to recover virus from either cells or
plasma.
DISCUSSION
Cellular immune mechanisms, in particular HIV-specific
CTL activity, are thought to be important means of immune-
mediated suppression of HIV, and stimulation of the CTL re¬
sponse is increasingly being used as a measure of the efficacy
of experimental vaccines. In this study we have asked which
HIV antigens stimulate CTLs in vertically infected children,
and have begun to address the question of whether CTL activity
correlates with clinical stability and virus activity.
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The main result of the study is the different specificity of
CTL target recognition of the children compared with adults
from the same cohort. The predominant HIV antigens recog¬
nized by this group of infected children were Pol and Tat. Gag
and Env were recognized by only one infected child each. The
second observation was a pattern of recognition in the infected
children that was related to age, and therefore to time after in¬
fection. Although the numbers are small, the children come
from a relatively homogeneous cohort, and it is possible that
similar changes in CTL target recognition take place in the indi¬
vidual children. If this is confirmed, it may be important for in¬
fants and young children that anti-HIV immune therapy be di¬
rected against the epitopes recognized early in the course of
infection, that is, Pol and Tat, rather than, or in addition to. Gag
and Env sequences.
Our results are consistent with those of Luzuriaga et a/.,10
who found anti-Gag and -Env activity in only a proportion of
vertically infected children, but differ from those of Cheynier et
al.n and Bruseyne et al.,n who found CTL activity to HIV
Gag, Env, Pol and Nef in a high proportion of children tested.
There are a number of possible explanations for these differ¬
ences. The possibility that the results are due to technical or
methodological differences cannot yet be ruled out. The effec¬
tor cells are grown from comparatively small blood samples,
and may be kept in culture for longer periods than is required
for adult samples. Bulk-cultured effector cells, in one experi¬
ment, which were tested at two separate time points, showed
differing target specificities, suggesting that different CTL
clones may expand at different rates and become dominant at
different times after stimulation. Differences may also result
from variations in virus strain or sequences used for the vac¬
cinia constructs. The causes of these differences need to be clar¬
ified if CTL activity is to become a valid measure of vaccine ef¬
fectiveness.
To address the question of whether CTLs are effective in
vivo we examined the case notes for these children for evidence
of HIV disease progression and of intercurrent infections.
During the period of the study, eight of the nine children, that
is, five with CTL activity and the three without, were stable
with regard to HIV disease progression. Of the two children fol¬
lowed from birth, the child who made a transient CTL response
deteriorated clinically, whereas the second, who was CTL neg¬
ative, was clinically stable. All three CTL-negative children
had recorded intercurrent infections, compared with three of the
six CTL-positive children. The data, although preliminary, sug¬
gest that CTLs may be associated with fewer intercurrent infec¬
tions, although it is too early to draw any conclusions about
long-term HIV disease prognosis.
In a cross-sectional comparison of CTL activity, virus cocul-
ture, and HIV PCR results, we found no relationship. The virus
test results, however, were qualitative, and this comparison may
mask quantitative changes. Further longitudinal, quantitative
comparisons are in progress.
The second main result of the study is the relatively high pro¬
portion of exposed but presumed uninfected children that have
HIV-specific CTLs. Two of 11 presumed uninfected children
had strong CTL activity on 1 occasion and a further 2 had bor¬
derline levels (Fig. 2). Evidence of cellular immune responsive¬
ness to HIV in uninfected individuals has been reported by a
number of groups.1 Li3,i4 -phe intracellular processing and pre¬
sentation of viral peptide to CTLs is thought to require infection
of the target cell, implying that these children have been ex¬
posed to live, although possibly nonreplicating, virus. Of inter¬
est is the transient nature of the CTL response. Child No. 20,
who was assayed twice, lost the response on the second occa¬
sion, suggesting that CTL precursors were no longer present in
the circulation and raising the question of whether this child has
retained immunological sensitivity to HIV. Other laboratory
tests, including HIV antibody, antigen culture, and PCR, were
consistently negative (data not shown), and the child was diag¬
nosed as uninfected. It is possible, however, that some virus is
still present in the lymphoid tissues of the children with
CTLs,1546 capable of emerging at a later date, as occurred in
one child studied by Luzuriaga et at.10
It is still not confirmed that CTL activity is universally bene¬
ficial to the individual infected with HIV. Although studies
have shown that loss of CTL activity in asymptomatic individu¬
als occurs before clinical disease progression, the finding of
CTLs in bronchial lavage17 and cerebrospinal fluid18 indicates
an inflammatory response that may contribute to the pathologi¬
cal manifestations of HIV disease. Early infection with HIV (in
utero, rather than at delivery) may lead to a degree of tolerance
and therefore a lack of cytotoxicity, resulting in more rapid pro¬
gression, as the infection has been able to proceed for a longer
time in the absence of a competent immune system. It is impor¬
tant to establish whether slow clinical progression is due to the
effectiveness of the immune response, and if CTLs contribute
to this.
In conclusion, our results show a vigorous CTL response in
the majority of infected children, and in a significant proportion
of uninfected children, with target specificities primarily
against HIV Tat and Pol, but changing as the children get older.
The study needs to be continued until the infected children
reach a clinical end point, to determine the in vivo anti-HIV ef¬
fectiveness of CTLs with different specificities. The study also
needs to be repeated in other cohorts of children, and in newly
infected adults, to determine whether the pattern of responses
relates to time after infection, or whether HIV antigen presenta¬
tion and the immune response in children differ from that in
adults.
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HIV-specific cytotoxic T-cell
activity in an HIV-exposed but
uninfected infant
Sarah L. Rowland-Jones
Douglas F. Nixon Marian c. Aldhous
Frances Gotch Koya Ariyoshi
Nicholas Hallam J. Simon Kroll
Karin Froebel Andrew McMichael
The factors necessary for protective immunity
against HIV-1 are unknown. Important information
about these factors should come from study of
people at high risk of HIV infection who have not
apparently become infected. Among these are the
estimated 60-85% of children who may be exposed
in utero or perinatally to HIV-1 but do not become
infected. We observed the transient appearance of
HIV-specific cytotoxic T-lymphocyte (CTL) activity
in a baby born to HIV-1 -infected parents, in whom
all standard markers of infection remained negative.
These findings suggest that HIV-specific CTLs may
be a marker for recently exposed, but uninfected,
individuals.
Lancet 1993: 341:860-61.
An important advance in the rational design of a
prophylactic vaccine against human immunodeficiency
virus (HIV) would be identification ofpeople who have been
exposed to HIV and generated an immune response, but not
become persistently infected. A characteristic feature of the
immune response to HIV is presence in healthy seropositive
subjects of vigorous HIV-specific cytotoxic T-lymphocyte
(CTL) activity. Cytotoxic T cells appear early in the
immune response to most viral infections and are thought to
have an important role in the eradication of virus, or in the
control of viral replication in persistent infections.1 The
specific CTL response to HIV is ofmuch greater magnitude
than that observed in almost any other viral infection, and is
thought to be one of the main factors contributing to the long
symptom-free period.2 HIV-specific CTLs can readily be
detected in seropositive patients but are not normally
observed in uninfected subjects. We describe the finding of
HIV-specific CTL activity in a child bom to an HIV-
infected mother; all standard markers of HIV infection in
the child were negative by the age of 13 months.
The wife ofan H IV-infected haemophiliac was first diagnosed as
anti-HIV-positive in January, 1989. Two years later she became
pregnant and gave birth to a healthy boy by spontaneous vagina!
delivery. During the pregnancy she had symptoms that were
probably related to HIV infection, including diarrhoea, weight loss
and oral candidiasis. Her absolute CD4 count ranged from 0-17 to
0-3 x 10"L and p24 antigen was consistently positive.
At delivery, cord blood from the baby was anti-HIV-positive
(Behrtng Enzygnost 1/2 enzyme immunoassay [EIA]) (presumed
maternal antibody) and negative for p24 antigen (Abbott). Cord
blood mononuclear cells enriched on a Ficoll-Hypaquc gradient,
co-cultured with phvtohaemagglutinin-stimulated lymphoblasts
from an anti-HIV-negative donor, and assayed weekly for p24
antigen in the culture supernatant showed no evidence of HIV
infection. HIV-specific CTL activity against gag and pol antigens
could not be detected either from freshly isolated cord blood
mononuclear cells or with cells cultured with autologous
phytohaemagglutinin-stimulated lymphoblasts in the presence of
interleukin 2 (phytohaemaggiutinin increases expression of
autologous viral antigens in HIV-infected ceils and these antigens
would be expected to stimulate proliferation of HIV-specific CTL
in culture2)-
At the age of 5 months, the child was thriving and developing
normally. His blood was still seropositive for maternal HIV
antibody but negative on all other tests for HIV infection, including
p24 antigen, viral co-culture, and polymerase chain reaction with
HIV-gqj-specific primers. However, HIV-gag-specific CTL
activity could be detected with peripheral blood mononuclear cells
expanded in vitro, as outlined above (figure). Target cells were an
Epstei.n-B.irr-virus-transformed B-cell line from the baby, which
were infected with recombinant vaccinia viruses expressing HIV
gag or a control protein from influenza, and labelled with
"chromium. Specific lysis was also observed when target ceils were
incubated with a synthetic peptide from HIV gag containing a CTL
epitope restricted by HLA-B8, which the child shares with his
father. We have described recognition of this peptide epitope,
p24—13, by CTLs from the father.' It was possible to grow a CTL
line from the baby specific for the p24-13 peptide with irradiated
peptide-pulsed autologous B cells as stimulators.
Studies that used the antibody UCHL-1 to measure surface
expression of the CD45RO antigen associated with "memory"
antigen-specific T cells, showed abnormally high proportions of
CDS lymphocytes expressing this marker—ie, 42% of CDS T cells
expressing CD45RO at 5 months old (normal for this age 0-15%).
Increased concentrations of circulating CD8 T cells that stain with
UCHL-1 antibody are strongly associated with HIV infection in
children born to infected mothers.2
3 months later, the baby still had HIV antibody, although
concentrations had declined, but viral culture for HIV was
again negative and there was no evidence of HIV RNA or
DNA by polymerase chain reaction with nested gag and pol
primers. Immunoglobulins and the CD4/CD8 ratio were
normal. At the age of 13 months, the child was healthy
and anti-HIV (Behring Enzygnost HIV1/2 EIA,








Bulk culture p24-l3 CTL line
CTLs from the baby recognise HLA-B8-restricted antigen in
HIV gag.
See text for details of assay j-0 = no added peptide; E.T
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first time. HIV antigen testing (Organon Vironostika) was
negative and polymerase chain reaction analysis showed no
evidence ofHIV RNA or DNA. HIV-specific CTL activity
could no longer be detected and the proportion ofCD45RO
CD8 lymphocytes was normal—ie, 20% ofnormal (range at
13 months 4-20%). At 18 months, the child is well and
continues to grow and develop normally.
Although diagnosis of paediatric HIV infection may be
difficult, it is generally agreed that a seronegative child with
no clinical symptoms or immunological or virological
evidence of infection after a year can be regarded as
uninfected.6 Some of the large cohort studies of children
bom to infected mothers7,8 have identified a small
population (2-5-T-7%) of seronegative children in whom
viral markers have been or continue to be positive. The
longterm outlook of such children is unknown, but studies
suggest that they have a good prognosis. Exhaustive studies
in the child reported have shown no evidence of active HIV
infection. Only the transient appearance of HIV-specific
CTL activity at the age of 5 months, in parallel with
an increase in a marker on CDS lymphocytes thought
previously to indicate HIV infection, suggests that the child
was exposed to HIV-1. These signs returned to normal and
by all currently accepted criteria, the child is not infected.
However, if the child has never been infected it is difficult
to explain the finding of HIV-specific CTL activity, which
normally requires actively replicating virus for stimulation.
It is possible that transfer across the placenta ofmaternal p24
antigen or defective vims incapable of replication might
have stimulated production of HIV-,gag-specific CTLs.
Transfer of maternal CTLs is unlikely because the baby's
CTLs responded to the same peptide epitope as CTLs from
his father, presented by the HLA molecule B8, which the
mother does not share. Similarly, antibody-dependent
cellular cytotoxicity, mediated by transferred maternal
antibody, could not account for the specificity of CTL lines
grown for some weeks in culture from the child.
It is possible, therefore, that the child had encountered
HIV but subsequently controlled or even cleared the vims,
and that his CTL activity may have contributed to this
process. In 20 children bom to HIV-l-infected mothers,9 a
strong CTL response correlated with a better clinical
course. This study also noted HIV-specific CTL activity in
3 children who later became seronegative; viral studies in
these children were also negative, although 1 had presented
with symptoms of HIV-1 infection at age 5 months.
There has been much interest in markers of immunity in
HIV-exposed but seronegative individuals: such patients
include haemophiliacs who are known to have received
contaminated factor VIII and the sexual partners of
HIV-infected people who continue high-risk behaviour. A
study10 ofhelper T-cell reactivity, measured by interleukin 2
production from peripheral blood mononuclear cells in
response to synthetic HIV-envelope peptides, found
evidence of HIV-specific activity in 5 anti-HIV-negative
homosexual men at continued high-risk ofHIV infection, in
whom other markers of viral infection were negative; CTL
activity was not measured in these men. 1 man subsequendy
seroconverted, but the others remain apparendy uninfected,
suggesting that there may have been exposure to HIV at a
level sufficient to prime T-cell immunity but insufficient to
induce antibody production.
Further studies of exposed but uninfected people are
essential to provide information on the components of
protective immunity to HIV, which might then form the
basis of an effective prophylactic vaccine.
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Transmural myocardial infarction
with sumatriptan
J. P. Ottervanger H. J. A. Paalman
G. L. Boxma B. H. Ch. Stricker
For sumatriptan, tightness in the chest caused by
an unknown mechanism has been reported in 3-5%
of users. We describe a 47-year-old woman with an
acute myocardial infarction after administration of
sumatriptan 6 mg subcutaneousiy for cluster
headache. The patient had no history of underlying
ischaemic heart disease or Prinzmetal's angina. She
recovered without complications.
Lancet 1993; 341: 861-62.
Sumatriptan is a serotonin-1 agonist used to treat acute
attacks of migraine and cluster headache.1 In trials,
sensations of pressure and tightness in the chest occurred in
3% of patients treated with 100-300 mg orally and in 5% of
